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GENERAL INTRODUCTION 
Vitamin D regulates calcium and phosphorus blood levels and bone metabolism 
via effects on intestine, kidney, and bone. Vitamin D is formed from 
7-dehydrocholesterol in the skin by ultraviolet irradiation or is taken up from dietary 
sources. Vitamin D must be metabolically altered successively in the liver and kidney 
to form the biologically most active compound, 1,25-dihydroxyvitamin D3. This active 
compound acts through binding to a specific receptor, the vitamin D receptor, which 
is a member of the steroid hormone receptor family. 
During the last fifteen years, it has become apparent that the active form of 
vitamin D exerts effects on a variety of tissues apparently unrelated to calcium 
homeostasis. 1,25-Dihydroxyvitamin D3 has been shown to promote cellular 
differentiation and inhibit proliferation of haematopoietic cells, cancer cells, and 
keratinocytes. In addition, studies with animal models for cancer have shown that 
1,25-dihydroxyvitamin D3 administration can prolong the survival of leukaemic mice 
and suppress the growth of tumours of different origin, including breast, colon, skin, 
and lung. 
These newly discovered properties suggested a possible role of the hormone in 
the treatment of cancer. However, a major drawback for a clinical application is that 
high doses are needed. These doses cause serum levels of 1,25-dihydroxyvitamin D3 
far above the physiological level, which may lead to a dangerous elevation of the 
blood calcium concentration. To circumvent this problem many investigators have 
tried to change the 1,25-dihydroxyvitamin D3 molecule in a way that it retains its 
antiproliferative and differentiation inducing activity, but has a reduced effect on 
calcium and bone metabolism. This strategy has resulted in new synthetic vitamin D3 
analogues with clinical potential. 
This thesis focuses on a possible role of vitamin D in the treatment of breast 
cancer. For the experimental work breast cancer cell lines were used, which are 
tumour cells originally derived from patients. TIlese cells are cultured continuously in 
the laboratory and form a model system for breast cancer, in which under defined 
conditions the effect of individual test compounds can be studied. The studies in this 
thesis were undertaken to gain insight into the mechanism of the tumour suppressive 
action of 1,25-dihydroxyvitamin D3 and vitamin D3 analogues. Furthermore, it was 
studied whether a combination therapy with tamoxifen, the widely used hormonal 
drug for breast cancer treatment, may have clinical potential. 
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Chapter 2 
2.1 VITAMIN D METABOLISM 
2.1.1 Sources of vitamin D 
Vitamin D3 (cholecalciferol) is either synthesized in the skin from 
7-dehydrocholesterol in a reaction catalyzed by ultraviolet light, or is obtained from 
the diet. Adequate amounts of vitamin D3 are produced in the skin with casual 
exposure to sunlight and therefore, vitamin D3 is not a vitamin in the sen~e of an 
essential nutritional substance. The major dietary sources of this fat-soluble vitamin 
are fortified dairy products (milk, milk products, butter), margarine, fatty fish, and 
fish liver oils. Fortified foods contain either vitamin D3 or vitamin D2 (ergocalciferol) 
which behaves metabolically like vitamin D3 (1-3). 
2.1.2 Biological activation of vitamin D 
Vitamin D3 itself is biologically inert. First, it is metabolized in the liver to 25-
hydroxyvitamin D3 and then in the kidney to 1,25-dihydroxyvitamin D3 (ca!citriol), 
which is the biologically most active form (Figs. 2.1 aud 2.2). 
The hydroxylation of vitamin D3 in the liver is catalyzed by the enzyme 25-
hydroxylase. This metabolic step is not strictly regulated and 25-hydroxyvitamin D3 is 
stable with a half-life of approximately three weeks. Accordingly, the serum 
concentration of 25-hydroxyvitamin D3 is a reflection of the vitamin D status of a 
person and summates the concentrations derived from both the diet and photo-
formation. 
The conversion of 25-hydroxyvitamin D3 into the active hormone 1,25-
dihydroxyvitamin D3 in the kidney by the enzyme la-hydroxylase is under stringent 
control. The most important stimulatory factors of la-hydroxylase activity are 
parathyroid hormone, and reduced plasma calcium and phosphate levels, whereas the 
la-hydroxylase activity is inhibited by 1,25-dihydroxyvitamin D3 via a negative 
feedback loop. Other factors that have been implicated in the regulation of renal 
1,25-dihydroxyvitamin D3 synthesis are oestrogen, prolactin, growth hormone, and 
insulin. The half-life of 1,25-dihydroxyvitamin D3 is 4 to 6 hours. As a result normal 
circulating levels of 1,25-dihydroxyvitamin D3 are precisely controlled and fluctuate in 
response to the mineral needs of a person. 
The kidney can also convert 25-hydroxyvitamin D3 to 24,25-dihydroxyvitamin D3 
by the enzyme 24-hydroxylase. Under circumstances of relative vitamin D3 deprivation 
the kidney produces only 1,25-dihydroxyvitamin D3. If the supply of vitamin D3 is 
adequate both dihydroxylated metabolites are formed. Whether 24,25-dihydroxyvita-
4 
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Figure 2.1. Metabolic activation of vitamin D. 
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Figure 2.2. Chemical structures of vitamin D3 and 1,25-dihydroxyvitamin D3- The numbering of the 
carbon atoms and the ring Ilomenclature is shown for vitamin D3- Vitamin D3 has a side-chain of 8 
carbon atoms (carbon 20-27). Note that the B ring is broken at the 9-10 carbon-carbon bond. 
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min 0 3 has a biological role or whether its production initiates only a catabolic 
pathway is still under debate (1-3). 
2.1.3 Inactivation of vitamin D metabolites 
In addition to vitamin 0 3 and its metabolites 25-hydroxyvitamin 0 3, 1,25-
dihydroxyvitamin 0 3, and 24,25-dihydroxyvitamin 0 3, a large number of other 
metabolites have been isolated from humans and animals. To date, these other 
metabolites have not been shown to possess any unique biological properties and 
appear to be breakdown products. The inactivation of vitamin 0 3 metabolites takes 
place by sequential oxidations of the side-chain of the molecule (1,4). 
2.1.4 Transport of vitamin D metabolites 
Vitamin 0 3 and its metabolites circulate in the blood primarily through binding 
to the vitamin 0 binding protein. This protein binds vitamin 0 3 and its metabolites 
with a high affinity and is structurally homologous to two other blood proteins, 
albumin and a-fetoprotein. Besides binding to the vitamin 0 binding protein, vitamin 
0 3 metabolites bind with low affinity to albumin and low-density lipoproteins (5,6). 
2.2 MECHANISM OF ACTION OF 1,25-DIHYDROXYVITAMIN D3 
2.2.1 The vitamin D receptor 
The biological action of 1,25-dihydroxyvitamin 0 3 is mediated through binding 
to a specific receptor, the vitamin 0 receptor. This receptor is an intracellular protein 
with a molecular weight of 50-60 kDa, which binds both 1,25-dihydroxyvitamin 0 3 
(KD: 10-1°_10- 11 M) and DNA. The vitamin 0 receptor is a member of the steroid 
receptor family, which are nuclear transcription factors. Other members of this family 
are the glucocorticoid, oestrogen, retinoic acid, and thyroid hormone receptor. 
Comparison of the amino acid sequences of the vitamin 0 receptor and the 
other members of the steroid receptor family reveals a similarity in structural and 
functional organization. The proteins have six domains of evolutionarily conserved 
amino acids (region A to F in Fig. 2.3). 
The region that exhibits the greatest degree of amino acid homology among the 
members of the receptor family is the DNA binding domain (region C). This region is 
required for DNA sequence recognition and receptor dimerization. The DNA binding 
domain consists of about 70 amino acids that folds in two so-called zinc-finger motifs. 
6 
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Each finger binds a zinc ion that is tetrahedrally coordinated by four cysteines (Fig. 
2.3). 
The DNA binding domain is followed by a hinge region (region D) that links 
the DNA binding domain to the hormone binding domain (region E) located at the 
carboxy terminus of the receptor. The hormone binding domain, that encompasses 
about 210 amino acids, is moderately conserved and determines the steroid binding 
specifity of the receptor. It also participates in hormone-dependent transcriptional 
activation and receptor dimerization. 
The amino-terminal domain (region A/B) is the most variable region and the 
length differs between the members of the family. The vitamin D receptor has a 
relatively short A/B domain of only 20 amino acids. The function of this region is less 
well-defined. For some receptors a trans activating function, which seems to be 
independent of ligand binding, has been assigned to this region (7-11). 
REGION 
FUNCTION 
DNA BINDING 
LIGAND BINDING 
DIMERIZATION 
NUCLEAR 
LOCALIZATION 
C "zn" C 
C / 'C 
c'Zn"c 
c/ 'c 
~ C ~ 
N---1 DNA H 
TRANSACTIVATION <='1 
E F 
LIGAND ~c 
Figure 2.3. Structural and functional organization of steroid hormone receptors. 
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2.2.2 Phosphorylation of the vitamin D receptor 
The vitamin 0 receptor, like other members of the steroid receptor family, can 
be phosphorylated (12). This phosphorylation is enhanced by the presence of 1,25-
dihydroxyvitamin 0 3, However, also ligand-independent phosphorylation has been 
observed. Certain kinases have been shown to phosphorylate the vitamin 0 receptor, 
including protein kinase C-Ll (13,14), casein kinase II (15,16), and cAMP-dependent 
protein kinase (PK-A) (17). The phosphorylation occurs predominantly on serine 
residues. Specific phosphorylation sites have been located at serine residues 51 (13) 
and 208 (15) of the vitamin 0 receptor. 
Although the exact function of the receptor phosphorylation is not clearly 
defined, several studies have shown that phosphorylation affects the transcriptional 
activation capacity of the vitamin 0 receptor complex (13,14,16-18). 
2.2.3 Vitamin D response elements 
A vitamin 0 response element is a nucleotide sequence located in the 
regulatory region of a gene, that is recognized by the DNA-binding domain of the 
vitamin 0 receptor. These sequences mediate the responsiveness of a gene to 1,25-
dihydroxyvitamin 0 3 through its receptor. The vitamin 0 response element is 
structurally similar to the general steroid hormone response elements. 
Response elements are organized in two half-sites of 6 conserved nucleotides 
which are directly adjacent to each other or spaced by 1-5 unconserved nucleotides. 
The nucleotide sequence, orientation of the half-sites (direct repeat, palindromic, or 
inverted palindromic), and the spacing between the half-sites dictate selective 
recognition of the receptor. Vitamin 0 response elements have been identified in 
several genes that are induced by 1,25-dihydroxyvitamin 0 3 (Table 2.1). Generally, 
the vitamin 0 response element is an imperfect direct repeat of 6 nucleotides 
separated by a 3-nucleotide spacer. 
Receptors bind to their response elements as dimers, with each part of the 
dimer binding one half-site of the response element. The vitamin 0 receptor binds 
the vitamin 0 response element as a heterodimer with the retinoic acid receptor X-
type (the retinoic X receptor). Alternatively, the vitamin 0 receptor may act as a 
homodimer or as a heterodimer with other, still unidentified nuclear accessory factors 
(8,11,19). 
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Table 2.1. Vitamin D response elements 
Gene 
Rat osteocalcin 
Human osteocalcin 
Mouse osteopontin 
Rat calbinrun D9K 
Rat 24-hydroxylase I 
Rat 24-hydroxylase II 
Mouse calbindin D28K 
Human PTH 
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Vitamin D response element 
GGGTGA ATG AGGACA 
GGGTGA ACG GGGGCA 
GGTTCA CGA GGTTCA 
GGGTGT CGG AAGCCC 
CGCACC CGC TGAACC 
GCGGGA GTG AGTGGA 
GGGGGA TGTG AGGAGA 
... TGAACC T ... 
Most vitamin D response elements (VDREs) involved in activation of gene expression are imperfect 
direct repeats of 6 nuc1eotides separated by a 3-nuc1cotide spacer. Exceptions are the mouse 
osteopontin VDRE that has two identical half-sites and tbe mouse ca1bindin D28K VDRE tbat has a 
4-nuc1eotidc spacer. The human PTH VDRE is the fust example of a VDRE that mediates 
suppression of gene transcription. 
2.2.4 Modulation of gene expression by 1,25-dihydl'oxyvitamin D3 
The 1,25-dihydroxyvitamin D3-receptor complex, once bound to the vitamin D 
response element, can either stimulate or repress the transcription rate of a target 
gene, thus resulting in an increased or decreased production of a mRNA species. This 
mRNA molecule is translated into a protein product, which after being processed, is 
ultimately responsible for the biological activity of 1,25-dihydroxyvitamin D3 (Fig. 2.4). 
It is not completely understood how the activated steroid hormone receptor, 
once positioned on the right promoter, activates gene transcription. Gene 
transcription involves the assembly of a stable preinitiation complex near the 
transcription start site. This complex is composed of multiple transcription initiation 
factors which interact with the DNA and/or with each other. When all factors are 
present RNA polymerase II can initiate the transcription of the target gene. Steroid 
receptors might stabilize the preinitiation complex, or stimulate the assembly of the 
complex. These interactions might involve co-activators that serve as a bridge between 
the receptor and the transcription initiation complex (7,9-11). 
The mechanism behind negative regulation of transcription is also not well 
understood. For the human parathyroid hormone gene a distinct vitamin D response 
element (Table 2.1) has been identified, which suppresses gene expression in the 
presence of cell specific factors (20). In the osteocalcin promoter, the consensus 
sequence (AP-I site) for the nuclear protooncogene encoded Fos and Jun proteins 
9 
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overlaps the vitamin 0 receptor binding domain, and thereby one regnlator (Fos-Jun 
dimer) may prevent the other regnlator (1,25-dihydroxyvitamin D3-receptor complex) 
from promoting transcription. Also, alternative mechanisms for hormonal repression 
have been proposed, e.g. a heterodimerization between the occupied receptor 
monomer and another nuclear factor, thereby preventing DNA binding or gene 
activation (9-11,21). 
Upstream activating 
sequences 
Induced or 
repressed genes 
1.25·(OH),D3 
~ 
RNA synthesis 
~ 
processing 
~ 
-----+ BIOACTIVE 
PROTEINS mRNA 
Figure 2.4. General mechanism of action of 1,25-dihydroxyvitamin D3. R 
receptorj Rs := occupied (phosphorylated) receptor 
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Table 2.2. A selection of vitamin D regulated genes 
Gene or gene product Regulation VDRE Gene or gene product Regulation VDRE 
MInerai nnd bone metabolism Hormone and cytokine production 
Calbindin D9K pos. yes Parathyroid hormone neg. yes 
Calbindin D28K pos. yes Calcitonin neg. no 
CoUagcn type I neg. yes Intcrleukin II neg. no 
24·Hydroxylase pos. yes Tumour necrosis factor a pos. no 
Osteocalcin pos. yes Proliferation and diITerentiation 
Osteopontin pos. yes fos pos. no 
Vitamin D receptor pos. no fms pos. no 
Fibronectin pos. nn myb neg. nn 
mye neg. nn 
histone H4 neg. no 
An extensive number of genes arc regulated by vitamin D. A selection of vitamin D regulated genes 
are indicated to illustrate the diversity of these genes, For references see Darwish and De Luca (11), 
Minghetti and Norman (22), and Walters (23). VDRB, vitamin D response element identified; 
pos.jneg., positive/negative regulation of gene expression. 
2.2.5 Vitamin D regulated 'genes 
Several vitamin D regulated genes have thus far been identified in a number of 
different cell types and tissues from several species. These genes are associated with 
divergent functions, like mineral homeostasis, the metabolism of vitamin D, the 
secretion of peptide hormones, cellular proliferation and differentiation. A number of 
vitamin D regulated genes are shown in Table 2.2. 
Despite the extensive number of genes and proteins that appear to be regulated 
by 1,25-dihydroxyvitamin D3, evidence that the hormone directly modulates gene 
transcription exists only for some of these genes. Direct evidence achieved via the 
identification of a functional vitamin D response element has been obtained for the 
genes mentioned in Table 2.1. 
2.2.6 Non~genomic mechanisms of action of vitamin D 
1,25-Dihydroxyvitamin D3 has been shown to regulate intracellular signalling 
processes, which have previously been associated with the signal transduction by 
polypeptide hormones through binding to their membrane-bound receptors. In a 
variety of tissues 1,25-dihydroxyvitamin D3 has been shown to exert rapid effects 
11 
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(within a few minutes) on intracellular calcium levels, phospholipid metabolism, and 
protein kinase C activity, which were insensitive to RNA and protein synthesis 
inhibitors (23-25). In the intestine, 1,25-dihydroxyvitamin D3 induces a rapid 
stimulation of calcium transport, termed transcaltachia, which is also insensitive to 
RNA and protein synthesis inhibitors (26). 
These data have indicated that the classical steroid hormone mechanism of 
action may not be the only mechanism by which 1,25-dihydroxyvitamin D3 mediates 
cellular responses. To account for these apparently non-genomic actions a membrane-
bound vitamin D receptor has been suggested, which may act in analogy to peptide 
hormone receptors (25). Recently, a 1,25-dihydroxyvitamin D3 receptor has been 
isolated from the basal lateral membrane of chick intestinal epithelium, which is 
implicated in transcaltachia (27). However, in a number of other systems, genomic 
effects seemed to be involved in the 1,25-dihydroxyvitamin D3-induced changes of 
intracellular signalling processes (23). In these cases the 1,25-dihydroxyvitamin D3-
induced calcium influx was slow and sustained, and abolished by RNA and protein 
synthesis inhibitors. Also, several reports have shown that 1,25-dihydroxyvitamin D3-
induced changes in phospholipid biosynthesis were sensitive to RNA and protein 
synthesis inhibitors, and a report of Obeid et al. (28) showed that 1,25-
dihydroxyvitamin D3 induces protein kinase C gene transcription. 
2.3 1,2S-DIHYDROXYVITAMIN D3 REGULATES MINERAL AND 
BONE METABOLISM 
2.3.1 Maintenance of mineral homeostasis 
The principal physiological role of 1,25-dihydroxyvitamin D3 is the regulation of 
plasma calcium and phosphate levels. This is achieved through actions on the 
intestine, kidney, and bone. The main action of 1,25-dihydroxyvitamin D3 is to 
stimulate the absorption of dietary calcium and phosphate from the intestine. Further, 
1,25-dihydroxyvitamin D3 modulates calcium and phosphate reabsorption in the 
kidney, and when the dietary calcium intake is insufficient, 1,25-dihydroxyvitamin D3 
mobilizes calcium from bone. 
1,25-dihydroxyvitamin D3 works in concert with parathyroid hormone. A low 
serum calcium concentration stimulates the parathyroid glands to secrete parathyroid 
hormone. This hormone acts on bone and kidney to increase the serum calcium 
concentration. In addition, parathyroid hormone increases the serum calcium 
concentration indirectly via the stimulation of 1,25-dihydroxyvitamin D3 synthesis in 
12 
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the kidney (see Section 2.1.2). 1,25-Dihydroxyvitamin D3 and an elevated serum 
calcium concentration suppress the production of parathyroid hormone in a negative 
feedback loop (1,3,29). 
2.3.2 Bone metabolism 
Bone tissue undergoes constant remodelling which is mediated by the bone 
resorbing cells, the osteoclasts, and the bone forming cells, the osteoblasts. Under 
normal conditions bone resorption and bone formation are in equilibrium. 1,25-
Dihydroxyvitamin D3, parathyroid hormone and a variety of other local and systemic 
factors regulate these dual processes. 
1,25-Dihydroxyvitamin D3 is an essential hormone for bone mineralization as 
well as a potent bone resorbing agent. 1,25-Dihydroxyvitamin D3 promotes the 
mineralization of bone indirectly by providing calcium and phosphorus (see Section 
2.3.1). On the other hand, 1,25-dihydroxyvitamin D3 influences the action of the 
osteoblasts, which possess vitamin D receptors. A variety of effects of 1,25-
dihydroxyvitamin D3 on osteoblasts have been reported, e.g. regulation of osteoblast 
proliferation, regulation of the production of alkaline phosphatase, osteocalcin, 
osteopontin, and pro collagen type I. 
The osteoclasts are responsible for bone resorption. 1,25-Dihydroxyvitamin D3 
does not exert direct effects on osteoclasts, which lack vitamin D receptors, but 
influences the osteoblasts to secrete as yet uncharacterized factors that activate 
osteoclasts to resorb bone. Additionally, 1,25-dihydroxyvitamin D3 plays a role in 
osteoclastgenesis (see Section 2.4.2) and thereby influences the bone resorptiou 
process on the long term (1,3,30,31). 
2.4 1,25.DIHYDROXYVITAMIN D3 MODULATES CELLULAR 
PROLIFERATION AND DIFFERENTIATION: TIlE BASIS OF 
NEW CLINICAL APPLICATIONS 
2.4.1 Tissue distribution of the vitamin D receptor 
The vitamin D receptor is not confined to tissues that play recognized roles in 
mineral metabolism, like intestine, kidney, bone, and parathyroid gland. Also a wide 
variety of tissues not primarily related to calcium and bone metabolism have been 
shown to express the vitamin D receptor. In addition to normal tissues and organs, 
the vitamin D receptor has been demonstrated in a number of malignant cell types. 
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Given the widespread tissue distribution of the vitamin D receptor, there are many 
putative target tissues for 1,25-dihydroxyvitamin D3 (1,23). 
2.4.2 Haematopoietic cells 
A role of 1,25-dihydroxyvitamin D3 in the differentiation of haematopoietic 
stem cells was suggested in 1981 by Abe and coworkers (32). They have demonstrated 
that immature mouse myeloid leukaemia cells differentiated towards more mature 
macrophage-like cells. This differentiation process was accompanied by a reduced 
growth rate. These observations were later extended to human leukaemic cell lines, 
and currently the cell lines HL60 (human promyelocytic leukaemia) and U937 
(human histiocytic lymphoma) are frequently used to study the effects of vitamin D3 
compounds on haematopoietic differentiation and proliferation. 
These ill vitro studies suggested that 1,25-dihydroxyvitamin D3 may be of clinical 
use in the treatment of leukaemia, since the hormone may induce the abnormal 
haematopoietic cells to differentiate into more mature, less aggressive cells. Honma 
and coworkers (33) suggested for the first time that a differentiation therapy with 
1,25-dihydroxyvitamin D3 may be operative ill vivo: the survival of athymic mice that 
had been inoculated with mouse myeloid leukaemia cells was prolonged significantly 
by the administration of la-hydroxyvitamin D3. 
In addition to leukaemic cells. 1,25-dihydroxyvitamin D3 induces differentiation 
of normal bone marrow cells. Immature bone marrow cells of the monocyte-
macrophage lineage are believed to be precursors of the osteoclasts. 1,25-
dihydroxyvitamin D3 induces differentiation of immature myeloid cells towards 
monocytes-macrophages, and also activation and fusion of some macrophages. From 
these results is has been postulated that 1,25-dihydroxyvitamin D3 stimulates 
differentiation and fusion of osteoclast progenitors into osteoclasts (31,34). Thus, the 
differentiation inducing capacity of 1,25-dihydroxyvitamin D3 may also play an 
important role in the regulation of calcium and bone metabolism. 
1,25-Dihydroxyvitamin D3 has been shown to affect a wide range of specific 
functions of haematopoietic cells, e.g. it has been shown to inhibit the production of 
interleukin-2. interferon-gamma, and granulocyte-macrophage colony-stimulating 
factor by activated T cells, to inhibit the production of immunoglobulins by activated 
B cells, and to modulate the production of tumour necrosis factor-a and interleukin-l 
by monocytes (35-38). Although dependent on the culture conditions and mode of 
activation, the ill vitro effects of 1,25-dihydroxyvitamin D3 are mainly 
immunosuppressive. By contrast, the effects of 1,25-dihydroxyvitamin D3 on immune 
responses ill vivo are more complex. In patients, a 1,25-dihydroxyvitamin D3 deficient 
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or resistant state is associated witb an impaired ratber tban enbanced immunity, 
indicating a role of vitamin D in sustaining normal functions of the immune system. 
On the other hand, an immunosuppressive effect of 1,25-dihydroxyvitamin D3 
administration bas been observed in animal models for autoimmunity and 
transplantation (35-38). 
2.4.3 Skin 
The skin may be another tissue in which 1,25-dihydroxyvitamin D3 exerts effects 
on cellular growth and differentiation. 1,25-Dihydroxyvitamin D3 causes a decrease in 
proliferation and an increase in the morphological and biochemical differentiation of 
cultured keratinocytes (34,39). 
In psoriasis the normal proliferation and maturation of epidermal cells is 
disturbed, resulting in a hyperproliferative state, and in addition, inflammatory 
processes are involved in this skin disease. Both processes represent potential targets 
for 1,25-dihydroxyvitamin D3. The realization that 1,25-dihydroxyvitamin D3 may have 
a role in the treatment of psoriasis, came from a case report of Morimoto el al. (40) 
in which a woman, treated with 1,,-hydroxyvitamin D3 for osteoporosis, had a 
dramatic remission of her psoriasis. This report was followed by a number of 
promising clinical studies with 1,25-dihydroxyvitamin D3, 1,24-dihydroxyvitamin D3, 
and 1,,-hydroxyvitamin D3, given orally or applied topically (38,41,42). 
A problem of treatment with these vitamin D3 metabolites is the risk of 
calcium-related side-effects. 111is applies both for oral and topical administration as 
vitamin D3 is absorbed by the skin. Calcipotriol (MC903) is a synthetic 1,24-
dihydroxyvitamin D3 analogue containing a double bond and a cyclopropane ring in 
the side-chain (Fig. 2.5). These modifications result in a rapid conversion into inactive 
metabolites when given intravenously to rats (43). Therefore, calcipotriol is less 
suitable for systemic treatment. However, clinical studies have indicated that topical 
application of calcipotriol ointment is an effective and safe drug for the treatment of 
mild to moderate psoriasis (38,41,42). Calcipotriol ointment (Daivonex, LEO 
Pharmaceutical Products) is now registrated as treatment of psoriasis in many 
countries. 
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Tllble 2,3.111 vivo effects of 1,25-dihydroxyvitamin D3 and la-hydroxyvitamin D3 in animal models for 
cancer 
Tumour Model Administrationa Effect Ref. 
Breast NMUb·induced breast 1a-(OH)D,', Tumour suppression 51 
cancer in rats Lp. 
Breast DMBAc·induced breast 1a-(OH)D3' Tllmour suppression 58 
cancer in rats orally 
Colon Human colon cell line 1,25-(OH)2D,., Tumour suppression 56,57 
implanted into nude Lp. 
mice 
Colon DMHd.induced colon 1,25-(OHhD3' Reduction of the 63 
cancer in rats s.c, incidence of colon 
adenocarcinomas 
Leydig tumour Leydig cell tumour 1,25-(OHhD3' Tumour suppression 60 
implanted into fats osmotic minipumps 
Lung Implantation of Lewis 1a-(OH)D3, Reduction of the 54 
lung carcinoma into stomach tube number of metastases 
mice (without suppression of 
primary tumour) 
Lung Implantation of lung 1,25-(OHhD3' Reduction of the 59 
carcinoma cells into i.p. number of metastases 
mice (without suppression of 
primary tumour) 
Melanoma Human melanoma cells 1,25-(OH),o3' Tumour suppression 56 
implanted into nude i.p. 
mice 
Osteosarcoma Human osteosarcoma 1a-(OH)D3, Tumour suppression 62 
cells implanted into j.p. 
nude mice 
Retinoblastoma Retinoblastoma cell line 1,25-(OHhD3' Tumour suppression 55 
implanted into nude Lp. 
mice 
Retinoblastoma Transgenic mice with 1,25-(OHhD3' Tumour suppression 61 
retinoblastoma Lp. 
Skin DMBA/TPA' -induced 1,25-(OHhD3' Inhibition of tumour 52 
skin tumours in mice topical formation 
Skin DMBA/TPA-induced 1,25-(OHhD3' J nhibition of tumour 53 
skill tumours in mice topical formation 
aThe dosage, duration of treatment, diet, and effects on serum/urinary calcium vary between the 
studies; bNMU, nitrosomcthylurca; cDMBA, 7,12-dimethylbenz[a]anthraccne; dDMH, 1,2-dimethyl-
hydrazine dihydrochloride; eTPA, 12-0-tetradecanoylphorbol-13-acetate; f1a-(OH)D3, la-hydroxy-
vitamin 03; gl,25-(OH}z03. 1,25-dihydroxyvitamin °3, 
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2.4.4 Carcinoma cells 
Receptors for 1,25-dihydroxyvitamin D3 have been demonstrated in a variety of 
non-leukaemia cancer cell lines. Analogous to its effects on leukaemic cell lines, 1,25-
dihydroxyvitamin D3 induces differentiation and/or inhibits the proliferation of a wide 
variety of cell lines that have been established from solid tumours, including breast 
(44,45), colon (46,47), prostate (48,49), and melanoma (44,50). Several in vivo studies 
have cordirmed the anti proliferative action observed in vitro. Table 2.3 summarizes 
the effects of 1,25-dihydroxyvitamin D3 and lor-hydroxyvitamin D3 in animal models 
for cancer. 
2.5 DEVELOPMENT OF NEW VITAMIN D3 ANALOGUES 
2.5.1 Rationale 
As discussed in Section 2.4, there are new putative applications for 1,25-
dihydroxyvitamin D3 in the treatment of hyperproliferative disorders and immune-
mediated diseases. However, the major problem is that higher than physiological 
doses of 1,25-dihydroxyvitamin D3 are required to be effective. Thus, the use of 1,25-
dihydroxyvitamin D3 is restricted by a considerable risk on severe complications, like 
hypercalcaemia, calciuria, soft tissue calcification, and increased bone turnover. 
To overcome these problems several pharmaceutical companies have developed 
new synthetic vitamin D3 analogues in order to improve the selectivity of the 
hormone and to reduce the dosage needed. The clinical potential of the hormone will 
increase when vitamin D3 analogues are available that have potent antiproliferative 
and differentiation inducing effects, or potent immunosuppressive effects, whereas the 
effects on calcium and bone metabolism are reduced (38,64). 
2.5.2 III vitro and ill vivo activity of new vitamin D3 analogues 
The majority of the new vitamin D3 analogues synthesized have modifications in 
the side-chain of the 1,25-dihydroxyvitamin D3 molecule (Fig. 2.5). Their ability to 
decrease proliferation and enhance differentiation is usually tested using the 
leukaemic cell lines U937 and HL60, which have well-defined differentiation markers. 
In Table 2.4 the ill vitro growth inhibitory and differentiation inducing potential of 
some of the main analogues are compared to those of the native compound 1,25-
dihydroxyvitamin D3. Although the maximal inhibition of these analogues is not 
dramatically increased, the median effective concentrations (EC50) of the analogues 
are sometimes several orders of magnitude lower. 
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Figure 2.5. Side-chain modifications of l,25-dihydroxyvitamin D3- The analogues shown are discussed in 
the text. MC903 is also referred to as calcipotriol, ocr as 22-oxa-calcilriol, and Ro24-5531 as 1a,25-
dihydroxy-16-ene-23-yne-26,27-hexafluoro-vitamin D3. Note that Ro24-553! has also a modification of the 
Dring. 
The calcaemic activity of new analogues is tested by measuring serum calcium 
levels and/or urinary calcium excretion of rodents treated with an analogue or, 
alternatively, by measuring the intestinal calcium absorption in rachitic chickens, The 
analogues that have an increased growth inhibitory potential, but a similar or even 
reduced calcaemic activity compared to 1,25-dihydroxyvitamin D3, offer promise for 
clinical applications (Table 2.4), Ultimately, these analogues have to be tested in 
animal models and in clinical studies to investigate whether the analogues inhibit 
tumour growth ill vivo. 
So far, only a few analogues have been tested in experimental animal models, 
The compound 1,25-dihydroxy-16-ene-23-yne-vitamin D3 (R023-7553) in.ceesed the 
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Table 2.4. Cell regulating and calcaemic activity of vitamin D3 analogues compared to 1,25-
dihydroxyvitamin D3 
RELATIVE TO 1,25.(OH),D, 
Inhibition of Induction of Calcaemic 
Vitamin D3 analogue proliferation differentiation activity 
1,25·(OH),o, 1 I 
CB966 8 5 0.2 
EB1089 68 67 0.4 
KHI060 14,000 200,000 1.3 
MC903 2 I om 
OCT 10 10 0.01 
Ro23·7553 4 2 0.03 
Ro24·5531 80 10 0.07 
Ref. 
72 
73 
72 
75 
74,78 
77 
76 
The effects on proliferation and differentiation were measured ill vitro using U937 or HUlO leukaemic 
cell lines. Based on the ECso values the relative potency compared to 1,25-dihydroxyvitamin D3 was 
determined. The calcaemic effects were determined ill vh'o by measuring serum calcium levels or 
urinary calcium excretion in rats or mice, or by measuring the intestinal calcium absorption in 
chickens. The chemical structures of the analogues are shown in Figure 2.5, with the exception of 
Ro23-7553, which is 1,25-dihydroxy.16·ene·23·yne-vitamin D3. 
survival time of mice inoculated with leukaemic cells, whereas no measurable 
hypercalcaemia developed (65). The analogue EB1089 prolonged the survival time of 
rats implanted with Leydig tumours (60). Further, the analogues 22·oxa·calcitriol 
(OCT) (66,67), EB1089 (68,69), CB966 (68), and 1",2S·dihydroxy.16·ene·23-yne-Z6,27-
hexafluoro-vitamin D3 (R024-SS31) (70) have shown promising results after systemic 
treatment of rats with mammary tumours. The mammary tumour models are further 
discussed in Section 3.5. In the only clinical study, which reported tumoursuppressive 
effects of vitamin D3 analogues, it was shown that topical application of calcipotriol 
(MC903) on cutaneous deposits did prove effective in some patients with advanced 
breast cancer (71). 
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2.5.3 Possible mechanisms for the selective actions of vitamin D3 analogues 
In this section I will discuss a number of mechanisms to explain how the action 
of a vitamin D3 analogue can differ from the action of 1,25-dihydroxyvitamin D3 in I) 
the activity, i.e. a specific biological response, like inhibition of cell growth, is 
achieved by lower concentrations of the analogue than of 1,25-dihydroxyvitamin D3, 
and 2) the selectivity, i.e. suppression of tumour growth without raising serum 
calcium. 
For a selective action on different target organs the pharmacological differences 
between the analogues and 1,25-dihydroxyvitamin D3 are believed to play an 
important role. In serum the binding of the analogues to the vitamin D binding 
protein may affect the biological half-life of the analogues. A decreased binding may 
result in a rapid clearance of the analogue resulting in a decreased biological activity. 
On the other hand, low binding may result in a higher concentration of free, 
biologically available analogue compared to 1,25-dihydroxyvitamin D3 (79,80). The 
transport of analogues may also proceed via other carrier proteins than the vitamin D 
binding protein. The analogue 22-oxa-calcitriol mainly circulates in the blood bound 
to lipoproteins, resulting in an altered pharmacokinetic profile compared to 1,25-
dihydroxyvitamin D3 (81). Thereby, an altered transport may account for a selective 
action on different target tissues. 
Each action of the vitamin D3 compounds has a distinct biological half-life. For 
example, Brown et a/. (82) have shown that the rate of calcium transport returns to 
pretreatment levels within a few hours after 22-oxa-calcitriol disappears from the 
circulation. However, 22-oxa-calcitriol has much more prolonged effect on other 
processes such as induction of calbindin D9K mRNA and 24-hydroxylase activity, and 
suppression of PTH secretion and l,,-hydroxylase activity. The short circulating half-
life of 22-oxa-calcitriol might exploit the differences in the biological half-life between 
calcium transport and other processes to provide a selective action. 
An altered metabolism at cellular level might contribute to the altered activity 
of vitamin D3 analogues. Modifications in the side-chain influence the catabolism of 
the molecule, because the side-chain is sensitive to oxidation. An impaired cellular 
metabolism may lead to an accumulation of the analogue in the target cell. 
Alternatively, the analogue may be metabolized intracellularly into an active 
metabolite, as has been reported for 26,27-hexafluoro-I,25-dihydroxyvitamin D3 (83). 
An additional factor involved in the selectivity of the analogues might be a 
differential intracellular metabolism in different target tissues. For example, the 
ability to degrade 22-oxa-calcitriol or 1,25-dihydroxyvitamin D3 was shown to differ 
between normal monocytes and parathyroid cells (84). 
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The vitamin D receptor may~~play_an important role in the selectivity and 
activity of the vitamin D compounds. An increased binding affinity to the vitamin D 
receptor could theoretically result in an increased activity. However, data obtained so 
far have shown no direct correlation between receptor binding and the biological 
activity of the analogues. Nevertheless, the presence of a vitamin D receptor seems to 
be essential for biological activity of 1,25-dihydroxyvitamin D3 or vitamin D3 
analogues, since vitamin D receptor-negative cells are insensitive to the action of 
vitamin D3 compounds (56,85). A selective action may be achieved via different types 
of the vitamin D receptor in the various target organs. However, it is currently 
accepted that vitamin D receptors are identical in all cell types. 
Binding of an analogue instead of 1,25-dihydroxyvitamin D3 to the vitamin D 
receptor may induce a different conformational change of the vitamin D receptor 
complex. This may lead to alterations in DNA binding, dimerization, phosphorylation, 
and intracellular clearance of the receptor complex, thus resulting in an altered 
transcriptional activation. All these changes may cause cell- and gene-specific actions 
of vitamin D3 analogues and may alter the magnitude of the biological response. 
Finally, there may be a difference between 1,25-dihydroxyvitamin D3 and 
vitamin D3 analogues in the activation of intracellular signalling processeS via an 
apparently non-genomic mechanism of action (see Section 2.2.6). The contribution of 
these non-genomic processes to the ultimate biological response may vary between 
cell types. Thereby, a differential activation of non-genomic processes may result in a 
selective action (86,87). 
A number of possibilities have been mentioned to explain the selectivity and 
altered activity of some vitamin D3 analogues. However, the precise mechanism of 
action of the vitamin D3 analogues has not yet been unravelled. Besides, it is 
conceivable that the explanation will differ for each of the analogues. Further 
research in this complex area will lead to a better understanding of the mechanism of 
action of vitamin D3 analogues, which is important to enable investigators to optimize 
vitamin D3 analogues for a specific application. 
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Chapter 3 
3.1 BREAST CANCER 
Breast cancer is the most frequent cause of cancer deaths in women in the 
western world. Breast cancer incidence and mortality rates for women in the USA are 
approximately 11 % and 3 %, respectively. A number of risk factors have been linked 
to the development of breast cancer, and many of these are related to oestrogens. 
Other factors are age, family history, and location of the country of residence (1-3). 
Breast carcinomas derive from the epithelial lining of the milk ducts and the 
duct lobules. The tumour can either be confined within the ducts or lobules, or 
invades the surrounding tissue and gives rise to distant metastases. Many studies have 
tried to identify the causal factors responsible for the uncontrolled growth of the 
tumour cells. A variety of biochemical and genetic changes have been identified in 
breast carcinomas, and a wide range of factors have been shown to influence breast 
cancer growth. However, the exact mechanism of breast cancer development and 
progression has not been unravelled. The heterogeneity of the disease on the clinical, 
biological, and genetic levels further complicates this research. 
3.2 SUNLIGHT AND BREAST CANCER INCIDENCE 
Descriptive epidemiological studies have indicated that vitamin D might playa 
protective role against breast cancer. Incidence and mortality of breast cancer vary 
considerably world-wide and reveal a geographical pattern. The lowest rates of breast 
cancer generally occur in countries close to the equator. AI) the latitude increases, 
reported breast cancer incidence and mortality rates also increase. Studies in the USA 
and the former USSR have shown a negative correlation between available sunlight 
and breast cancer death rates. Sunlight exposure is a measure of vitamin D produced 
in the skin (see Section 2.1.1). Further, it is known that the primary source of vitamin 
D for adults in the USA is casual exposure to sunlight. Therefore, it has been 
hypothesized that vitamin D formed in the skin may reduce the risk of breast cancer 
(4,5). 
3.3 THE VITAMIN D RECEPTOR IN BREAST CANCER 
The presence of the vitamin D receptor in breast cancer was first demonstrated 
in the human breast cancer cell line MCF-7 (6). Later studies have extended this 
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finding to other breast cancer cell lines and to surgically obtained normal breast and 
breast tumour tissue (7). 
The vitamin 0 receptor is present in approximately 80 % of human breast 
tumour specimens. The presence of the vitamin 0 receptor is not correlated to the 
presence of other steroid hormone receptors (oestrogen receptor, progesterone 
receptor) (8-11). Also, no relationship was observed between vitamin 0 receptor 
status and clinical indices (age, menopausal status, T-stage, histology, Iymphnode 
involvement) and overall survival (9-12). However, two studies reported that the 
receptor status correlated positively with disease-free interval (11,12). 
Regulation of the vitamin 0 receptor number may affect the cellular 
responsiveness to 1,2S-dihydroxyvitamin 0 3, the active form of vitamin 0 3, In a 
number of different systems regulation of the vitamin 0 receptor by 1,2S-
dihydroxyvitamin 0 3 itself (homologous upregulation), and by hormones and growth 
factors has been demonstrated (13-IS). In breast cancer a homologous upregulation of 
the vitamin 0 receptor has been observed in MCF-7 cells (16), and a heterologous 
upregulation by serum, growth factors (EGF, insulin, IGF-I), and oestradiol was 
noticed in MCF-7 and T47-0 cells (17,18). 
3.4 VITAMIN D INHIBITS THE GROWTH OF CULTURED BREAST 
CANCER CELLS 
Breast cancer cell lines have been established from primary breast tumours and 
pleural effusions of patients with advanced breast cancer. These cell lines have been 
proven to be very useful in studies of regulation of cell growth by steroid hormones 
and polypeptide growth factors. A number of cell lines have been widely used as 
models of oestrogen-responsive breast cancer, because they contain oestrogen 
receptors and their growth is stimulated by oestrogens. Oestrogen receptor-negative 
cell lines provide an in vitro model for oestrogen unresponsive breast cancer. 
The first studies on the effect of 1,2S-dihydroxyvitamin 0 3 on breast cancer 
cells showed a biphasic growth respoI15e of the oestrogen receptor-positive T47-0 
human breast tumour cell line. At low concentrations (10-11 M) a stimulation of cell 
growth was observed, whereas at higher concentrations (10-8 M) an inhibition was 
observed (7,19,20). The presence of a biphasic effect and the extent of the growth 
inhibition was shown to be dependent on the culture conditions, i.e. the concentration 
and charcoal treatment of foetal calf serum supplemented to the culture medium 
(7,20,21). 
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Table 3.1. Inhibition of breast cancer ceil gcmvth by vitamin D3 analogues 
Vitamin D3 Breast cancer Oestrogen Relative potency compared 
analogue ccllline receptor status (0 1,25-(OH),D3 Ref. 
ocr MCF-7 ER-pos. approx. 10 22 
ZR-75-1 ER-pos. 
T47-D ER-pos. 
MDA-MB-231 ER-neg. 
BT-20 ER-neg. 
EB1089 MCF-7 ER-pos. 50 25 
KH1060 T47-D ER-pos, 800 27 
MC903 MCF-7 ER-pos. 1 28 
R024-5531 MCF-7 ER-pos. 10 - 100 26 
T47-D ER-pos. 
Based on the ECso values for the growth inhibition, the relative potency compared to 1,25-
dihydroxyvitamin D3 was measured. A relative potency of 1 means equally potcnt as 1,25· 
dihydroxyvitamin D3- The chemical structures of the vitamin D3 analogues are shown in Fig. 2.5; 1,25-
(OHhD3' l,25-dihydroxyvitamin D3; ER-pos./-neg' j oestrogen receptor-positive/-negative. 
The growth inhibitory effect of 1,25-dihydroxyvitamin D3 was confirmed in 
other breast tumour cell lines and shown to be independent of the oestrogen receptor 
status (21,22). Treatment with 1,25-dihydroxyvitamin D3 resulted in morphological 
changes, which may resemble a more differentiated status of the cells (20,23,24). 
A few studies have demonstrated antiproliferative effects of synthetic vitamin 
D3 analogues on breast cancer cells. These analogues have been shown to be more 
potent than 1,25-dihydroxyvitamin D3 in the growth inhibition of leukaemic cells, 
whereas their in vivo calcaemic activity was similar or even reduced compared to 1,25-
dihydroxyvitamin D3 (see Section 2.5.2). The results are summarized in Table 3.1. 
3.5 IN VIVO TUMOUR SUPPRESSION BY VITAMIN D 
Several animal models for breast cancer are being used. Mammary tumours can 
be induced in rats by oral administration of the carcinogens N-nitroso-N-methylurea 
(NMU) or 7,12-dimethylbenz[aJanthracene (DMBA). NMU- and DMBA-indllced 
tumours form a model for hormone-dependent tumours as they contain considerable 
amounts of oestrogen receptors and regress on ovariectomy and antioestrogen 
treatment (29,30). The presence of the vitamin D receptor has been demonstrated in 
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NMU tumours (31). In the nude mice model, immunedeficient athymic mice are 
inoculated subcutaneously with human breast cancer cells derived from continuous 
cell cultures. Alternatively, transplantable breast tumours can be propagated ill vivo in 
the nude mice model. Both oestrogen· dependent and oestrogen-independent tumours 
can be studied in the nude mouse model (32). 
Oral or intraperitoneal administration of 1,25-dihydroxyvitamin 03 or la-
hydroxyvitamin 03' which is rapidly converted to 1,25-dihydroxyvitamin 03 in the 
liver, resulted in an inhibition of the growth of NMU- (12,28) and OMBA-induced rat 
mammary tumours (33,34). By contrast, Noguchi el al. (35) did not find an effect of 
1,25-dihydroxyvitamin 03 on the incidence and growth of OMBA-induced rat 
mammary tumours. In the latter study, 1,25-dihydroxyvitamin 03 was applied on 
shaved dorsal skin at doses that produced mild hypercalcaemia. 
In order to achieve tumour suppression, high doses of 1,25-dihydroxyvitamin 03 
or la-hydroxyvitamin 03 were needed. TIlese high doses, approximately 0.5 I'g/kg 
BW, resulted in the development of hypercalcaemia and subsequent weight loss. In an 
attempt to overcome this problem, synthetic vitamin D3 analogues with low il/ vivo 
calcaemie activity have been developed (see Section 2.5.2). So far, only a few 
analogues have been evaluated for their potential use in the treatment of breast 
cancer. The data are summarized in Table 3.2, and show that with some analogues 
indeed an inhibition of tumour growth can be achieved, without raising serum calcium 
levels. 
To date, only one clinical study on the effect of vitamin D3 analogues on cancer 
growth in humans has been reported. Topical application of calcipotriol (MC903) in a 
small group of patients with locally advanced or cutaneous metastatie breast cancer 
showed a reduction of the size of treated lesions in 4 of 14 patients (36). 
3.6 CURRENT THERAPIES FOR BREAST CANCER 
Surgery and radiotherapy are used for treatment of the primary breast 
carcinoma and localized lesions. Endocrine and chemotherapy are given as systemic 
adjuvant therapy as part of the primary treatment, or for the treatment of advanced 
breast cancer, in order to manage distant (micro)metastases. Endocrine therapy is 
generally preferred, because in most cases it has lower toxicity and morbidity than 
chemotherapy. Chemotherapy is used for patients with aggressive or hormone 
receptor-negative tumours. In addition, patients failing to respond to, or relapsing 
after endocrine therapy are given chemotherapy (41,42). 
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Currently, a number of hormonal agents are used for endocrine treatment of 
breast cancer, namely antioestrogens, progestins, aromatase inhibitors, androgens, 
luteinizing hormone relea;ing hormone (LHRH) agonists, corticosteroids, and even 
high doses of oestrogens (41,43). The antioestrogen tamoxifen is the most widely used 
endocrine agent. Tamoxifen is effective in prolonging both disease-free interval and 
overall survival and has few side-effects. About one-third of all patients with breast 
cancer will respond to tamoxifen therapy. Patients with mammary carcinomas that are 
both oestrogen receptor- and progesterone receptor-positive display response rates of 
approximately 70 % compared to response rates of less than 20 % in patients with 
mammary carcinomas that are oestrogen receptor- and progesterone receptor-
negative (41,43,44). A major problem of tamoxifen therapy is that in case of response, 
the tumour almost inevitably progresses to a tamoxifen-resistant state during 
prolonged therapy. Further, long-term tamoxifen therapy has been linked to an 
increased risk on endometrial cancer. Despite the efficacy of tamoxifen for breast 
cancer, alternative endocrine therapies are warranted, especially for tamoxifen-
resistant and oestrogen receptor-negative tumours. 
3.7 COMBINATION THERAPIES WITH VITAMIN D: IN VITRO AND 
IN VIVO LABORATORY RESULTS 
The data obtained with 1,25·dihydroxyvitamin D3 and synthetic vitamin D3 
analogues offer promise for the use of vitamin D in endocrine treatment of oestrogen 
receptor-positive and -negative breast cancer. Single agent treatment with a low 
calcaemic vitamin D3 analogue could provide a new endocrine therapy, however, a 
combination therapy with established endocrine or cytotoxic agents may offer 
additional advantages, e.g. better response rates, lower dosages needed and thereby 
reducing the risk of negative side-effects. 
Several ill vitro and ill vivo studies have focused on possible future combination 
therapies with vitamin D3 compounds. Recently, Abe-Hashimoto et al. (39) observed 
a synergistic antiproliferative effect of submaximum dosages of 22-oxa-calcitriol and 
tamoxifen in MCF-7 and ZR-75-1 breast cancer cells. In addition, a synergistic action 
of 22-oxa-calcitriol and tamoxifen was observed ill vivo in athymic mice implanted 
with MCF-7 cells. Also, Demirpence et al. (45) and James et al. (46) observed an 
augmented inhibition of MCF-7 cell growth by combined treatment of vitamin D3 
compounds (l,25-dihydroxyvitamin D3 or the analogue BB 1089) and antioestrogens 
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Table 3.2, Antitumour effects of vitamin DJ analogues in animal models for breast cancer 
Vitamin D3 Effective dose Antitumour Calcaemic 
analogue Model (administration) effect effect Ref. 
ocr Athymic mice 0.Q1-1 pg/kg BW Tumour No rise in 22,39 
implanted with ER- (oral and suppression serUIll ea 
neg. MX -1 tumour intratumour) 
ocr DMBA-induced rat OJ, 1 pg/kg BW Tumour No rise in 37 
mammary tumour (Lm.) suppression serum ea 
ocr Athymic mice 0.001-1 pg/kg BW Tumour No rise in 39 
implanted with ER- (oral) suppression serum ea 
pos, MCF-7 cells 
MC903 NMU-induced rat 50 Irg/kg BW Tumour Small rise in 2S 
mammary tumour (Lp.) suppression serum ea 
EB1089 NMU-induced rat 0.5 pg/kg BW Tumour No rise in 38,40 
mammary tumour (oral) suppression serum ea 
CB966 NMU-induced rat 1 pg/kg BW Tumour Small risc in 40 
mammary tumour (oral) suppression serum ea 
R024-5531 NMU-induced rat 1.2 and 2.5 Decreased No rise in 26 
mammary tumour nmol/kg diet tumour serum Ca 
incidence 
The chemical structures of the vitamin D3 analogues are shown in Fig. 2.5. 
(tamoxifen or ICI182,780), compared with the action of the compounds alone. Anzano 
et al. (26) have studied a possible role of 1,25-dihydroxy-16-ene-23-yne-26,27F6-
vitamin D3 (R024-5531) in combination with low doses of tamoxifen for the 
prevention of breast cancer. They have observed Ihat R024-5531 significantly 
enhanced the ability of tamoxifen to reduce Ihe total tumour burden of rats treated 
with the carcinogen NMU. 
Also, combinations with other endocrine therapies than antioestrogens have 
been studied. In a study of lino et al. (33) la-hydroxyvitamin D3 (0.5 I'g/kg BW) was 
as effective as the progestin medroxyprogesterone acetate (MPA) (I mg/kg BW) in 
the DMBA-induced rat mammary tumour model. Although a combination therapy did 
not result in an enhanced antitumour effecl, MPA reduced the weight loss induced by 
]a-hydroxyvitamin D3. Vitamin A derivatives, like fenretinide, are currently tested in 
clinical trials as a preventive agent against recurrence of breast cancer, and animal 
studies point to a potential use of Ihese compounds as therapeutic agents for breast 
cancer (47). A combination of retinoic acid and 1,25-dihydroxyvilamin D3 was studied 
by Koga et al. (48) and they observed a synergistic growth inhibition of T47-D breast 
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cancer cells. 
Furthermore, combinations with vitamin 0 3 compounds and cytotoxic drugs 
have been studied. Abe et al. (22) have shown a more beneficial growth response by 
combined treatment with 22-oxa·calcitriol and adriamycin than by these agents alone, 
using athymic mice implanted with oestrogen receptor-negative MX-J breast tumours. 
lino et al. (33) have tested the effect of combined treatment with J,,-hydroxyvitamin 
0 3 and 5-fluorouracil in the OMBA-induced rat mammary tumour model. They have 
measured a similar tumour suppressive effect of 5-fluorouracil and J,,-hydroxyvitamin 
D3 after 4 weeks. However, the combination therapy did not result in an enilanced 
antitumour effect. Cho et al. (49) observed that low concentrations of carboplatin and 
cisplatin interacted synergistically with 1,25-dihydroxyvitamin 0 3 to inhibit MCF-7 cell 
growth. 
Finally, Hassan ef al. (50) have studied the effect of granulocyte-macrophage 
colony-stimulating factor (GM-CSF) on the antiproliferative effect of 1,25-
dihydroxyvitamin 0 3 in a MCF-7 clonogenic assay. They have observed that GM-CSF 
reduced the concentration of 1,25-dihydroxyvitamin 0 3 required to induce the same 
antiproliferative effect as in the absence of GM-CSF. 
3.8 MECHANISMS FOR THE ANTIPROLIFERATIVE ACTION OF 
VITAMIN D ON BREAST CANCER CELLS 
3.8.1 Modulation of oncogene expression 
Oncogenes affect cellular growth and differentiation through their protein 
products, which belong to various categories of the cell signalling machinery, such as 
growth factors, growth factor receptors, GTP-binding proteins, and nuclear proteins 
involved in transcription regulation (51,52). Oncogene expression at an inappropriate 
location or time period during cell cycle or maturation, overexpression of oncogenes, 
or mutations in oncogenes cause the transformation of cells in culture and induction 
of tumours in animals (51-53). A second class of cancer-related genes, the tumour 
suppressor genes, normally prevent tumour growth. Mutations or deletions in these 
genes cause their functional inactivation, which in turn contributes to cellular 
transformation (54,55). 
A number of oncogenes and tumour suppressor genes have been implicated in 
the development of breast cancer (Table 3.3). A large number of reports have 
described amplification and/or overexpression of the erbB-2, int-2, and myc 
oncogenes in a high percentage of human breast cancer specimens. Deletions or 
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mutations in the DNA of human breast cancer specimens have been associated with 
the tumour suppressor genes Rb and p53. The "int" oncogenes have been found 
adjacent to the mouse mammary tumour virus (MMTV) integration sites in mouse 
breast cancer. Furthermore, studies with transgenic mice have indicated causal 
relationships between the expression of myc, erbB-2, and Ha-ras and the development 
of breast tumours. Finally, specific point mutations in the Ha-ras oncogene have been 
detected in chemical-induced breast cancers in rodents (56-60). 
It has been proposed that oncogenes (and tumour suppressor genes) playa role 
in the tumour suppressive activity of vitamin 03 compounds. The role of oncogenes in 
the cell regulating activity of 1,25-dihydroxyvitamin 0 3 has been investigated most 
extensively in the leukaemic cell line HL60. In these cells 1,25-dihydroxyvitamin D3 
induced a progressive down-regulation of myc and a stimulation of fos and fms, which 
was initiated after approximately 4 hour of incubation and preceded the 
differentiation into monocyte-like cells and loss of proliferation capacity (61,62). In 
addition, 1,25-dihydroxyvitamin 03 modulated the expression of myc, fos, and jun in 
other cell types than HL60 cells (63-67). However, very little data are available on the 
regulation of oncogenes by 1,25-dihydroxyvitamin 03 in breast cancer cells. Only the 
report of Mathiasen el al. (25) describes a decreased myc expression after 3 hour, and 
a transient induction of fos expression with a maximum after 1 hour of 1,25-
dihydroxyvitamin 03 and EB1089 treatment of MCF-7 cells. 
Table 3.3. Oncogenes and tumour suppressor genes associated with breast cancer 
Oncogenes 
erbB·2 or HER-2 
int-2 
myc 
Ha·ras 
Tumour suppressor genes 
Rb gene 
p53 gene 
Description of gene product 
related to the epidermal growth factor receptor 
related to the fibroblast growth factor family 
nuclear protein 
G-protein 
nuclear phosphoprotein with DNA binding affInity 
nuclear phosphoprotein 
For reviews see Devilee and Cornelisse (56), Groner and Hynes (57), Mackay et af, (58), Van de 
Vijver and Nusse (59), and Groner (60), 
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3.8.2 Interaction with steroid hormones and polypeptide growth factors 
Breast cancer cell growth is regulated by steroid hormones, acting via nuclear 
steroid hormone receptors, and polypeptide growth factors, acting via membrane 
receptors. Steroid hormones (oestrogens, progestins) may act directly on the tumour 
cell to stimulate growth, or indirectly via regulation of growth factor production and 
growth factor receptors. Breast cancer cells secrete a number of growth factors 
including TGFa, TGFfl, IGF-I, IGF-II, and PO OF, which may act by autocrine loops, 
when the cells possess the adequate receptors. Alternatively, growth factors are 
derived from the circulation or are produced by stromal cells in the tumour and act 
by paracrine loops on breast cancer cells (68-71). 
1,Z5-0ihydroxyvitamin 03 may affect breast cancer cell growth by influencing 
these complex growth regulatory systems of steroid hormones and growth factors. 
I,Z5-0ihydroxyvitamin 03 may inhibit the secretion of stimulatory growth factors or 
stimulate the secretion of negative growth factors. Further, I,Z5-dihydroxyvitamin 03 
may regulate the number of growth factor or steroid receptors. In addition, I,Z5-
dihydroxyvitamin 03 may interfere with the action of steroid hormones on nuclear 
level, or with the intracellular signalling pathways of membrane bound growth factors. 
Studies of Oemirpence el al. (45) and James el al. (46) pointed to an 
interaction of 1,25-dihydroxyvitamin 03 with oestradiol. Both studies showed that 
I,Z5-dihydroxyvitamin 03 (and the vitamin 03 analogue EB1089) suppressed the 
mitogenic effect of oestradiol in MCF-7 cells. Further, it was shown that the 
oestrogen receptor concentration was decreased (46) and that oestrogen-induced gene 
transcription was inhibited (45) by treatment with 1,25-dihydroxyvitamin 03' 
There are some indications that 1,25-dihydroxyvitamin 03 can interfere with 
paracrine or autocrine acting growth factors in breast cancer. A possible interaction 
with a paracrine loop was suggested by Saez el al. (34), who have observed that MCF-
7 and BT-20 cells were growth stimulated by cocuHure with fibroblasts, whereas this 
process was reversed by I,Z5-dihydroxyvitamin 03 treatment. Furthermore, it has been 
shown that the number of EOF binding sites was decreased by 1,Z5-dihydroxyvitamin 
03 treatment in some breast cancer cell lines (MCF-7, T47-0), but increased in other 
cell lines (MOA-MB-231, BT-ZO) (34,72,73). As 1,25-dihydroxyvitamin 0 3 reduced the 
growth of all these cell lines, the relation between EGF receptor regulation and 
growth inhibition by 1,25-dihydroxyvitamin 03 is not clear. 
TGF-fl is a negative growth factor that is produced by breast cancer cell lines 
(74-76). In several cell systems interactions with TGF-fl and 1,25-dihydroxyvitamin 0 3 
have been described. For example, human keratinocytes treated with I,Z5-
dihydroxyvitamin 03 showed an increased expression of TGFfl, and the 
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antiproliferative activity of 1,25-dihydroxyvitamin D3 was partially blocked by 
neutralizing antibodies against TGF-Il (77). However, in breast cancer cells the effect 
of 1,25-dihydroxyvitamin D3 on TGF-Il production has not been studied in relation 
with the antiproliferative effects. Yet, one report described a stimulation of TGF-13 
secretion and TGF-13 mRNA expression by treatment with 1,25-dihydroxyvitamin D3 
and vitamin D3 analogues in BT-20 breast cancer cells (78). 
3.8.3 The mle of calcium 
Calcium (Ca2+) is an important intracellular regulatory molecule and acts as an 
intracellular messenger for extracellular signalling molecules. Because of the well-
known effects of 1,25-dihydroxyvitamin D3 on calcium translocation in the intestine, it 
has been suggested that the antiproliferative and differentiation inducing effects of 
1,25-dihydroxyvitamin D3 are mediated via the regulation of calcium-related 
processes. 
It has been demonstrated that 1,25-dihydroxyvitamin D3 increases the calcium 
uptake in a number of different cell types. This phenomenon can either be a rapid 
mobilization of calcium, probably via a non~genomic mechanism, or a slow calcium 
influx, which may proceed via a genomic mechanism (e.g. via the production of 
vitamin D dependent cal bind ins) (14,79). An elevation of intracellular calcium 
appears to participate in monocytic differentiation of leukaemic cells (80,81), but in 
most other systems the physiological significance of the calcium uptake has not been 
identified. 
The antiproliferative action of 1,25-dihydroxyvitamin D3 on malignant cells was 
shown to be dependent on the extracellular calcium concentration. The growth 
inhibition by 1,25-dihydroxyvitamin D3 was enhanced by a low extracellular calcium 
concentration in breast cancer cells (82), leukaemic cells (83,84), and colon cancer 
cells (85). However, the exact role of calcium in this enhanced growth inhibition 
remains to be determined. 
3.9 VITAMIN D AND ANGIOGENESIS, INVASION, AND 
METASTASIS 
The mechanisms of the antiproliferative action of vitamin D3 compounds 
discussed in Section 3.8 are studied in cell culture systems. For the tumour 
suppressive activity of vitamin D3 compounds ill vivo, additional aspects may be 
involved. Vitamin D has been suggested to play a role in the processes of 
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angiogenesis, invasion, and metastasis as discussed below. 
Angiogenesis, the formation of new capillary blood vessels, is an essential 
requirement for the growth of solid tumours. Inhibition of angiogenesis may 
contribute to the tumour suppressive activity of vitamin D compounds, as two groups 
have observed an anti-angiogenic effect of 1,25-dihydroxyvitamin D3 and 22-oxa-
calcitriol using different experimental model systems (86,87). 
Invasion and metastasis of tumour cells are the primary causes for the fatal 
outcome of cancer diseases. A recent report of Mark Hansen et al. (88) indicated that 
1,25-dihydroxyvitamin D3 may be effective in reducing the invasiveness of breast 
cancer cells. They have shown that 1,25-dihydroxyvitamin D3 irdlibited the invasion 
and migration of a metastatic human breast cancer cell line (MDA-MB-231) using the 
Boyden chamber invasion assay. 
Bone is the most frequent site of metastasis of advanced breast cancer (89). 
There are some indications from clinical studies that bone metastases develop 
preferentially in areas with high bone turnover (90,91). In contrast, agents that inhibit 
bone resorption have been reported to reduce the incidence of skeletal metastasis 
(92-94). As 1,25-dihydroxyvitamin D3 is an important stimulator of bone resorption 
(see Section 2.3.2), treatment with 1,25-dihydroxyvitamin D3 or vitamin D3 analogues 
for breast cancer, might increase the risk of skeletal metastases. So far, no ill vivo 
studies have been reported on this subject with respect to breast cancer. However, 
Krempien (95) has reported that following intra-arterial injection with Walker 256 
tumour cells, rats treated with 1,25-dihydroxyvitamin D3 developed significantly more 
bone metastases than untreated controls. 
3.10 CONCLUDING REMARKS 
The first reports on the antiproliferative action of 1,25-dihydroxyvitamin D3 on 
breast cancer cells ill vitro, 10 to 15 years ago, have since been confirmed til vivo in 
different animal models for breast cancer. It appears that the problem of the strong 
calcaemic activity of 1,25-dihydroxyvitamin D3 can be circumvented by the use of new 
synthetic vitamin D3 analogues, since it has been shown that a number of these 
analogues have more potent antiproliferative effects on breast cancer cells ill vitro, 
and suppress breast cancer growth ill vivo without marked calcaemic effects. However, 
it should be noticed that apart from calcaemic side-effects, other negative side-effects 
may arise, in particular immunosuppressive effects and an increased risk of bone 
metastases. But the development of new vitamin D3 analogues continues, and in the 
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future analogues with even stronger antiproliferative action and better selectivity may 
be available. 
The mechanism of the antiproliferative action of vitamin D remains largely 
unclear. There are some indications that vitamin D interferes with the action of 
oestrogen and polypeptide growth factors that influence breast cancer growth. More 
research is needed to define the role of oncogenes, tumour suppressor genes and 
intracellular calcium in the anti proliferative action of vitamin D. 
A major advantage of an endocrine therapy with vitamin D may be that vitamin 
D suppresses breast tumour growth independent of the presence of the oestrogen 
receptor. Most established endocrine therapies are based on antioestrogenic action, 
and for oestrogen receptor-negative tumours therapeutic choices are limited. Vitamin 
D treatment could theoretically be beneficial for a large group of patients, since the 
vitamin D receptor is expressed in about 80 % of human breast cancers. Another 
promising aspect of vitamin D treatment might be its combination with other 
established endocrine (tamoxifen) or cytotoxic agents. In addition, epidemiological 
studies and laboratory results have suggested a role for vitamin D in the prevention of 
breast cancer. In the next years, clinical studies will hopefully confirm that vitamin D3 
analogues, either alone or in combination witb other antitumour agents, can provide 
an effective treatment for breast cancer. 
3.11 SCOPE OF THE THESIS 
III vitro and ill vivo studies have indicated that 1,25·dihydroxyvitamin D3 and 
especially vitamin D3 analogues with low calcaemic activity have potential for the 
treatment of breast cancer (Chapters 2 and 3). Presently, the antioestrogenic drug 
tamoxifen is the most widely used endocrine agent in the treatment of breast cancer 
(Section 3.6). The studies described in this thesis deal with the potential benefit of a 
combination therapy with tamoxifen and 1,25-dihydroxyvitamin D3 or vitamin D3 
analogues. Furthermore, studies were undertaken in order to gain more insight into 
the antiproliferative action of vitamin D3 compounds. 
First of all, we have assessed the effect of combined treatment of 1,25-
dihydroxyvitamin D3 and tamoxifen on the growth of two oestrogen receptor-positive 
and vitamin D receptor-positive human breast cancer cell lines, MCF-7 and ZR-75-1 
(Chapter 4). In Chapter 5 we have evaluated the antiproliferative action of four 
promising vitamin D3 analogues (CB966, EBI089, KHI060, and 22-oxa-calcitriol) 
alone, and in combination with tamoxifen on MCF-7 and ZR-75-1 cells. The effect of 
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the vitamin 03 compounds on tamoxifen-resistant cells was studied in Chapter 5. 
Furthermore, we have addressed the question whether 1,25-dihydroxyvitamin 03 and 
analogues can interfere with the growth stimulation by oestradiol (Chapters 4 and 5), 
and evaluated a possible role of the myc oncogene in the growth inhibition by the 
vitamin 03 compounds (Chapter 5). 
In Chapter 6 we have extended the investigations of the combination of 1,25-
dihydroxyvitamin 03/analogues and tamoxifen to the regulation of bone resorption. 
As discussed in Section 3.9, treatment of breast cancer with 1,25-dihydroxyvitamin 03 
or vitamin 03 analogues might have an unfavourable effect on the incidence of bone 
metastases, due to the bone resorbing activity of vitamin 03 compounds. Tamoxifen, 
in contrast, has been shown to have protective effects on the skeleton (96,97). 
Therefore, it was studied in an ill vitro model whether tamoxifen inhibits the bone 
resorption induced by 1,25-dihydroxyvitamin 03 and two vitamin 03 analogues 
(EB1089 and KH1060), and thereby potentially reduces the risk of skeletal metastasis. 
In Chapters 7 and 8, it was investigated whether the tumour suppressive activity 
of 1,25-dihydroxyvitamin 03 and analogues could be explained by an interference with 
polypeptide growth factors. First, we have studied the effect of 1,25-dihydroxyvitamin 
03 and the analogue EB1089 on insulin- and IGF-I-stimulated growth of MCF-7 cells. 
Subsequently, we have investigated the effect of 1,25-dihYdroxyvitamin 03 and 
EB1089 on the number of insulin receptors and IGF-I receptors, and studied the role 
of the fos oncogene (Chapter 7). In Chapter 8 we have further evaluated a possible 
interaction of the vitamin 03 compounds with the IGF regulatory system, and studied 
the regulation of the expression of IGF-binding proteins and of the secretion of IGF-I 
by MCF-7 cells. 
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SUMMARY 
In the present study we assessed the effect of combined treatment with 1,25-
dihydroxyvitamin D3 (l,25-(OH}zD3) and tamoxifen (TAM) on the growth of 
oestrogen-responsive (MCF-7) and oestrogen-dependent (ZR-75-1) human breast 
cancer cells. Both basal and 17Ll-oestradiol (1711-E2)-stimulated growth were studied. 
1,25-(OH}zD3 (10-10 - 10-7 M) time- and dose-dependently inhibited basal growth of 
MCF-7 cells, with growth arrest at 10-7 M. Also, 17Ll-E2-stimulated growth of MCF-7 
and ZR-75-1 cells was inhibited by l,25-(OH)zD3 in a time- and dose-dependent 
manner. TAM inhibited 17Ll-E2-stimulated growth of both cell lines and at high 
concentration (10-6 M) it also inhibited basal growth of MCF-7 cells. 10-6 M TAM 
together with l,25-(OH}zD3 resulted in a further inhibition of basal (MCF-7 cells) as 
well as 17Ll-E2-stimulated proliferation (MCF-7 and ZR-75-1 cells) compared to the 
inhibition by these agents alone. TAM in combination with 10-7 M l,25-(OH}zD3 
resulted in growth arrest of 1711-E2-stimulated growth of MCF-7 cells. The inhibition 
of basal and 17Ll-E2-stimulated growth of MCF-7 cells was additive at early time 
points (4 days), but less than additive at later time points (8-10 days). It was 
demonstrated that with co-treatment of MCF-7 cells an equipotent inhibition of basal 
growth could be reached with lower concentrations of l,25-(OH}zD3' compared to 
treatment with 1,25-(OH}zD3 alone. Studies with low concentrations « 10-7 M) of 
TAM revealed a partial oestrogenic effect, i.e. stimulation of MCF-7 proliferation in 
the absence of 1711-E2. This effect, which may resemble TAM-induced tumour flare, 
was completely prevented by co-treatment with a low concentration of 1,25-(OH}zD3 
(10-9 M). Together, these results demonstrate the potent inhibition of breast cancer 
cell proliferation by l,25-(OH)zD3 combined with TAM and indicate a potential 
benefit of combining these agents for the treatment of breast cancer. 
INTRODUCTION 
The seco-steroid hormone 1,25-dihydroxyvitamin D3 (1,25-(OH}zD3) is the 
biologically most active form of vitamin D3 and plays an important role in the 
regulation of calcium homeostasis and bone metabolism. The effects of l,25-(OH}zD3 
are mediated via the vitamin D receptor (VDR) in target tissues such as bone, 
intestine and kidney (1). VDRs are not confined to the classical target tissues, but 
have also been demonstrated in a variety of cells and tissues not directly related to 
calcium homeostasis. Several studies have indicated that l,25-(OH}zD3 induces 
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differentiation and inhibits proliferation of haemopoietic, epidermal, and many cancer 
cells (1-3). 
The VOR is present in most breast cancer cell lines and tumours (2, 4-7) and 
1,25-(OHlzD3 has been shown to inhibit proliferation of breast cancer cells ill vitro 
irrespective of their oestrogen dependence (2, 7-11). Studies in vivo have shown that 
la-hydroxyvitamin 03' which is converted to 1,25-(OHlz03 in the liver, suppressed 
the growth of carcinogen-induced rat mammary tumours (7, 12). These findings 
implicate a potential use of 1,25-(OHlz03 for the treatment of breast cancer. 
However, high doses of the sterol are needed and it remains to be ~stablished 
whether 1,25-(OHlz03 can produce long-term antitumour effects without 
unacceptable side-effects, like the development of hypercalcaemia. 
Until now the most effective endocrine therapy for oestrogen receptor (ER)-
positive breast tumours is the treatment with synthetic antioestrogens e.g. tamoxifen 
(TAM) (13). TIle effect of TAM on breast cancer cells is believed to be 
predominantly mediated through competition with oestrogen for the ER thereby 
attenuating the proliferative effect of oestrogen (14, 15). Although antioestrogens are 
very effective in ER-positive tumours, not all ER-positive tumours respond favourably 
and during prolonged anti oestrogen therapy even patients with responsive tumours 
can be expected to become eventually resistant (16). For ER-negative tumours 
therapeutic choices are limited and therefore treatment with 1,25-(OHlzD3 may offer 
a new approach. 
In the present study we assessed the effects of combined treatment with 1,25-
(OHlz03 and TAM on the growth of the ER-positive and VDR-positive human 
breast cancer cell lines MCF-7 and ZR-75-1. The cell lines have different growth 
characteristics. MCF-7 cells have partially escaped from hormonal regulation and are 
called oestrogen-responsive. These cells are able to grow in steroid-free culture 
medium without further additions and are growth stimulated by 17Jl-E2. The 
proliferation of ZR-75-1 cells is dependent on the presence of oestrogens. We have 
studied the effects of co-treatment on basal as well as 17Jl-E2-stimulated proliferation. 
MATERIALS AND METHODS 
Muterials 
17f3-~, TAM, RPMI-1640 culture medium, etbidiulll bromide, DNA (type I, highly polymerized), 
and Ribonuclease A were purchased from Sigma Chemical Co., St. Louis, MO. l,25-(OH)zD3 was 
generously provided by LEO Pharmaceutical Products BV, Weesp, The Netherlands, Glutamine, 
penicillin, streptomycin, and foetal caU serum (peS) were obtained from Life Technologies, Breda, The 
Netherlands. Trypsin was from Boehringer, Manniteim, Germany, Hank's balanced salts solution was 
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from Imperial Laboratories, Andover, UK, and heparin solution (5000 IU /011) was from Organon, 
Doxtel, The Netherlands. 
Cell culture and gt'o\t1h·experiments 
MCP·7 and ZR-75-1 cells were generously provided by Dr. JA Foekens (Department of 
Endocrine Oncology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands). For 
proliferation studies cells were seeded in six-well dishes at a density of 16,000 cells/cru2 for MCF-7 and 
32,000 cells/cru2 for ZR-75-1 cells in phenol red-free RPMI-1640 medium supplemented with 2 mM 
glutamine, 100 units/rul penicillin, 100 J!g/ml streptomycin, 24 mM sodium bicarbonate, and 10% FCS. 
The cells were allowed to attach for 6-7 h. Next, medium was changed to medium with 2% charcoal-
treated pes (Cf.FCS) and the agents to he tested or vehicle (0.1% ethanol) were added. For MCF·7 
cells medium and agents were replaced every 24 h. For ZR-75-1 cells medium and agents were in initial 
experimcnts replaced every 24 h, in later experiments cvery 3 days, Similar results were obtained with 
both incubation procedures, At the end of the incubation medium Was aspirated and DNA content was 
measured according to the elhidium bromide method of Karsten and Wollenberger (17), Cells were 
scraped in 200 Itl trypsin solution (0,5 mg/ml in Hank's balanced saIts solution) and suspended in 1.5 ml 
PBS containing 0,1% Triton X-1OO (PBS-Triton). Cells were sonicated during 2 x 5 sec using a Soniprep 
150 (Sanyo Gallenkamp PLC), Aliquots of the DNA samples were adjusted to 0,5 ml witb PBS-Triton 
and incubated with 1 011 heparin solution (8,33 IU /ml in PBS) and 0,5 ml RNAse A solution (0,05 
mg/ml in PBS) for 30 min at 37°C, Next, 0.5 ml ethidium bromide solution (0.025 mg/ml in PBS) was 
added and the samples Were measured using a Perkin-Elmer LS-2B ftiterfJuorimeter, Excitation and 
emission wavelength were 340 and 590 nm, respectively, A DNA stock solution (25 pg/ml in PBS-Triton) 
was used for a standard curve, 
VDR levels of MCF-7 and ZR-75-1 cells, 28 ± 12 and 40 ± 9 fmol/mg protein respectively, were 
determined as described previously (18), 
Data presented are representative for at least 2 independent experiments, All values are presented 
as mean ± SD of duplicate wells. Where no error bar appears the error is smaller than the symbol. 
RESULTS 
Effect of 1,2S-(OH}zD3 on basal and 171l-Er stilllulated growth of MCF-7 cells 
As shown in Fig. 4.1A, l,2S-(OH)zD3 inhibited proliferation of MCF-7 cells in a 
time- and dose-dependent manner. The first significant effects were observed with 
10-7 and 10,8 M l,2S-(OHhD3 after 4 days. After 6 days 10,9 M, and after 8 days 
10,10 M l,2S-(OH)zD3 also significantly inhibited cell growth. 10'7 M l,2S-(OHhD3 
arrested cell growth, but after 4 and 10 days of incubation cell growth could be 
regained by adding fresh medium supplemented with 10% FCS (data not Shown). 
After evaluating the effect of 1,2S-(OHlzD3 on basal cell growth, we 
investigated whether l,2S-(OHlzD3 was able to inhibit 1711-E2,stimulated 
proliferation. 1711,E2 stimulated cell growth very potently and maximal stimulation 
was already reached at 10-11 M. Comparison of Figs. 4.1A and 4.1B demonstrates that 
l,2S-(OHhD3 inhibited basal growth more potently than 1711-Ez-stimulated growth. 
With 10-7 M l,2S-(OH)P3 basal cell growth was arrested, whereas on day 10 this 
concentration inhibited 1711,~-stimulated cells by only 50%. Also, with a lower concentration 
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Figures 4.1A nnd B. Effect of 1,25.(OHhD3 on basal and 176-~-stimulatcd proliferation of MCF-7 
ce)Js. MCF-7 cells were cultured in 2% CI'·FCS containing medium without (A) or with lO- tO M 176-~ 
(B), and a dose-range of 1,25-(OH)2D3 (1,25). DNA was measured at the indicated times, 
of 1,25-(OHlzD3 (10-10 M) an inhibition of 23% of basal proliferation was observed, 
whereas it had no effect on 17J3-Ez-stimulated proliferation. 
Effect of TAM on basal and 170-E2-stimulated growth of MCF-7 cells 
TAM had a biphasic effect on the proliferation of MCF-7 cells. 10-8 M TAM 
stimulated proliferation, whereas with 10-6 M an inhibition was observed. (Figs. 4.2, 
4.3, 4.6). In contrast to the biphasic effect on basal growth, both concentrations of 
TAM inhibited 17J3-Ez-stimulated (10-11 M) growth, with 10-6 M being more potent 
than 10-8 M (Fig. 4.2). With a higher dose of 17J3-Ez (10-9 M) the effect of 10-6 M 
TAM could partially be reversed (data not shown). With ZR-75-1 cells a similar 
phenomenon was observed (Fig. 4.7). 
Combined effects of 1,2S-(OH)zD3 and TAM on MCF-7 proliferation 
Subsequently, we investigated a possible interaction between 1,25-(OHlzD3 and 
TAM. First, we assessed the effect of co-treatment with 1,25-(OHlzD3 and a growth 
inhibitory dose of TAM (10-6 M). Fig. 4.3 shows that 10-6 M TAM alone resulted in 
an inhibition of 6S% on day 10. A further inhibition up to 100% could be achieved by 
co-treatment with 1,25-(OH)zD3 (10-10 - 10-7 M). At early time points (4 days) an 
additive effect could be observed i.e. the reduction in DNA content, expressed in 
I'g/well, by TAM and 1,25-(OH}zD3 alone adds up in the combined treatment. At 
later time points (S-lO days) the effect of combined treatment was, although not addi-
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Figure 4.2. Dose-response of TAM in the 
presence and absence of 178-~, MCF-7 cells 
were cultured in 2% Cf-pes containing 
medium with the indicated concentrations of 
TAM in the presence or absence of lO·n M 
170-~. After 4 days DNA content was 
measured, a, p<O.OS versus control (no TAM); 
h, p<O.OOl versus 10-11 M 17J3·~ (no TAM:) as 
calculated with the Student's I-test. 
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Figure 4.3. Combined treatment with 1,25-
(OH)zD3 and a growth-inhibitory dose of TAM. 
MCF-7 cells were cultured in 2% cr·FCS 
containing medium with 10-6 M TAM plus the 
indicated concentrations of 1,2S-(OH)zD3 (1,25). 
Control cultures received vehicle only. DNA 
content was measured every two days. 
tive, stronger than the effect of either compound alone. The co·treatment was 
cytostatic rather than cytotoxic, since cell growth could be regained by adding fresh 
medium supplemented with 10% FCS after 4 and 10 days of incubation with 10.7 M 
1,25-(OH)P3 together with 10,6 M TAM (data not shown). 
Fig. 4.4 shows the percentage inhibition by treatment with 1,25-(OHhD3 alone 
and in combination with 10.6 M TAM on days 6 and 10. This figure illustrates for 
example that on day 6 an inhibition of 70% was achieved with 5.10.8 M 1,25-
(OHhD3' whereas a similar inhibition was achieved with a 50 times lower 1,25· 
(OHhD3 concentration (1W9 M) when combined with TAM (Fig. 4.4A). In addition, 
on day 10, 80% inhibition was achieved with 3.10'8 M 1,25-(OHhD3 alone and with 
4.10-10 M 1,25-(OH)P3 when combined with TAM (Fig. 4.4B). In this situation a 75 
times lower concentration of 1,25-(OHhD3 resulted in a similar inhibition when used 
in combination with TAM. 111e effect of co-treatment with 1,25·(OHhD3 and TAM 
(10.6 M) on 17J3·ET stimulated proliferation is shown in Figure 4.5. Although TAM 
was a very potent inhibitor of 17J3-E2-stimulated proliferation (Fig. 4.2), 10,6 M TAM 
did not completely inhibit the growth of MCF-7 cells. Co-treatment with 1,25-
(OHhD3 resulted in a further dose-dependent inhibition and growth arrest at 10-7 M 
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Figure 4.4. Comparison of the effect of 1,25-
(OH)2D3 alone and in combination wilh TAM 
on basal growth. MCF-7 cells were treated for 6 
days (A) and 10 days (B) with 1,25.(OH),D, 
(1,25) alone (Of en circles) or with 1,25-
(OH),D, plus 10' M TAM (solid circles). DNA 
values were corrected for DNA values on day 0 
and expressed as percentage inhibition (elath'e 
to control (vehicle only). 
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1,25-(OHhD3' 
Next we investigated the effect of 
co-treatment with 1,25-(OHhD3 and 
agrowth-stimulatory dose of TAM (10-8 
M). As shown in Fig. 4.6, 1,25-
(OH)P3 inhibited TAM-stimulated 
growth in a time- and dose-dependent 
manner. 10-10 M 1,25-(OHhD3 caused 
a small reduction of TAM-stimulated 
growth whereas 10-9 M1,25-(OHhD3 
resulted in an inhibition to control 
level (no TAM), thereby completely 
preventing TAM-induced growth 
stimulation. 10-8 and 10-7 M 1,25-
(OHhD3 even suppressed TAM-
stimulated growth to below control 
level. 
Effects of 1,25-(OH)2D3 and TAM 011 
ZR-7S-J cells 
Besides MCF-7 cells we tested 
the effects of 1,25-(OH)P3 and TAM 
on the proliferation of another ER-
positive breast cancer cell line. ZR-
75-1 cells did not grow in the steroid-
free culture medium we used for the 
proliferation experiments with MCF-7 cells. Addition of 17B-E2 to the culture 
medium resulted in a dose- dependent stimulation of proliferation. TAM (10-6 M) 
caused a complete inhibition of 10-10 M 17fl-E2-stimulated growth whereas the effect 
of 10-9 M 17fl-E2 was partially inhibited (Fig. 4_7)_ 
1,25-(OH)P3 inhibited 17fl-E2-stimulated growth of ZR-75-1 cells in a dose-
dependent manner (data not shown). 10-7 M 1,25-(OHhD3 completely inhibited 10-10 
M 17B-E2-stimulated growth similar to TAM (10-6 M)_ Also, an almost complete 
inhibition of 10-9 M 17fl-E2-stimulated growth was observed using 10-7 M 1,25-
(OHhD3' whereas 10-6 M TAM was less potent (Fig_ 4_7). Further, the inhibition of 
17fl-E2-stimulated growth by 1,25-(OHhD3 was more effective in ZR-75-1 cells 
compared to MCF-7 cells. Comparison of Figs. 4.1B and 4.7 shows a partial inhibition 
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Figure 4.5. Combined treatment with 1,25-
(OH)2D3 and TAM of cells stimulated with 
17J3-~, MCF·7 cells were cultured in 2% cr· 
pes containing medium with 10-10 M 176-E:2 
and 10.-6 M TAM (solid triangles) and were co-
treated with a dose range of 1,2S.(OHhD3 
(1,25; open symbols). DNA was measured at the 
indicated limes. 
of 10.10 M 17J3·E2"stimulated growth of 
MCF·7 cells by 10.7 M 1,25(OH)zD3 
and a complete inhibition of ZR·75·1 
cells after 9 days. This may be directly 
related to the difference in response to 
17B·E2. However, in several 
experiments it was observed that an 
equipotent growth stimulation by 171l· 
E2 of MCF·7 and ZR-75-1 cells was 
also inhibited more potently by 10.7 M 
1,25-(OH}zD3 in ZR-75-1 cells (data 
not shown). 
Although treatment with 1,25-
(OH}zD3 (10.7 M) and TAM (10.6 M) 
alone resulted in a complete inhibition 
of 10.10 M 171l-Ez stimulated growth, 
still a further inhibition to below 
control level was observed when used 
in combination. Also, at higher concen-
tration 171l-Ez (10.9 M) the effect of co-treatment was 1Il0re potent than the effect of 
either compound alone (Fig. 4.7). 
DISCUSSION 
The present study describes for the first time effects of combined treatment with 
1,25-(OH}zD3 and TAM on the growth of ER-positive and VDR-positive human 
breast cancer cells ill vitro. As circulating levels of oestrogens are believed to play an 
important role in promoting the growth of ER-positive breast tumours, we have 
studied the effects of both compounds on basal as well as 17J3-Ez-stimulated 
proliferation. The current data show that basal growth of MCF-7 cells is inhibited by 
1,25-(OH)zD3. ZR-75-1 cells did not grow in the absence of 171l-Ez and therefore no 
effects on basal growth could be assessed. Our data are consistent with several reports 
describing the inhibitory effect of 1,25·(OH}zD3 on human breast cancer cells (2, 7-
11). In these studies the inhibition of cell proliferation was investigated using culture 
media supplemented with FCS or CT-FCS but to our knowledge the effect of 1,25-
(OH}zD3 on a specific growth stimulus like 171l-E2 was not studied. Our data 
demonstrate that 1,25-(OH)zD3 inhibits 17B-Ez-stimulated proliferation of both MCF7 
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(OHhD3 and a growth-stimulatory dose of 
TAM, MCF-7 cells were cultured in 2% cr-
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the indicated concentrations of 1)25-(OH)zD3 (1,25). Control cultures received vehicle only. 
DNA content was measured every two days. 
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Figure 4.7. Combined treatment with 1,25-
(OH),D, and TAM of ZR·75·1 cells, ZR-7H 
cells were cultured in 2% Cf·FCS containing 
medium with vehicle, 10-10 Of 1O-'J M 17B-~ 
(~) for 9 days. Cells were treated with 10-6 M 
TAM or 10.7 M 1,25-(OH~DJ (1,25) or 10.6 M 
TAM together with 10" M 1,25-(OH),D" 
Medium and test agents were replaced every 
three days. DNA content was measured on days 
o and 9. 
and ZR-75-1 cells, Although the VDR levels were comparable, 17B-E2 stimulated 
growth of ZR-75-1 cells is more sensitive to 1,25-(OHhD3 than 17B-E2-stimulated 
growth of MCF-7 cells. These results are suggestive for a difference in stimulation by 
17B-E2' It has been reported (19, 20) that 17B-Ez acts synergistically with insulin and 
possibly insulin-like growth factors on MCF-7 cells, whereas others (21) did not find 
this synergistic action on ZR-75-1 cells, Therefore, the 17B-EZ-stimulated growth we 
observed in MCF-7 cells could be the result of a synergistic action of 17B-Ez with 
serum-derived insulin-like growth factors, whereas the growth stimulation by 17B-Ez 
in ZR-75-1 cells could be less sensitive to serum factors, 
TAM antagonizes 17B-Ez-stimulated growth by competition with 17B-Ez for the 
ER (14, 15)_ Consistent with these findings TAM dose-dependently inhibited 171l-Ez-
stimulated growth of MCF-7 and ZR-75-1 cells, It was also observed that 10.6 M 
TAM inhibited the growth of MCF-7 cells in steroid-free culture medium_ 111is might 
be explained by antigrowth factor activity of TAM which has been demonstrated in 
several reports (20, 22, 23), 
Both basal proliferation (MCF-7 cells) and 171l-Ez-stimulated proliferation 
(MCF-7 and ZR-75-1 cells) were inhibited more potently by the combination of 1,25-
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(OHhD3 and TAM than by either compound alone. We have shown that an 
equipotent inhibition of basal growth of MCF-7 cells could be achieved with lower 
concentrations of 1,25-(OHhD3 when combined with TAM compared to treatment 
with 1,25-(OHhD3 alone. TI,is is an interesting observation since it is of clinical 
importance to use 1,25-(OHhD3 as an antiproliferative compound at the lowest 
possible doses in order to prevent the development of hypercalcaemia. 
In MCF-7 cells we observed a growth stimulation by TAM at low concentrations 
« 10-7 M) in the absence of oestrogens. This effect is consistent with previous work 
(20, 24) and is thought to be due to a partial oestrogen agonistic action mediated via 
the ER. It is hypothesized that TAM-induced tumour flare, which is often observed in 
patients, is the result of this oestrogenic effect of TAM (25). We observed that growth 
stimulation by TAM was already completely prevented by a low concentration 
(10-9 M) of 1,25-(OHhD3' Thereby these data are pointing to a possible role of 1,25-
(OHhD3 in the prevention of tumour flare. A further interesting observation was that 
a growth-stimulatory concentration of TAM (10-8 M) was nevertheless able to inhibit 
17Jl-E2-stimulated growth. This phenomenon agrees with previous studies (20, 24), 
however, the underlying mechanism is not yet clear. 
The observation that at early time points the inhibitory effects of 1,25-(OHhD3 
and TAM on the proliferation of MCF-7 cells are additive suggests that they inhibit 
cell growth via different mechanisms. This could indicate that 1,25-(OHhD3 acts 
independent of the 1711-E2-induced pathway leading to proliferation. Further support 
for this 1711-E2-independent action comes from the observations in previous reports 
that both ER-positive and ER-negative breast cancer cell lines are growth-inhibited 
by 1,25-(OHhD3 (2, 7-11). Further, in MCF-7 cells 1,25-(OH)P3 inhibited basal 
growth more potently than 17f3-Er stimulated growth. However, several observations 
do point to an interference of 1,25-(OH)P3 with the 17Jl-~-induced pathway. Firstly, 
in ZR-75-1 cells 1,25-(OHhD3 caused a complete blockade of 1711-E2-induced growth. 
Secondly, TAM-stimulated growth of MCF-7 cells, which is probably mediated via the 
ER, was potently inhibited by 1,25-(OHhD3' Moreover, a recent report about a 
synergistic growth inhibition of MCF-7 and ZR-75-1 cells by a vitamin D3 analog and 
TAM (26) is suggestive for an interaction. More experiments are needed to define 
precisely whether 1,25-(OHhD3 interferes with the 1711-E2-mediated pathway and 
presently we are investigating the role of 1,25-(OH)P3 in other 1711-~-mediated 
responses. 
In conclusion, the current results demonstrate a potent inhibition of breast 
cancer cell proliferation by combined treatment with 1,25-(OHhD3 and TAM. The 
combined treatment may provide the advantages that a) tumours positive for both ER 
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and VDR have a more beneficial response, b) lower doses of 1,25-(OH}zD3 can be 
used which do not cause hypercalcaemia, and c) in tumours heterogenous for the ER 
both ER-positive and ER-negative cells can be inhibited. In addition, TAM may 
diminish the stimulatory side-effect of 1,25-(OH}zD3 on bone resorption since several 
reports have indicated that TAM exerts positive oestrogenic effects on bone and 
protects against steroid-induced bone loss (27, 28). An important drawback for the 
clinical use of 1,25-(OH}zD3 as an antiproliferative compound is the development of 
hypercalcaemia at high doses. At the moment, numerous attempts are being made to 
develop vitamin D3 analogues with potent growth inhibitory, and reduced calcaemic 
activity. In the future co-treatment with these vitamin D3 analogues and TAM may 
provide an even greater benefit and studies on this subject are currently in progress. 
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ABSTRACT 
The steroid hormone l,25-dihydroxyvitamin D3 (1,25-(OHlzD3) has potential 
to be used as an antitumour agent, but its clinical application is restricted by the 
strong calcaemic activity. Therefore, new vitamin D3 analogues are developed with 
increased growth inhibitory and reduced calcaemie activity. In the present study, we 
have examined the antiproliferative effects of four novel vitamin D3 analogues 
(CB966, EBlO89, KHlO60, and 22-oxa-calcitriol (ocr» on breast cancer cells, either 
alone or in combination with the antioestrogen tamoxifen. The oestrogen-dependent 
ZR-75-1 and oestrogen-responsive MCF-7 cell lines were used as a model. It was 
shown that, with EBlO89 and KH1060 the same growth inhibitory effect as 1,25-
(OHlzD3 could be reached at up to IOO-fold lower concentrations, whereas CB966 
and ocr were nearly equipotent with 1,25-(OHlzD3. The growth inhibition by the 
vitamin D3 compounds could be augmented by combined treatment with tamoxifen. 
At the maximal effective concentrations of the vitamin D3 compounds, the effect of 
combined treatment was additive (MCF-7 cells) or less than additive (ZR-75-1 cells). 
Tamoxifen increased the sensitivity of the cells to the vitamin D3 compounds 2- to 
4000-fold, which was expressed by a shift to lower median effective concentration 
values. Thereby, the vitamin D3 compounds may be used at even lower dosages in 
combination therapy with tamoxifen. A major problem of tamoxifen therapy is the 
development of tamoxifen-resistance. We have observed that tamoxifen-resistant 
clones of ZR-75-1 cells retain their response to the vitamin D3 compounds. 
Regulation of the growth-related oncogene c-myc (mRNA level) and the oestrogen 
receptor (protein level) were studied but appeared not to be related to the 
antiproliferative action of the vitamin D3 compounds. Together, our data point to a 
potential benefit of combination therapy with 1,25-(OHhD3 or vitamin D3 analogues 
and tamoxifen for the treatment of breast cancer. 
INTRODUCTION 
The seco-steroid hormone l,25-dihydroxyvitamin D3 (1,25-(OHhD3)' the 
biologically most active metabolite of vitamin D3, is a well-known regulator of 
calcium homeostasis and bone metabolism (I). Over the last decade, evidence has 
accumulated that 1,25-(OHlzD3 is also involved in the regulation of proliferation and 
differentiation of cells and tissues not primarily related to mineral metabolism (2). 
Also in breast cancer cells and tumours, an antiproliferative effect of 1,25-(OHlzD3 
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has been demonstrated (3-5). These nonclassical effects offer promise for the use of 
1,25-(OH)zD3 as an antiproliferative drug (6). A major drawback for its clinical 
application is that high doses are needed for tumour suppression, which may result in 
negative side-effects like the development of hypercalcaemia. Therefore, vitamin D3 
analogues were developed in an attempt to dissociate effects on growth and 
differentiation from effects on intestinal calcium absorption and bone resorption. 
Most analogues synthesized have modifications in the side-chain of the 1,25-
(OHlzD3 molecule. The vitamin D3 side-chain analogues used in this study, CB966, 
EBI089, KH1060, and 22-oxa-calcitriol (ocr), have been shown to be more potent 
than 1,25-(OHlzDJ in the inhibition of proliferation of leukaemic cells, whereas the 
calcaemic activity in vivo was similar or even weaker (7-10). A few studies have also 
demonstrated antiproliferative effects of ocr, EB 1089, and KH 1060 on breast cancer 
cells in culture (8,11-13). In addition, in animal models for breast cancer, ocr and 
EB1089 suppressed tumour growth without development of hypercalcaemia (11,12). 
Thereby these data, together with the high incidence of vitamin D receptors in human 
breast tumours (14,15), demonstrate the potential role of vitamin D3 analogues in the 
treatment of breast cancer. Presently, the mechanism of the suppression of tumour 
growth by 1,25-(OHlzD3 and analogues is still unclear. 
The growth of normal and many breast carcinoma cells is regulated by 
oestrogens. Antioestrogens are effective in controlling the growth of oestrogen-
responsive tumours, and the antioestrogen tamoxifen is currently widely used in 
endocrine therapy for breast cancer (16). During prolonged treatment, however, most 
tumours become eventually resistant to tamoxifen (17). For ER-negative tumours and 
tamoxifen-resistant tumours, therapeutic choices are limited. Because 1,25-(OH)zD3 
and analogues have been shown to inhibit breast cancer growth irrespective of the 
oestrogen dependence (4,11), treatment with vitamin DJ analogues may be effective 
for ER-positive, ER-negative, and tamoxifen-resistant breast tumours. Moreover, 
combined treatment with tamoxifen and vitamin D3 analogues may provide a more 
beneficial effect on breast cancer. 
In an earlier report we established a complementary action of tamoxifen and 
1,25-(OHlzD3 on the growth of MCF-7 and ZR-75-1 oestrogen-responsive breast 
cancer cells (18). In view of the promising effects of low calcaemic vitamin D3 
analogues (7-9,11-13), we examined in the present study whether these compounds, in 
combination with tamoxifen, resulted in an even better inhibition of breast cancer cell 
growth. In addition, we have studied ER regulation and evaluated a possible role of 
the growth-related oncogene c-myc in the growth inhibition by 1,25-(OHlzD3 and 
analogues. 
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MATERIALS AND METHODS 
Chemicals 
1,25.(OHhD3' CB966, EB1089, and KHI060 were kindly donated by Dr. L. Binderup of LEO 
Pharmaceutical Products (Bal1erup, Denmark), and OCT by Dr. N. Kuhodera of Cbugai Pharmaceutical 
Co. (Shiruoka, Japan). The chemical structures of the vitamin D3 compounds are depicted in Fig. 5.1. 
{23,24.3H]-l,25-(OH)2D3 (120 Cifmmol) was purchased from Amersharu International (Aylesbury, 
United Kingdom). 171l-oestradiol, tamoxifen, RPMI·1640, human transferrin, and sodium selenite were 
purchased from Sigma Chemical Co. (St. Louis, MO). Bovine serum albumin fraction V was from leN 
Biomcdicals Inc. (Costa Mesa, CA). Glutamine, penicillin, streptomycin, and Fes were obtained from 
Life Technologies (Breda, The Netherlands). Insulin (Actrapid) was from Novo Nordisk A/S (Bagsvaerd, 
Denmark). 
CB966 
OH 
EB10B9 
KH1060 
HO " 
1 ,25-(OH) ,D 3 OCT 
Figure 5.1. Chemical structures of 1,25-(OH)2D3 and vitamin D3 side· chain analogs. The analogs have 
different types of side-chain modifications: elongation (CB966, EB1089, and KHI06O), introduction of an 
oxygen atom at the C22 position (ocr and KHI060), unsaturation (EBI089), and altered conformation 
at the C20 position (KHI060). 
Cell culture 
MCF-7 and ZR·75·1 cells were generously provided by Dr. JA. Foekens (Department of 
Endocrine Oncology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands). MCP·7 cells 
were maintained in RPMI·l640 supplemented ,vith 2 mM glutamine, 100 units/ml penicillin, 100 j'(g/ml 
streptomycin, 24 mM sodium bicarhonate (basal RPMI medium), 10% pes, and 10 j'(g/ml insulin. ZR· 
75-1 cells were maintained in basal RPM! medium supplemented with 10% Fes and 1 nM 17J3·Ez. Both 
cell lines were passaged weekly. Tamo;.dfcn·resistant derivatives of ZR-75·1 cells were isolated and 
cultured as described previously (19). ZR/HERc cells, which are EGF receptor·positive derivatives of 
ZR-75·1 cells, were isolated and cultured as described by Van Agtboven et al. (20). 
Growth expel'imenfs 
Cells were seeded into six·well dishes at a density of 16,000 cells/cm2 for MCF· 7 and 32,000 
cells/cm2 for ZR·75-1 cells in phenol red-free basal RPMI medium supplemented with 2% charcoal· 
treated pes. Cells were allowed to attach for 24 h. Next, medium was changed to SFM (basal RPM! 
medium supplemented ,vith 30 nM sodium selenite, 10 j'(g/ml transferrin, and 0.2% bovine serum 
albumin). After another 24 h the medium was refreshed and the agents to be tested or vehicle (0.2% 
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ethanol) was added, Medium and test agents were replaced after 2 and 5 days of incubation, and after 8 
days of incubation, DNA content was measured using the ethidium bromide method as described 
previously (18). Proliferation experiments with tamoxifen-resistant ZR-75-1-derived cells and ZR/HERc 
cells were performed using crystal violet absorbance (21), Parental ZR-75-1 cells were seeded 2000 
cells/well; clones XI 13 and VIII 24 (19) 5000 cells/well; and ZR/Hcrc cells 120) 2200 cells/well into 96 
well microplates in basal RPMI medium supplemented with 10% FCS, 10-1 M 17J3-E2 was added to 
parental ZR-75-1 cells and to ng/ml EGP to ZR/Herc cells, Cells were incubated 5 to 7 days after a 
single addition of the vitamin D3 compounds. 
RNA Isolation and hybridIzation 
To study the effects of 176.E2 and vitanlin DJ compounds on c-mye mRNA expression we have 
used a similar incubation procedure as in the grov.1h experiments, i.e., 24 h after seeding (1.5 x 106 cells 
. in 25 cm2 culture flasks) in basal RPMI medium with 2% charcoal-treated-PCS, medium was changed to 
SPM, and after another 24 h test agents were added. Total RNA was prepared by acid guanidinium 
thiocyanate-phenol-chloroform extraction (22), Samples of 10·20 Jl.g RNA were fractionated on a 1% 
agarose-2% formaldehyde gel and transferred onto a Hybond N + nylon membrane (Amersham; Ref, 
23). The membrane was prehybridized for at least 2 It at 42°e in hybridization buffer (50% formamide, 
6% dextran sulphate, Ix Denhardt's solution, 1 Jl.g/ml denatured herring sperm DNA, 5x sse (Ix SSC = 
150 mM sodium chloride, 15 mM sodium citrate), 0.2% SDS, and 0,02 M NaH2P04). Hybridization was 
carried out at 42°C for 16·24 h. The probes, a 1.4 kilobase CfaI-EcoRI fragment of the human c-mye 
gene ~24) and a 0.8 kilobase EcoRI-Hi"dIII fragment of the human GAPDH gene (25), were labelled 
with r 2pJATP using random primers, After hybridiz..1tion, membranes were washed twice in 2x SSC, 
0,1% SDS for 5 min at room temperature, twice in 2x SSC, 0.1% SDS for 20 min at 42°C, and twice in 
O.5x sse, 0.1% SDS for 20 min at 42°e. Membranes were exposed to medical X-ray mms (Fuji Photo 
Film Co" Tokyo, Japan), and autoradiographs were quantified using a Bio-Rad Videodensitometer 
(Richmond, CA). Before rchybridization, membranes were washed at least 2 h at 65°C in 5 mM Tris-
HCI (pH 8,0), 0.2 mM EDTA (pH 8,0), 0,05% sodium pyrophosphate, and O,lx Denhardl's solution, 
Determinallon of oestrogen receptor content 
Cells were grown to subconfluence in 175 cm2 culture flasks. Next, cells were washed 2 times in 
SFM during 24 h to remove steroids, Cells wcre incubated with the vitanlin D3 compounds or vehicle 
(0.1% ethanol) in SFM for 24 or 48 h prior to harvesting \vith 3 mM EDTA in phosphate-buffered 
saline. Cell pellets were quickly frozen in liquid nitrogen and homogenized using a microdismembrator as 
described by Van Agthoven et al. (20), Cytosolic extracts were prepared by high-speed centrifugation at 
100,000 x g for 20 min and ER content was measured with an enzyme immunoassay (Abbott ER-ElAj 
Abbott Laboratories, Chicago, IL). 
Vitamin D receptor bInding assay 
Cells were grown to subconfluence and washed for 24 h in SFM to remove steroids. A VDR 
binding assay was performed as described previously (26). Briefly, cells were harvested by trypsinization, 
and the cell pellets were extracted on ice in a hypertonic buffer consisting of 300 mM KCI, 10 mM Tris-
HCI, 1 mM EDTA, 5 mM dithiotreitol, 10 mM sodium molybdate, and 0.1% Triton X-tOO (pH 7.4). 
High-speed supernatants were obtained by centrifugation at 100,000 x g for 1 h at 4°C. Aliquots of 
crosolic extracts (containing approximately 1 mg protein{ were incubated for 3 h at O°C with 0.25 nM 
f HJl,25-(OHhDJ and increasing concentrations (5 x 10- 1 M - 5 x to-7 M) of unlabelled 1,25.(OH)2D3 
or vitamin D3 analog. Receptor-bound and free eHJl,25-(OH)zDJ were separated by charcoal 
adsorption, The 1,25-(OH)zDJ/allaiog concentrations resulting in 50% displacement of bound eHJl,25-
(OH)zD3 were calculated, 
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RESULTS 
Effect of vitamin D3 compounds on the growth of MCF-7 cells 
MCF-7 cells were able to grow exponentially in SFM without further additions 
(= autonomous growth). After an 8-day incubation period, DNA content of control 
cultures increased from 6 I'g/well to about 50 I'g/well. A, shown in Fig. 5.2, 1,25-
(OHhD3 and the synthetic analogues OCT, CB966, EB1089, and KHI060 inhibited 
autonomous growth. The chemical structures of the analogues are depicted in Fig. 5.1. 
The maximum effect (25% inhibition) was similar for 1,25-(OHhD3 and analogues, 
and was reached at approximately 10.8 M EB1089 and KHI060, 10.7 M 1,25-(OHhD3 
and CB966, and 10,6 M OCT. The concentrations of the analogues needed to achieve 
the half-maximal effect of 1,25-(OHhD3 (designated as ECso) were assessed, and 
based on these concentrations, the relative potencies with respect to 1,25-(OHhD3 
were calculated. 
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Figure 5.2. Inhibition of autonomous growth of 
MCF· 7 cells by t,25-(OH)zD3 and vitamin D3 
analogs. MCF-7 cells were cultured for 8 days in 
SFM as described in "Materials and Methods" in 
the absence or presence of various 
concentrations of the vitamin D3 compounds. 
DNA content of the control cultures was set at 
100% (49 JIg DNA/well). Data represent the 
mean of three separate experiments each 
consisting of duplicate wells. 
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Figure 5.3. Inhibition of 170·~-stimulated 
growth of MCF-7 cells by combined treatment 
with tamoxifen and vitamin D3 compounds. 
Cells were cultured for 8 days in SFM 
supplemented with 10-10 M 1713-~ and 10..(; M 
tamoxifen, in the absence or presence of various 
concentrations of the vitamin D3 compounds. 
Tamoxifen alone reduced 170-Ez-stimulated 
proliferation to 30% (30 Jlg DNA/well), which 
is indicated as the starling value on the vertical 
axis. Data represent the mean of three separate 
experiments each consisting of duplicate wells. 
Symbols, see Fig. 5.2. 
Table S.l. Growth inhibition of MCF·7 cells by 1,25·(OHhD3 and vitamin D3 analogs and their affinity for the VDR 
GROWTH INHIBmON 
171l-E;,-stimulated growth 
Autonomous growth Without tamoxifen With tamoxifen Ratio of ECso 
without and VDR bmding 
Relative to Relative to Relative to with relative to 1,25~ 
Analogue ECso (M)a 1,25-(OH)2D3 ECso (M) 1,25-(OH),D3 ECso (M) 1,25-(OHlzD3 tamoxifenb (OH)2D3 
1,25-(OH),D3 2 x 10-8 1 1 x 10-8 1 5 x 10~11 1 200 1 
ocr 8 x 10-8 0.25 2 x 10-8 0.50 2 x 10-10 0.25 100 0.1 
CB966 1 x 10-8 2 1 x 10..s 1 8 x 1O~11 0.63 125 0.7 
EB1089 3 x 10"10 67 1 x 10-10 100 5xlo-11 1 2 0.7 
KH1060 2 x 10~10 100 1 x 10-10 100 7 x 1O~12 7 14 0.7 
aThe concentrations of the analogs needed to achieve the half~maximaI effect of 1,25~(OH)2D3 (designated as ECso) were assessed on basis of the data 
in Figs. 5.2 and 53. The maximum inhibition of autonomous growth was 25%, and of 17B-~-stimulated growth U%. Tamoxifen inhibited 17B-~­
stimulated growth by 70% and tamoxifen combined with the vitamin D3 compounds resulted in a maximum inhibition of 83%. 
bThe ratio expresses the magnitude of the shift of the ECso by cotreatment with tamoxifen and was calculated by division of the ECso in the absence 
of tamoxifen by the ECso in the presence of tamoxifen. Binding of 1,25-(OH);P3 and analogs to the VDR was measured in cytosolic extracts by 
displacement of [3Hj1,25_(OH),o3. 
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OCT displayed a somewhat decreased potency and CB966 a small increased potency, 
whereas EBl089 and KH1060 were clearly more potent than 1,25-(OHhD3' 67 and 
100 times, respectively (Table 5.1). 
Since 171l-E2 plays an important role in breast cancer development and growth, 
we have investigated the effect of the vitamin D3 analogues on 171l-E2-stimulated 
proliferation of MCF-7 cells. 17B-E2 (10-10 M) resulted in a 2-fold stimnlation of 
control cultures. Inhibition of 17B-E2-stimulated growth by the vitamin D3 compounds 
was relatively small (approximately 12%; data not shown). The absolute inhibition of 
171l-E2-stimulated growth expressed in I'g DNA/well was similar to the absolute 
inhibition of the autonomous growth, indicating that there was no specific inhibition 
of the 17B-E2 effect. Also, the ECsos of 1,25-(OHhD3 and analogues were in the 
same order of magnitude as for autonomous growth (Table 5.1). 
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,Figure 5.4. Growth inhibition of ZR-75-1 cells 
by 1,2S.(OHhD3 and vitamin D3 analogs. ZR-
75·1 cells were grown for 8 days in SFM 
supplemented with 10-10 M 170-Hz in the 
presence or absence of various concentrations of 
the vitamin D3 compounds, DNA values of 
control cultures (no vitamin D added) increased 
from 7 to 21 J,tg DNA/well in 8 days. The 
absolute increase in DNA content (14 Jtg 
DNA/well) was set at 100%. Data represent the 
mean of three separate experiments each 
consisting of duplicate wells. Symbols, sec Fig. 
5.2. 
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Figure 5.S. Growth inhibition of ZR-75-1 ceUs 
by combined treatment with tanlOxifen and 
vitamin D3 compounds. Cells were cultured for 
8 days in SFM supplemented with 10,10 M 170-
Ez and 10'7 M tamoxifen, in the absence or 
presence of various concentrations of the 
vitamin D3 compounds. DNA content was 
measured and corrected for DNA content at the 
start of the experiment. Tamoxifen alone 
reduced 170-Ez-induced proliferation to 49%, 
which is indicated as the starling value on the 
vertical axis. Data represent the mean of three 
separate experiments each consisting of 
duplicate wells. Symbols, see Fig. 5.2. 
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Table 5.2. Growth inhibition of ZR-75-1 cells by 1,2S-(OHhD3 and vitamin D3 analogs 
17B-~·stiruulated growth 
Ratio of 
Without tamoxifen With tamoxifen ECso 
without and 
Relative to Relative to ,vith 
Analogue ECso (M)' l,2S-(OH),D, ECso (M) l,25-(OH),D, tamoxifenb 
l,25-(OH),D, 2 x 10-8 1 x 10.9 1 20 
OCT 4 x 10-8 0.5 1 x 10-11 100 4000 
CB966 2 x 10-8 1 1 x 10-9 1 20 
EBI089 7 x 10-10 29 2 x 10-10 5 4 
KHI060 2 x to- IO 100 2 x to-II 50 10 
aThe concentrations of the analogs needed to achieve the half-maximal effect of 1,25-(OHhD3 
(designated as ECso) were assessed on basis of the data in Figs. 5.4 and 5.5. The maximal inhibition of 
the 17fi-~·stilllulated growth was 40%. Tamoxifen inhibited the 17B-~-stimulatcd growth 51% and 
tamoxifen combined with the vitamin D3 compounds resulted in a maximum inhibition of 79%. 
bThe ratio expresses the magnitude of the shift of the ECso by eotreatment with tamoxifen and was 
calculated by division of the ECso in the absence of lamoxifen by the ECso in the presence of 
tamoxifen. 
Inhibition of 17B-E2-stimulated growth of breast cancer cells by the 
antioestrogen tamoxifen is well documented. In MCF-7 cells, tamoxifen not 
onlycompletely blocked 17B-ET stimulated growth but also inhibited part of the 
autonomous growth of MCF-7 cells, i.e., DNA values of cultures treated with 10-10 M 
17B-E2 and 10-6 M tamoxifen (30 I'g/well) were lower than DNA values of control 
cultures (49 I'g/well). Subsequently, we examined the effect of combined treatment 
with l,25-(OHhD3/analogues and tamoxifen on 17B-E2-stimulated growth. Fig. 5.3 
shows that, although tamoxifen alone causes a potent growth inhibition (reduction to 
30% of 17B-E2-stimulated growth), addition of 1,25-(OHhD3 or analogues resulted in 
a still further inhibition (from 30% down to 17% of 17B-E2-stimulated growth). In 
combination with tamoxifen, the ECsos of l,25-(OHhD3 and analogues shifted lower 
concentrations. The ECsos of l,25-(OHhD3' CB966, and OCT were 200-, 125- and 
lOa-fold lower, respectively, in the presence of tamoxifen, whereas the ECsos of 
KHlO60 and EBI089 were only 14- and 2-fold lower, respectively (Table 5.1). 
Consequently, the differences between 1,25-(OHhD3 and the analogues are smaller 
in the presence of tamoxifen. Although the sensitivity to 1,25-(OHhD3/analogues was 
increased by combined treatment with tamoxifen the inhibitory effect at the maximal 
effective concentrations of l,25-(OHhD3/analogues was additive. 
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Table 5.3. Growth inhibition of tamoxifen-resistant and EGF receptor-positive derivatives of ZR-75-1 
cells by 1,25-(OH),D, and KHI060 
% of control 
Condition ZR-75-1 Xl 13 VIII 24 ZR/HERc 
Control 100 ± 6 100 ± 3 100 ± 3 100 ± 9 
10-9 M 1,25-(OH)'D, 107 ± 9 113 ± 3 88 ± 4 98 ± 6 
W-' M 1,25-(OH)'D, 55 ±8 78 ± 3 35 ± I 30 ± 7 
10-9 M KHI060 59 ± 6 80 ± 4 37 ± 3 29 ± 7 
10-' M KHl060 49 ± 4 79 ± 3 35 ± 3 28 ± 7 
Cells were cultured in basal RPM I medium supplemented with 10% FCS in the absence or presence 
of 1,2S-(OH)2D3 or KHI060. 17B-~ (to,10 M) was added in cultures of parental ZR-75-1 cells and 
EGF (10 ng/lUI) in cultmcs of EGF receptor-positive ZR/HERc cells to induce the growth of these 
cells, The tamoxifen·resistant XI 13 and VIII 24 cells are able to grow autonomously. Proliferation of 
XI 13 cells was measured after 5 days, and proliferation of ZR-75-1, VIII 24, and ZR/HERc cells 
after 7 days by crystal violet absorbance. Data are expressed as the percentage of control and 
represent mean ± SD of nine wells. 
Effect of vitamin D3 compounds on the growth of ZR·75-1 cells 
Next, we studied the effect of the vitamin D3 compounds on another 
oestrogen-responsive breast cancer cell line. As opposed to MCF-7 cells, ZR-75-1 
cells are dependent on 17Jl-E2 for growth. 17B-E2 (10-10 M) induced an increase in 
DNA from 7 to 21 I'g DNA/well in 8 days. Fig. 5.4 shows that, in contrast to 17Jl-E2-
stimulated growth of MCF-7 cells, 17J3-E2-stimulated growth of ZR-75-1 cells was 
potently inhibited by the vitamin D3 compounds. The ECsos for the growth inhibition 
of ZR-75-1 cells were similar to those of MCF-7 cells with the exception of EB1089, 
which had a somewhat reduced potency in ZR-75-1 cells (Table 5.2). 
Analogous to MCF-7 cells, we have analyzed the combined effects of vitamin 
D3 analogues and tamoxifen on the growth of ZR-75-1 cells. Tamoxifen (10-6 M) 
completely blocked 17B-Ez-stimulated growth of ZR-75-1 cells and, thereby, the entire 
proliferation. 111erefore, we have used a suboptimal concentration of tamoxifen 
(10-7 M) to test whether there is an interaction between tamoxifen and vitamin D3 
compounds. Fig. 5.5 demonstrates that the inhibition by tamoxifen (reduction to 49% 
of 17Jl-E2-stimulated growth) can be augmented by addition of 1,25-(OHhD3 or 
analogues (further reduction from 49% down to an average of 21% of 17J3-E2-
stimulated growth). Similar to MCF-7 cells, the EC50s for the inhibition by the 
vitamin D3 compounds were shifted to the left in the presence of tamoxifen. The 
EC50 of OCT was even 4000 times lower; the EC50s of 1,25-(OHhD3 and CB966, 20 
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times; and the ECsos of EB1089 and KHI060, 4 and 10 times; respectively (Table 
5.2). Despite the increased sensitivity of 1,25-(OHhD3 and analogues, the effect of 
comhined treatment with tamoxifen was less than additive at the maximal effective 
concentrations of the vitamin D3 compounds. 
To assess whether treatment with 1,25-(OH)2D3/analogues could be useful in 
an antiestrogen-resistant situation, we have tested the effect of 1,25-(OHhD3 and 
KH1060 on tamoxifen-resistant derivatives of ZR-75-1 cells. TIlese resistant cells were 
cloned from oestrogen-dependent ZR-75-1 cells subjected to tamoxifen selection after 
retrovirus infection (19). Table 5.3 demonstrates that the growth of the resistant XI 
13 and VIII 24 cells was indeed inhibited by 1,25-(OH)zD3 and KH1060, with 
KHI060 being more potent. Furthermore, EGF-dependent proliferation of EGF 
receptor-positive derivatives of ZR-75-1 cells (20) was strongly inhibited by 1,25-
(OHhD3 and KHI060 (Table 5.3). 
Regulation of oestrogen receptor content 
To study whether vitamin D3 compounds exert their effects on proliferation via 
regulation of ER level, we have measured ER content of both cell lines using an 
enzyme immunoassay. The vitamin D3 compounds 1,25-(OHhD3' CB966, EB1089, 
KH1060 and OCT (10-8 M) had no effect on the ER level of MCF-7 (750 fmol/mg 
protein) and ZR-75-1 cells (180 fmol/mg protein) after 24 and 48 h of incubation 
(data not shown). 
Regulation of e-mye mRNA expression 
To study a possible involvement of c-myc in the growth inhibition by vitamin 
D3 compounds, we have studied c-myc mRNA expression in MCF-7 and ZR-75-1 
cells. In an attempt to relate growth inhibition to effects on c-myc mRNA expression, 
we have measured c-myc under the same conditions as the proliferation experiments. 
c-myc mRNA levels of autonomously growing MCF-7 cells incubated with 10-7 M 
1,25-(OH)zD3 for 0.5 up to 48 h did not change significantly with respect to the 
control incubation (vehicle added; data not shown). 17J3-E2-stimulated growth of 
MCF-7 and ZR-75-1 cells was studied using 10-10 M 1713-E2. At this concentration, 
c-myc was rapidly induced in MCF-7 cells (25-fold) and ZR-75-1 cells (2-fold) with a 
peak at 1 h and a gradual return towards prestimulation level in 4 h. In MCF-7 cells 
10-10 M 173-E2 was the maximal effective concentration, whereas in ZR-75-1 cells a 
maximal 6-fold stimulation was achieved at 10-9 M 1713-E2. Fig. 5.6 demonstrates that 
neither 1,25-(OHhD3 nor vitamin D3 analogues modulated the 17J3-E2-induced c-myc 
mRNA expression in MCF-7 cells (Fig. 5.6, lanes 2-17). Tamoxifen (10.6 M) almost 
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FIgure 5.6. Northern analysis of c-myc in MCP·7 cells. Autoradiograph of RNA hybridized with 32p_ 
labeled c-myc and GAPDH probes. GAPDH was used to cbeck equal loading of the lanes and ribosomal 
RNA bands (28 S, 18 S) served as molecular weight markers. Cells were cultured as described in 
Materials and Methods and incubated for 1 h with vehicle (lane 1 and 18), 10.10 M 17J3-~ (lanes 2-21), 
or 10-6 M tamoxifen (lanes 18-21). l,25-(OH}zD3 (10.9, 10-8, and 10'7 M) was added in lanes 3-5 and 19-
21, CB966 in lanes 6-8, EB1089 in lanes 9-11, KHI060 in lanes 12-14, and ocr in lanes 15-17. 
completely inhibited c-myc induction by 1713-E2 (Fig. 5.6, lane 18), With ZR-75-1 cells 
similar results were obtained (data not shown). Subsequently, we have tested in MCF-
7 cells the combined effects of 1,25-(OHlzD3/analogues and tamoxifen, The 
inhibition of 1713-E2-induced c-myc expression by tamoxifen was neither augmented by 
combined treatment with 1,25-(OHlzD3 (Fig. 5,6, lanes 19-21) nor by the vitamin D3 
analogues (data not shown), 
Vitamin D receptor binding 
VDR binding of the analogues was measured to study whether the differences 
between the vitamin D3 analogues in their ability to inhibit breast cancer cell growth 
were related to their affinity for the VDR, It is demonstrated in Table 5.1 that the 
analogues had a lower affinity for the VDR compared to 1,25-(OH)zD3. The reduced 
growth inhibitory potential of ocr corresponded with a lower VDR affinity 
compared to 1,25-(OHhD3' but the increased growth inhibitory potential of EB1089 
and KH1060 did not correspond with their lower VDR affinity, 
To study whether the increased sensitivity to the vitamin D3 compounds by 
cotreatment with tamoxifen was caused by increased VDR binding, we have measured 
VDR concentration in MCF-7 cells after incubation for 24 h with 10-6 M tamoxifen, 
The VDR concentration of 15 fmol/mg protein was not changed by treatment with 
tamoxifen, Also, 1713-E2 had not effect on VDR levels, 
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DISCUSSION 
The present data show that the growth inhibitory action of vitamin D3 
compounds and tamoxifen are complementary. In MCF-7 cells, which have partially 
escaped from oestrogenic control, combined treatment resulted in a stronger 
inhibition, than treatment with either compound alone. In ZR-75-l cells, which are 
fully oestrogen-dependent, the entire proliferation could be blocked by a high 
concentration of tamoxifen, whereas at lower tamoxifen concentration, vitamin D3 
compounds were able to augment the inhibitory effect of tamoxifen, similar as in 
MCF-7 cells_ The clinical use of lower dosages of tamoxifen may be beneficial, 
considering the relationship between tamoxifen and an increased risk on endometrial 
cancer (16)_ Resistance to tamoxifen therapy frequently occurs (17), and in this 
situation, treatment with vitamin D3 analogues could also be usefuL This is supported 
by our data that derivatives of ZR-75-l cells, which had acquired resistance to 
tamoxifen as a result of retroviral insertional mutagenesis (19), had not lost their 
response to the growth-inhibitory action of the vitamin D3 compounds. 
Despite the promising antiproliferative effects ill vitro, the calcaemic effects of 
vitamin D3 compounds may result in the development of hypercalcaemia when 
applied ill vivo. The present data show that the analogues EB1089 and KHl060 have 
the same growth-inhibitory action as 1,25-(OHhD3 at up to lOO-fold lower 
concentrations, whereas ill vivo studies have shown that the calcaemic activity of these 
compounds was equal or even lower (8,9). These results support the idea that the 
antiproliferative effects can be (partly) dissociated from the calcaemic effects. Our 
data on the potent growth inhibitory effects of EB 1089 and KH1060 are in line with 
other reports (8,12,13). Additionally, we show for the first time that EBl089 and 
KHI060 can also inhibit the growth of a fully 1711-E2-dependent cell line (ZR-75-l) 
with increased potency compared to 1,25-(OHhD3' In various ER-positive and ER-
negative human breast cancer cell lines OCT was 10 times more potent than 1,25-
(OHhD3 (II). In our hands the potency of OCT was somewhat diminished compared 
to l,25-(OH)zD3 in both cell lines studied. The reason for this discrepancy is not yet 
known. CB966 and l,25-(OH)zD3 were equipotent, and to our knowledge there are 
no other reports on the effect of CB966 on breast cancer cells. 
For translation of the antiproliferative action of vitamin D3 analogues on 
breast cancer cells in culture to the in vivo situation, the pharmacokinetic properties 
of the analogues play an important role (27). Further, negative side-effects have to be 
monitored. Apart from the development of hypercalcaemia other effects may arise, 
for instance the oxa-compounds OCT and KHI060 have been shown to exert strong 
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immunosuppressive activity (S,2S), and stimulation of bone resorption might increase 
the incidence of skeletal metastases (29) 
In view of the clinical importance of using low doses, the observation that, in 
combination with tamoxifen, the ECsos of 1,25-(OHh03 and analogues shifted to 
lower concentrations might be of interest. This shift was more pronounced for 1,25-
(OH)P3 and the compounds with an ECso close to 1,25-(OHhD3 (ocr and CB966) 
than for the compounds with a more favourable ECso (EBlOS9 and KHI060) in the 
absence of tamoxifen. TIJereby the differences in potencies between the analogues 
were smaller in the presence of tamoxifen. The shift of the ECsos of the vitamin D3 
compounds in the presence of tamoxifen points to an interaction between both types 
of growth inhibitors. This is in agreement with a report from Abe-Hashimoto et al. 
(30), who have observed synergism between ocr and tamoxifen in MCF-7 and ZR-
75-1 cells ill vitro as well as in MCF-7 tumour ill vivo. The mechanism of the 
interaction between tamoxifen and vitamin D3 compounds is yet unclear, but the 
present data show that it was not achieved via a change in VDR level. 
Notwithstanding the interaction between both growth inhibitors, at the maximal 
effective concentrations of the vitamin D3 compounds the effect of combined 
treatment with tamoxifen was additive (MCF-7 cells) or less than additive (ZR-75-1 
cells). 
Our data on the effect of combined treatment with tamoxifen and vitamin D3 
compounds point to several potential advantages when applied ill vivo: (a) a more 
beneficial response can be achieved than by either agent alone; (b) lower 
concentrations of 1,25-(OHlz0ianalogues and tamoxifen can be used with reduced 
risk of negative side~effects (hypercalcaemia, increased bone turnover, endometrial 
cancer); (c) since tumours are believed to be heterogenous with respect to ER status 
(31), combination therapy may have the advantage that both ER-positive and ER-
negative cells are inhibited; (d) tumour flare in response to tamoxifen may be 
prevented since 1,25-(OHhD3 has been shown to inhibit the oestrogenic effect of 
tamoxifen (IS); and (e) tamoxifen may attenuate the negative effects of vitamin D3 
compounds on bone metabolism by its positive oestrogenic effect on bone (32). 
Since 171l-E2 is an important regulator of breast cancer growth, we have 
addressed the question whether vitamin 03 compounds can interfere directly with the 
growth stimulation by 171l-E2. TIle data obtained with MCF-7 cells clearly indicate an 
oestrogen-independent mechanism of action: (a) the inhibition of 171l-E2-stimulated 
growth, expressed in I'g DNA/well, by the vitamin D3 compounds was similar to the 
inhibition of autonomous growth (maximum and ECsos); (b) the ER level was not 
down-regulated; (c) the rapid induction of c-myc mRNA, which is thought to mediate 
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the growth effect of 17B-E2 (33) was not affected; and (d) the expression of the 1713-
E[regulated pS2 gene was not changed 1. Moreover, an oestrogen independent 
mechanism of action is consistent with the fact that 1,25-(OHhD3 or analogues 
inhibit breast cancer cell growth irrespective of the presence of the ER (4,11). The 
inhibition of 17B-E2-induced growth of ZR-75-1 cells seems to contradict an entirely 
17B-E2-independent mechanism of action of the vitamin D3 compounds. However, as 
in MCF-7 cells, the ER and c-myc levels were not affected. Furthermore, EGF-
dependent proliferation of ZR/HERc cells (derived from ZR-75-1) was also 
inhibited, indicating that vitamin D3 compounds affect ZR-75-1 cell growth at a late 
stage of the signal cascades used by both the ER and EGF receptor. This may be 
achieved by induction of a negative growth factor or the inhibition of an autocrine 
loop. Also, the observed interaction between vitamin D3 compounds and tamoxifen 
may occur at this level, since tamoxifen has been shown to exert antioestrogenic as 
well as antigrowth factor activity mediated via the ER (34). 
In MCF-7 cells and several other cell types it has been demonstrated 1,25-
(OHhD3-induced differentiation and growth inhibition was preceded by a decrease in 
mRNA of the protooncogene c-myc (13,35-37), indicating that c-myc gene regulation 
could be involved in the pathway for 1,25-(OHhD3-mediated control of cell 
proliferation. However, we did not find changes in c-myc mRNA hy 1,25-(OHhD3 
neither in autonomously growing MCF-7 cells nor in 1713-E2-stimulated MCF-7 and 
ZR-75-1 cells, suggesting that downregulation of c-myc mRNA is not a prerequisite 
for the growth inhibition by vitamin D3 compounds in breast cancer cells. 
The differences between the growth inhibitory potential of the analogues are 
difficult to explain. The present data show that the maximal inhibition by 1,25-
(OHhD3 and analogues was the same, suggesting that they all act via the same 
pathway. Measurements of VDR affinity showed that the increased growth inhibitory 
potential of EB 1089 and KHI060 was not related to a higher VDR affinity. Also, 
VDR-independent or nongenomic mechanisms of action have been attributed to 1,25-
(OHhD3 and analogues (2). However, it has been reported that the antiproliferative 
action of 1,25-(OHhD3/analogues is restricted to VDR-positive cells (38). Other 
explanations could be differences in cellular metabolism of the analogues, receptor 
phosphorylation or conformational changes of the receptor-ligand complex. 
In conclusion, a more beneficial growth response of ER-positive breast cancer 
cells was observed by combined treatment with vitamin D3 analogues and tamoxifen 
than by treatment with these compounds alone. The vitamin D3 analogues were active 
IT. Vink-van Wijngaarden, H.A.P. Pols, J.C. Birkenhager, and J.P.T.M. van Leeuwen, unpublished data. 
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at up to IOO-fold lower concentrations than the native compound 1,25-(OH}zD3' 
which is important to reduce the risk on negative side-effects. Tamoxifen increased 
the sensitivity to 1,25-(OH}zD3 and analogues, which could implicate that in 
combination therapy even lower concentrations of the vitamin D3 compounds can be 
used. Further, it was shown that also the growth of antioestrogen-resistant cells could 
be inhibited by 1,25-(OH}zD3 and analogues. Thereby, vitamin D3 analogues are 
interesting candidates for breast cancer therapy. 
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ABSTRACT 
1,25-Dihydroxyvitamin D3 (1,25-(OHhD3) has been shown to inhibit breast cancer 
cell growth both ill vitro and ill vivo. A major drawback is that high doses of 1,25-
(OHhD3 are needed which may result in undesirable side effects like the development 
of hypercalcaemia and an increased risk of bone metastases due to the stimulation of 
bone resorption by 1,25-(OH)P3' Several newly developed 1,25-(OHhD3 analogues 
have a reduced calcaemic activity, but their direct effects on bone resorption have not 
yet been examined. Presently, the anti oestrogen tamoxifen is the most important 
endocrine therapy for breast cancer. Recent studies have demonstrated the benefit of the 
combination tamoxifen and 1,25-(OHhD3janalogues for the inhibition of breast cancer 
cell growth. Besides inhibition of breast cancer growth tamoxifen appeared to have 
beneficial effects on bone. The purpose of the present study was to investigate the effect 
of tamoxifen on 1,25-(OHhD3- and analogues (EBl089 and KH1060)-stimulated bone 
resorption in an in vitro model. Bone resorption was stimulated by 1,25-(OHhD3 and 
analogues in a dose-dependent manner with KH1060 and EB1089 being more potent 
than 1,25-(OHhD3' Tamoxifen caused a strong dose-dependent inhibition (70 % at 10 
I'M) of 1,25-(OHhD3- and EB1089-stimulated bone resorption. KH1060-stimulated bone 
resorption was also inhibited by tamoxifen but to a lesser extent (36 %). Also the pure 
antioestrogen ICI164,384 but not 17Il-oestradiol inhibited 1,25-(OHhD3-stimulated bone 
resorption. Together, this study demonstrates that tamoxifen considerably reduces 1,25-
(OHhD3janalogues-stimulated bone resorption and therefore may be useful to reduce 
the risk of bone metastases. This together with the observed beneficial effects on breast 
cancer cell growth indicates that tamoxifen together with 1,25-(OHhD3 janalogues is an 
interesting combination for the treatment of breast cancer. The mechanism of the bone 
resorption inhibitory action is not yet known but seems to be independent of the 
oestrogen pathway. 
INTRODUCTION 
Besides regulation of calcium and bone metabolism, both in vivo and in vitro 
studies have shown that 1,25-dihydroxyvitamin D3 (1,25-(OHhD3) inhibits the growth of 
breast cancer cells (1,2). These findings suggest a potential use of 1,25-(OHhD3 for the 
treatment of breast cancer. However high doses of the sterol are needed. Therefore it 
remains to be established whether 1,25-(OHhD3 can produce long term anti tumour 
effects without unacceptable side effects, like the development of hypercalcaemia. Also, 
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the relation between increased bone resorption, which is stimulated by 1,25-(OHlzD3, 
and the development of bone metastases has been described (3-6)_ Rats treated with 
1,25-(OHlzD3 had significantly more skeletal metastases than untreated controls when 
intra-arterially injected with Walker 256 tumour cells (5)_ A number of vitamin D3 
analogues have been developed which inhibit breast cancer cell growth at lower con-
centrations compared to 1,2S-(OHlzD3 (7,8)_ The analogues EB 1089 and 22-oxa-calcitriol 
inhibited tumour growth without marked hypercalcaemic effects in animal models for 
breast cancer (9,10)_ So far, the effects on bone resorption have not been examined_ 
Tamoxifen is currently the most widely used endocrine therapy for breast cancer_ 
Recently, interactions between 1,25-(OH)2Dianalogues and tamoxifen with respect to 
growth inhibition of breast cancer cells have been observed (8,11)_ We have shown that 
in combination with tamoxifen significantly lower concentrations could be used which 
would increase the therapeutic potential of 1,25-(OH}zD3/analogues (8)_ Finally, in 
breast cancer patients it was shown that tamoxifen has protective effects on the skeleton 
(12,13)_ 
In the present study we extended the investigations on the combination of 1,25-
(OHlzD3/ analogues and tamoxifen to the regulation of bone resorption_ Thereby these 
data may provide evidence whether tamoxifen combined with 1,25-(OH)2D3/analogues 
not only enhances the inhibition of breast cancer cell growth but that tamoxifen also 
potentially reduces the risk of skeletal metastases by inhibiting 1,25(OHlzD3/analogues-
stimulated bone resorption_ 
MATERIALS AND METIIODS 
Chemicals 
1,2S-(OH)2D3' EBI089 (7), and KHI060 (16) were kindly donated by Dr. L, Binderup, LEO Pharm. 
Products, Ballerup, Denmark. Tamoxifen, 17fl-oestradiol, and MIT were purchased from Sigma Chemical 
Co. st. Louis, MO, USA, and 45 CaCI2 from Amersham, Aylesbury, UK. ICI164,384 was a generous gift of 
Dr. AE. Wakeling, leI Pharm., UK. 
III ~'ifro bone resorption 
The ill vitro bone resorption assay is based on the release of 45Ca from prclabelled fetal mouse long 
bones, radii and ulnac, during two successive culture periods of three days and performed as described 
previously (14). The 4SCa content of the medium at 3 and 6 days and of 5 % formic acid extracts of the 
bones were measured by liquid scintillation counting and used to calculate the cumulative percentage 4SCa 
released. 
Toxicity assay 
In order to test the toxicity of the antiocstrogens in the long bone cultures we have measured at the 
end of each resorption experiment the conversion of MIT into formazan by viable cells by measuring the 
absorbance at 540 om (14,15). 
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Data analysis 
Interactions between l,2S-(OHhD3/analogues and the antioestrogens and 170-oestradiol were 
evaluated using analysis of variance for two-way design, 
RESULTS 
1,25-(OHlzD3, EBI089, and KH1060 stimulated ill vitro bone resorption in a dose-
dependent manner (Figs. 6.2A-C). Based on EDso, KH1060 and EBI089 were about 100 
and 10 times more potent than 1,25-(OHlzD3, respectively. As shown in Fig. 6.1, 1,25-
(OHlzD3-stimulated bone resorption was inhibited by 1 I'M tamoxifen both after 3 (47 
% inhibition) and after 6 days (50 % inhibition) . 
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Figm'c 6.1. Inhibition of 10'9 M i,25-(OHhD3-
stimulated bone resorption by 1 /tM tamoxifen 
after 3 and 6 days of culture. Data are expressed 
as mean ± SEM of 3 independent experiments, 
each consisting of 4 bones per group. a: p<O.OO5j 
b: p<O.OOOl calculated as the significance of 
interaction between l,25-(OH)zD3 and tamoxifen. 
EB1089- and KHlO60-stimulated bone resorption was also inhibited after 3 as well as 
6 days of culture (data not shown). Tamoxifen inhibited the 1,25-(OHlzD3- and EB1089-
stimulated bone resorption in a dose-dependent manner with 10 I'M tamoxifen being the 
most potent. In all experiments performed 10 I'M but not 1 I'M tamoxifen caused a small 
but significant reduction (p<0.001) of basal bone resorption (Figs. 6.2A-C). Maximally 
stimulated bone resorption by 10-9 M 1,25-(OH)zD3 and EBI089 was almost completely 
reduced to control level by 10 I'M tamoxifen (Figs. 6.2A and B). KHlO60-stimulated 
bone resorption was also inhibited by tamoxifen. However, in contrast to 70 % inhibition 
of the 1,25-(OHhD3 and EB 1089 effect, 10-9 M KHI060-stimulated bone resorption was 
only reduced by 36 % by 10 I'M tamoxifen (Fig. 6.2C). Concentrations up to 10 I'M 
tamoxifen were not toxic, whereas with higher concentrations (25 and 50 I'M) cell death 
was observed (data not shown). 1,25-(OHhD3-stimulated bone resorption was also 
inhibited by the 4-hydroxy metabolite of tamoxifen (data not shown). 
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Figures 6.2A, HJ and C. Inhibition of A) 1,25· 
(OH),D,-, B) EBl089-, and c) KHI060-
stimulated bone resorption by tamoxifen after 6 
days of culture. Data are expressed as mean ± 
SEM of 2-4 independent experiments, each 
consisting of 4 bones per group. a: p<O,OS, b: p<-
0.025, c: p<O.OOO5 calculated as the significance of 
interaction between l,25·(OH)2D3/ analogues and 
tantoxifen, 
As tamoxifen has been reported to have oestrogen agonistic and antagonistic 
activity both the effects of a pure antioestrogen, ICI164,384, and that of 17fl-oestradiol 
on 1,25-(OHhD3-stimulated bone resorption were examined. 17l3-oestradiol alone did 
not change in vitro bone resorption nor inhibited 10-9 and 10-8 M 17l3-oestradiol 1,25-
(OHhD3-stimulated bone resorption (data not shown). Like tamoxifen, the pure 
antioestrogen ICI164,384 (10 I'M) inhibited 10-9 M 1,25-(OH)zD3-stimulated bone 
resorption after 3 and 6 days of culture by 47 and 61 %, respectively (Fig. 6.3). With 5 
I'M ICI164,384 a small but not significant inhibition was observed whereas 1 I'M was not 
effective (data not shown). 
In order to investigate whether the inhibitory effect of tamoxifen was specific for 
1,25-(OH}zD3/analogues the effect on PTH-stimulated bone resorption was studied. 
Tamoxifen (10 I'M) caused a small but not statistically significant reduction of 10-9 M 
PTH-stimulated bone resorption. 
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ICI164,384 . 
A potential side-effect of treatment of breast cancer by l,25-(OHhD3/analogues 
is the increased risk of skeletal metastases due to the stimulation of bone resorption by 
l,25-(OHhD3 and analogues (5). Several studies have described the relation between 
bone resorption and metastasis to bone (3,4,6). In contrast to the development of 
hypercalcaemia during treatment with 1,25-(OHhD3/analogues, in the in vivo studies 
performed so far with 1,25-(OHhD3 and analogues in relation to tumour growth 
inhibition this aspect has not been addressed (9,10). The present study demonstrates for 
the first time that bone resorption stimulated by 1,25-(OHhD3 and 1,25-(OHhD3-
analogues can be inhibited by the antioestrogen tamoxifen. Although we have not directly 
measured bone metastases, this study suggests that a tamoxifen-I,25-(OHhDi analogues 
combination therapy may result in a reduced risk of skeletal metastases due to 1,25-
(OHhD3/analogues-stimulated bone resorption. 
The' analogues EB1089 and KHlO60 are potent inhibitors of breast cancer cell 
growth (8). However, these analogues are also more potent stimulators of in vitro bone 
resorption compared to 1,25-(OHhD3' Irrespective of their difference in bone resorbing 
potency tamoxifen caused a similar inhibition of 1,25-(OHhD3- and EBlO89-stimulated 
bone resorption. KH lOGO-stimulated bone resorption was also reduced by tamoxifen, but 
to a much lesser extent. It is unlikely that KH1060 will be a possible candidate for treat-
ment of breast cancer or other malignancies as it has a profound immunosuppressive 
effect (16), whereas with EB1089 already promising animal studies have been performed 
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(10). An explanation for the observed discrepancy between 1,25-(OHhD3/ EB1089 and 
KH1060 is unknown and studies on the precise inhibitory mechanism of tamoxifen and 
the mechanism of action of KH1060 are needed. 
Tamoxifen is a widely used anti oestrogen in the treatment of breast cancer in 
postmenopausal women (17). However, it exhibits antioestrogenic as well as oestrogenic 
properties, depending on the organ or cellular response studied. On bone tamoxifen acts 
as a partial oestrogen agonist (18,19), moreover it has protective effects on the skeleton 
in breast cancer patients (12,13). The present data question whether the observed 
inhibition of bone resorption is due to an oestrogenic effect because with 17l3-oestradiol 
no inhibition of stimulated bone resorption was observed. Moreover, the pure 
anti oestrogen ICI164,384, which lacks oestrogen agonistic activity (20), caused a com-
parable inhibition of 1,25-(OHhD3-stimulated bone resorption as tamoxifen. The 
mechanism by which tamoxifen and ICI164,384 inhibit stimulation of bone resorption is 
yet unknown. Protein kinase C is a p.ossible target as tamoxifen has been described to 
inhibit protein kinase C (21) and we have shown that protein kinase C is involved in the 
stimulation of bone resorption by 1,25-(OH)P3 (14). The inhibitory effect of tamoxifen 
(up to 10 I'M) seems to be specific for 1,25-(OHhD3/analogues as PTH-stimulated bone 
resorption was not affected. This is in accordance with data of Stewart and Stern (22). 
In contrast, they observed inhibition of the PTH action with higher concentrations (40 -
100 I'M) of tamoxifen. However, these concentrations appeared to be toxic in our 
studies. 
Finally, the current study adds important data to the observed beneficial effects 
of combined treatment of breast cancer cells with tamoxifen and 1,25-
(OHhD3/analogues (8,11,23). These latter studies showed that co-treatment with 1,25-
(OHhD3/analogues and tamoxifen results in a stronger growth inhibition of breast 
cancer cells and that lower concentrations of 1,25-(OHhD3 and analogues can be used 
to achieve a similar effect. Together these data underscore the potential benefit of the 
combination of tamoxifen and 1,25-(OHhD3/analogues in the treatment of breast 
cancer. 
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ABSTRACT 
1,25 Oihydroxyvitamin OJ (1,25-(OHlz0J) and a number of synthetic vitamin 
OJ analogues with low calcemic activity, have been shown to inhibit breast cancer cell 
growth ill vitro as well as ill vivo. The purpose of the present study was to investigate 
a possible interaction of 1,25-(OHlz0J and the vitamin OJ analogue EBI089 with the 
insulin/IGF-I regulatory system. The oestrogen receptor-positive MCF-7 human 
breast cancer cells used in this study are able to grow autonomously and their growth 
is stimulated by insulin. In order to avoid interference of IGF-binding proteins (IGF-
BPs) we have used an analogue of IGF-I, long RJ IGF-I, which stimulated MCF-7 
cell growth similar to insulin. The growth stimulation by insulin and by long RJ IGF-I 
was completely inhibited by 1,25-(OHlzDJ and EBI089. Also the autonomous growth 
was inhibited by 1,25-(OH)PJ and EB1089. The analogue EB1089 was active at 50 
times lower concentrations than 1,25-(OH)PJ. It was shown that the growth 
inhibition was not achieved via a down-regulation of the insulin and IGF-I binding 
after 48 h. Paradoxically, after prolonged treatment (8 days) an upregulation of the 
insulin and IGF-I binding was observed. Two possible intracellular mediators of the 
insulin/IGF mitogenic signal are c-fos and mitogen activated protein (MAP) kinase. 
Insulin-induced c-fos mRNA was inhibited by 1,25-(OHlz0J, suggesting that c-fos 
could be involved in the growth inhibition by 1,25-(OHlz0J. MAP kinase activation 
appeared not to be involved in the growth stimulation by both insulin and IGF-I. 
Together, the present study demonstrates that vitamin OJ compounds can block the 
mitogenic activity of insulin and IGF-I, which may contribute to their tumour 
suppressive activity observed in vivo. 
INTRODUCTION 
Besides regulation of calcium and bone metabolism the most active metabolite 
of vitamin 0, 1,25·dihydroxyvitamin 03 (1,25-(OH)PJ) regulates growth and 
differentiation of a wide variety of cells and tissues (1,2). Both ill vitro and ill vivo 
studies have shown that 1,25-(OHlz0J inhibits the growth of breast cancer cells (3-7) 
and these findings suggest a potential use of 1,25-(OHlz0J for the treatment of breast 
cancer. A major drawback is that high doses are needed for tumour suppression. This 
may result in undesirable side-effects, like the development of hypercalcemia. To 
overcome these problems, a number of promising synthetic vitamin 03 analogues 
have been developed, with more potent effects on growth and differentiation and a 
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reduced ill vivo ca!cemic activity (8,9). 
Breast cancer growth is regulated by numerous factors, including steroid 
hormones and polypeptide growth factors (10). Insulin, insulin-like growth factor I 
(IGF-I) and insulin-like growth factor II (IGF-II) are structurally related molecules 
which are believed to play an important role in promoting breast tumour growth (11-
14). The IGFs and insulin are derived from the circulation. The IGFs are also 
produced by breast tumour cells and by neighbouring stromal cells in the breast 
tumour and can act in an autocrine or paracrine manner (11,13,15). These three 
polypeptide hormones exert their biological activity by binding to distinct 
transmembrane receptors: the closely related insulin and type I IGF receptor, and the 
type II IGF receptor or mannose-6-phosphate receptor. Considerable cross-reactivity 
exists between the various ligands and receptors (16). In addition to the three 
receptors, the IGFs bind to other binding proteins which are found in serum and are 
produced by a wide variety of different cell types. To date six IGF binding proteins 
(IGF-BPs) have been cloned (17). Breast tumours and breast cancer cell lines express 
IGF-BP2 to IGF-BP6 in a heterogenous pattern, while little or no expression of IGF-
BPI is seen (18-20). At the cellular level IGF-BPs can either potentiate or suppress 
the activity of the IGFs (17,18). 
In earlier reports we have studied the interference of 1,25-(OH)z03 with the 
growth stimulation of human breast cancer cell lines by oestradiol. It was shown in 
MCF-7 cells that the inhibition by 1,25-(OH)P3 and several vitamin 03 analogues 
was independent of oestradiol (7,21). So far, no data are available on the interaction 
of vitamin 03 compounds with the insulin and IGF-I regulatory system of breast 
cancer cells. In the present study, we have investigated the effects of 1,25-(OH)z03 
and a promising vitamin 03 analogue, EBI089, on iruulin- and IGF-I-stimulated 
growth of MCF-7 cells. As IGF-BPs are important, but often complex regulators of 
IGF actions, we have avoided an interference with IGF-BPs produced by MCF-7 cells 
by using insulin and analogues of IGF-I, long R3 IGF-I and des(I-3)IGF-I, which have 
a reduced binding to IGF-BPs. Furthermore, we have studied the effects of 1,25-
(OH)z03 and EB1089 on insulin and IGF-I binding, and intracellular mediators of 
the insulinjIGF signal: c-fos mRNA expression (22,23) and mitogen-activated protein 
(MAP) kinase activity (24). 
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MATERIALS AND METIIODS 
Chemicals 
l,2S-(OHhD3 and EBI089 (25) were kindly donated by Dr. L. Binderup of LEO Pharmaceutical 
Products (Ballerup, Denmark). The chemical structure of EB1089 is depicted in Figure 7.1. Insulin, 
RPMI-l640 cell culture medium, human transferrin, sodium selenite, and bacitracin were purchased from 
Sigma Chemical Co. (St. Louis, MO, U.SA.). IGF-I, long R3 IGF-I, and des(1-3)IGF.I were from 
GroPcp Pty. Ltd, (Adelaide, Australia). Long R3 IGF-I is an analogue of human IOF-J synthesized in 
E.coli and has a substitution of an ARG for OLU at position 3 and an extension of 13 amino acids at the 
N-terminus (26). Oe5(1-3) is a truncated form of IOF-l which lacks three N-terminal amino acids (27). 
e25I]-insulin labeled at tyrosine-A14 (2000 Ci/mmol) and e25I]-IGF-I (2000 Cifmmol) were from 
Amersbam International (Buckinghamsbire, U.K.). The aIR3 antibody against the type I IGF receptor 
was purchased from Oncogene Science Inc. (Uniondale, NY, U.SA.). Bovine serum albumin fraction V 
(BSA) was purchased from ICN Biomedicals Inc. (Costa Mesa, CA, U.SA.). Glutamine, penicillin, and 
streptomycin were obtained from Life Technologies (Paisley, U.K.), and fetal calf serum (FCS) was from 
Sera-Tech ZeUbiologiscbe Produkte GmbH (SI. Salvator, Germany). 
HO/'''''' OH 
1,25-(OH)2D3 
I 
I 
HO /,,,,,, OH 
EB 1089 
OH Cell culture 
MCF-7 cells were generously provided 
by Dr. JA. Foekens, Dr. Daniel den Hoed 
Cancer Center (Rotterdam, The Netherlands). 
MCF-7 cells were routinely maintained in 
phenol red-free RPMI-1640 medium 
supplemented with 2 ruM glutamine, 100 
units/ml penicillin. 100 pg/ml streptomycin, 24 
mM sodium bicarbonate (= basal RPMI. 
medium) plus 10% FCS and 10 Jtg/ml insulin. 
Prior to the start of the experiments the cells 
Figure 7." Chemica! structures of 1,25- were deprived from insulin and serum as 
(OH}zD3 and EB1089. foUows: the cells were trypsinin~d and seeded in 
phenol red-free basal RPMI medium supple-
mented with 2% charcoal-treated FCS (25,000 cells/cm2). The FCS was addcd for the attachement of the 
cells. After 24 h the medium was changed to serum-free basal RPMl medium supplemented ,vith 2 
mg/ml BSA, 10 Jlg/ml transferrin, and 30 nM sodium selenite (= SFM). Next, the medium was 
refreshed every two or three days. After one week the ceUs had grown to subconfluence and the 
procedure was repeated. For the experiments we have used cells that were cultured in SFM: for several 
weeks. The experiments were started by seeding the cells in basal RPMJ medium supplemented with 2% 
charcoal-treated FCS. After 24 h the medium was changed to SFM and after another 24 h the SFM was 
refreshed and the agents to be tested were added. For long-term experinlents the medium and test 
agents were replaced every 3 days. 
Proliferation expel'imenls 
MCF·7 cells were seeded into 24-well dishes at a density of 4000 cclls/cm2 and incubated with 
the compounds to be tested as described in the section "Cell Culture". After 8 days of incubation DNA 
content was measured using the ethidium bromide method as described previously (7). 
Insulin Rnd IGF·I binding 
The insulin and IGF·I binding a<;say was performed as described by Maassen et al. (28). For the 
short-term incubations MCF-7 cells were grown to subconflucnce in SFM in six-well dishes and were 
subsequently exposed to the vitamin 0 3 compounds for 24 or 48 h. For the long-term incubations (8 
days) the cells were exposed to the vitamin D3 compounds from the start of the experiment as described 
in the seelion "Cell Culture". At the end of both the short- and long-term incubations, the cells were 
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washed twice in PBS (pH 7,8) plus 10 mg/ml BSA. Subsequently the cells were incubated with 3 x 10.11 
M 2P2511·insulin in PBS (pH 7.8) plus 10 mg/ml BSA for 2.5 h at room temperature or with 3 x 10'11 M 
[1 I1-IGF-I in PBS (pH 7,8) plus 10 mg/ml BSA and 2 rug/ml bacitracin for 3.5 h at 4 C. Non-specific 
binding was assessed by incubating the cells with labeled insulin in the presence of 1 pM unlabeled 
insulin or with labeled JGF-J in the presence of 0.1 11M unlabeled IGF-I. After the incubation the cells 
were washed 5 times with ice-cold PBS flUS 1 mgJml BSA and solubilized in 0.1 M NaOH, 0.1% SDS. 
The amount of bound [l25IJ-insulin or [ 2S1]-IGF-I was determined in a gamma counter (NEl600, NE 
Technology Ltd.) Reading, U.K.) and corrected for the absorption at 260 nm, which was used as a 
measure for the cell number. 
Assay of MAP kinase aclivity 
MCF-7 cells were seeded (2 x 104 cells/cm2) and incubated with the compounds to be tested for 
5 to 30 min as described in the section "Cell Culture". Upon activation MAP kinase is phosphorylated. 
Activation of MAP kinase was detected by immunoblotting of cell homogenates as described by Van den 
Berghe et al. (29). The method is based on a shift in gelelcctrophorelie migration due to phosphorylation 
of MAP kinase. 
RNA isolation and hybridization 
Cells were seeded (1.5 x 106 cells/25 cm2 flask), and incubated with the compounds to be tested 
as described in the section "Cell Culture". Total RNA was isolated by guanidinium thiocyanate-phenol-
cWoroform extraction and Northern analysis with 10-20 Ilg RNA was performed as described previously 
(21). Northern blots were hybridized with f 2P].labeled human cDNA fragments specific for c-fos (30) 
and GAPDH (31). Afler hybridization the Northern blots were washed twice in 2x SSC, 0.1% SDS for 5 
min at room temperature, twice in 2x SSC, '0.1% SOS for 20 min at 60 C, and twice in 0.5x SSC, 0.1% 
SDS for 20 min at 60 C. Membranes were exposed to medical X-ray films (Fuji Photo Film Co.) Tokyo, 
Japan) with intensifying screens at ·80 C, and the autoradiographs were quantified using a ScanJet IIcx 
seauller (Hewlett-Packard Co., Minneapolis, U,S.A,). Before rehybridization with OAPDH, Northern 
blots were washed in 5 mM Tris-HCI (pH 8.0), 0.2 ruM EDTA (pH 8.0), 0.05 % sodium pyrophosphate, 
and 0.1x Denhardt's solution for at least 2 h at 65 C. 
RESULTS 
Inhibition of insulin- and IGF-I-stimulated growth by vitamin D3 compounds 
The MCF-7 cells in our laboratory are able to grow autonomously in SFM 
without further additions. The autonomous growth was stimulated by treatment with 
insulin. After 8 days of treatment the DNA content of the wells containing SFM 
supplemented with insulin was 1.5- to 2-fold higher than the DNA content of the 
control wells without insulin. The insulin dose-response curve was steep with the 
maximum growth stimulation reached at 5 I'g/m1 and a median effective concen-
tration of 1 I'g/ml insulin (Fig. 7.2). 
The growth stimulation by 10 I'g/m1 insulin could be dose-dependently 
inhibited both by 1,25-(OH)zD3 and the vitamin D3 analogue EB1089 (Fig. 7.3). 
Based on the median effective concentration, EB 1089 was approximately 50 times 
more potent than 1,25-(OHhD3 in the inhibition of insulin-stimulated growth. Both 
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Figure 7.2. Growth stimulation of MCP·7 cells 
by insulin and long R3 IGF-I. CeUs were 
cullured for 8 days in SFM as described in the 
section "Cell Culture" with various 
concentrations of insulin or long R3 IGP·I, 
Subsequently DNA content was measured, Each 
point represents mean ± SD of duplicate wells. 
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Figure 73. Inhibition of insulin-stimulated 
growth of MCF-7 ceUs by 1,25-(OH),o, aod 
EB1089. Cells were cultured for 8 days in SFM 
supplemented with 10 Ilg/ml insulin and the 
indicated concentrations of the vitamin D3 
compounds or vehicle (0.1% ethanol) as 
described in the section "Cell Cuhure", Each 
point represents mean ± SD of duplicate wells. 
vitaminD3 compounds not only reversed the growth stimulation by insulin but also 
inhibited part of the autonomous growth of MCF-7 cells. 
Since insulin binds not only the insulin receptor but also the IGF type I 
receptor with low affinity (16), it is possible that the observed stimulation by 
supraphysiological concentrations of insulin is mediated via the type I IGF receptor. 
To test this possibility we have studied whether the insulin-stimulated growth could be 
inhibited by the type I IGF receptor blocking antibody "IR3. The antibody inhibited 
the insulin-stimulated growth by 24%. A small inhibition of the autonomous growth 
(9%) was observed (Fig. 7.4). 
Next, we have examined the mitogenic effect of IGF-I on MCF-7 cells. To 
avoid an interference with IGF-BPs secreted by MCF-7 cells, we have tested two 
analogues of IGF-I, long R3 IGF-I and des(I-3)IGF-I, which have a reduced binding 
to IGF-BPs (26,27). Fig. 7.2 demonstrates that MCF-7 cells respond to long R3 IGF-I 
with a similar increase of DNA content as obtained with insulin. The median effective 
concentration was 0.5 I'g/ml long R3 IGF-I. Also for des(I-3)IGF-I relatively high 
concentrations were needed to elicit a proliferative response. Des(I-3)IGF-I was not 
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Figure 7.4. Effect of aIR3 on insulin· 
stimulated growth of MCF·7 cells. Cells were 
cultured for 8 days in SFM (autonomous 
growth), or SFM supplemented with 10 
f1~/ml insulin. The cells were treated with or 
WJlhout 10 ttg/mi aIR3. Data are presented 
as mean ± SD of duplicate wells. a: 
p<O.025, b: p<O.OOl vs, autonomous control, 
and c: p<O.OOl vs. insulin-slimulated control. 
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Figure 7.5. Inhibilion of autonomous and long R3 
IGF-I-stimulated growth of MCF-7 cells by 1,25-
(OHhD3 and EBI089, Cells were cultured for 8 
days in SFM (autonomous growth), or SFM 
supplemented with 1 llg/ml long R3 IGF-I. The 
cells were treated with vehicle (0,1% ethanol), 1,25-
(OHhD3 (1,25) or EB1089 as indicated in the 
legend. Data arc presented as mean ± SD of 
duplicate wells, 
active at concentrations below 1 I'g/ml (data not shown). Several studies have shown 
a synergistic action of insulin/IGF-I and oestradiol (32-34). However, in our culture 
system the mitogenic effects of insulin and the IGF-I analogues could not be 
sensitized by co-treatment with oestradiol (data not shown). 
Similar to the inhibition of insulin-stimulated growth, the growth stimulation by 
long R3 IGF-I could be completely reversed by 1,25-(OHh03 and the analogue 
EB1089 (Fig. 7.5). At 10-9 M the differences in potency between 1,25-(OHh03 and 
EB1089 are clearly demonstrated. In addition, Fig. 7.5 demonstrates that the 
autonomous growth was also potently inhibited by 1,25-(OHh03 and EB1089. 
Insulin and IGF-I binding 
Insulin binding was maximal after 2 h and non-specific binding was 9% of the 
total binding. For !GF-I the non-specific binding was 22% of the total binding. 
Competitive binding studies of [125IJ-insulin showed that insulin competed at 
approximately 300 times lower concentrations than IGF-I (Fig. 7.6). 
Next, we have studied whether the vitamin 03 compounds could exert their 
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antiproliferative action on insulin- and IGF-I-stimulated growth via regulation of 
insulin or IGF-I binding. Incubations for 48 h with 1,25-(OH)P3 and EB1089 (10-9, 
10-7 M) had no effect on the specific insulin or IGF-I binding (Table 7.1). In addition 
we have studied the effect of long-term incubations with 1,25-(OHhD3 and EB1089 
at time-points where the growth inhibition by the vitamin D3 compounds was 
observed. As shown in Table 7.1, treatment with 1,25-(OHhD3 and EB1089 resulted 
in a stimulation of approximately 2-fold the control insulin binding and 3-fold the 
control IGF-I binding. 
Table 7.1. Insulin and IOF-I binding of MCF-7 cells treated with 1,25-(OHhD3 and EBI089. 
Short-term incubation (48 h) 
Condition Insulin binding IGF-! binding 
exp.l exp.2 exp.l exp.2 
Control 100 ± 13 100 ± 5 100 ± 2 100 ± 7 
10.9 M 1,25-(OH),D3 103 ± 9 99± N.D. N.D. 
10-7 M 1,25-(OH),D3 122 ± 11 125 ± 33 135 ± 3 106 ± 5 
10,9 M EBI089 129 ± 23 98 ± 2 N.D. N.D. 
10'7 M EB1089 112 ± 0 85 ± 10 120 ± 8 101 ± 8 
Long-term incubation (8 days) 
Condition Insulin binding IOp·I binding 
exp.l exp.2 exp.l exp.2 
Control 100 ± 20 100 ± 9 100 ± 2 100 ± 4 
10'9 M 1,25,(OH),D3 98 ± 2 125 ± 26 N.D. N.D. 
10,7 M 1,25-(OH),D3 153 ± 18 165 ± 11 268 ± 10 392 ± 1 
10,9 M EBI089 135 ± 13 239 ± 46 N.D. N.D. 
10,7 M EB1089 198 ± 49 230 ± 45 274 + 1 263 ± 35 
MCF-7 cells were incubated during 48 h or 8 days with or without 1,25-(OH)2D3 and EB1089 and 
subsequently the specific (l2SJJ-insulin and [l25IJ-IGF-I binding was measured as described under 
"Materials and Methods". The specific binding was corrected for the cell number and expressed of % 
of control ± SD of duplicate wells. N.D., not determined. 
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Figure 7.6. Binding of insulin to monolayers of 
MCF~7 cells. MCP·7 cells were grown to 
confluence in SFM and incubated witb 3 x 10- 11 
M e25I]-insulin for 2.5 h in the presence of the 
indicated concentrations of unlabeled insulin 
(solid circles) or IGF-I (tdangles). Bound e25I] . 
insulin was measured as described under 
"Materials and Methods", Data are expressed as 
mean ± SD of duplicate wells. 
Effect of the vitamin D3 compounds on intracellular mediators of the insulin/lGF-1 
signal: c-fos mRNA expression and MAP kinase 
Induction of c-fos expression is believed to play a central role in the 
transduction of mitogenic signals in the nucleus (22,23). c-fos mRNA expression was 
rapidly induced by insulin with a peak at 30 to 60 min and a gradual return towards 
prestimulation level in 4 h (Fig. 7.7). Figure 7.8 shows that the rapid induction of c-
fos mRNA by insulin was inhibited by treatment with 1,2S-(OH}zD3' Basal c-fos 
mRNA expression was not affected by 1,2S-(OHhD3 (not shown). 
Activation of MAP kinase is another intracellular mechanism involved in the 
signal transduction of growth factors (24). We wanted to study whether the vitamin 
D3 compounds could affect MAP kinase activity as a mechanism for the observed 
inhibition of insulin-/long R3 IGF-I-stimulated growth. However, in MCF-7 cells there 
was no detectable activation of MAP kinase by insulin, nor by long R3 IGF-I in a 
time course from S to 30 min. As a positive control of the assay 10% FCS was used, 
which caused activation of MAP kinase after 10 min of incubation (not shown). 
DISCUSSION 
In the present study we show that 1,2S-(OH}zD3 and the vitamin D3 analogue 
EB1089 are able to reverse the mitogenic effect of insulin and an IGF-I analogue 
(long R3 IGF-I) on MCF-7 breast cancer cells. The vitamin D3 analogue EB1089 was 
active at SO-fold lower concentrations than the native compound 1,2S-(OH}zD3' This 
is in line with other studies on the antiproliferative action of EB 1089 on breast cancer 
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induced c-fos mRNA expression. MCF· 
7 cells were incubated with 10 pg/rut 
insulin for 0, 0.5, 1, 2, Of 4 h. RNA was 
isolated and Northern blots Were 
prepared as described under "Materials 
and Methods" and the blots were 
hybridized with e2p].labeled fos and 
GAPDH probes. 
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Figure 7.8, Inhibition of insulin-induced c-fos mRNA by 
l,25·(OHhD3. MCF-7 ceJls were treated without insulin 
(C) or with 10 {(g/ml insulin and 10.10 - 10.7 M 1,25-
(OH),D3 (10 - 7) or vchicle (0) for 30 min. Subsequently 
RNA was isolated, Northern blots were prepared and 
hybridized e2p).Jabeled probes specific for GAPDH (1.6 
kb mRNA) and dos (2.2 kb ",RNA). The 
autoradiograph shown was quantitated densitometrically. 
The c-fos signal was divided by the GAPDH signal to 
correct for equal loading of the lanes. 
cells (21,35,36)_ Tn vivo studies with rats have shown that EB1089 has a decreased 
ability to affect calcium metabolism compared to 1,25-(OHhD3 (36). Moreover, 
Colston et aI_ showed that EB1089 suppressed tumour growth in rals with chemical-
induced breast cancer (35). Thereby, EB1089 appears to be a promising analogue for 
the treatment of breast cancer. 
IGF-I as well as insulin are believed to play an important role in the 
development and growth of breast tumours (11-14). In oestrogen-responsive cells 
insulin and the IGFs can contribute to oestrogen-induced growth (32-34). Thereby, 
interruption of insulin/IGF-induced growth by the vitamin D3 compounds may affect 
both oestrogen-independent and oestrogen-dependent breast tumours. This may 
provide an explanation for the observation that vitamin D3 compounds inhibit the 
growth of breast cancer cells and tumours irrespective of the presence of the 
oestrogen receptor (4,37). 
Although most attention has been focused on the tumour promoting role of 
the IGFs, also insulin may playa role in breast tumour growth and development 
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acting through its own receptor (12). The high doses of insulin needed for growth 
stimulation of MCF-7 cells (ECso = I I'g/ml) suggested that insulin was acting 
through the type I IOF receptor, which has a low affinity for insulin, and mimicked 
the effect of IOF-I. However, the small inhibition of insulin-stimulated growth by 
,dR3 (24% inhibition) suggested that insulin acted predominantly via the insulin 
receptor. The antibody was tested in a concentration 100-fold higher than the KD of 
aIR3 for binding to the type I IOF receptor in MCF-7 cells (38). Also the studies of 
Milazzo el al. (12) and Cullen el al. (14) with alR3 suggested an involvement of the 
insulin receptor in the transmission of the mitogenic effect of insulin in breast cancer 
cells. The presence of specific insulin binding sites on MCF-7 cells was demonstrated 
by binding studies with [12sI1_insulin. Half-maximal displacement of [12sI1-insulin was 
achieved with insulin at 300 times lower concentrations than with IOF-I. Also other 
reports have demonstrated the presence of functional insulin receptors on several 
breast cancer cell lines, including MCF-7 (12). In addition, a role of the insulin 
receptor in breast cancer initiation and/or progression is supported by the 
observations that the insulin receptor expression is increased in human breast cancer 
specimens and that the insulin receptor content is positively correlated with tumour 
grade and size (39). Lastly, an insulin analogue with enhanced mitogenic activity 
increased the incidence of mammary tumours in female rats (40). 
Besides insulin, also the IOF-I analogues long R3 IOF-I and des(I-3)IOF-I 
were needed in high concentrations (0.5 I'g/m1 or more) to stimulate the growth of 
MCF-7 cells, whereas previous studies have shown that IOF-I and the IOF analogues 
can elicit a proliferative response at concentrations ranging from 1 to 50 ng/ml 
(13,14,26). 11lere are several possible explanations for the low sensitivity of the MCF-
7 cells to insulin and IOF-I, regardless of the receptor activation pathway. Firstly, we 
have used serum-free culture conditions, and possibly additional serum-derived factors 
playa synergistic role in the growth stimulation by insulin and IOF-I. Secondly, the 
cells could be less responsive because of the high basal growth rate. The 
independence of supplemented growth factors for normal growth suggests that MCF-7 
cells produce autocrine acting growth factors (10). Possibly IOF-I is involved, as weI 
and others (15,41) have measured considerable amounts of immunoreactive IOF-I in 
the conditioned medium of MCF-7 cells. 
To gain insight into the mechanism of the antigrowth factor activity of 1,25-
(OHh03 and EB1089 we have studied several aspects of the insulin and IOF-I signal 
transduction pathway. Firstly, it was shown that 1,25-(OH)P3 and EBI089 did not 
suppress the insulin and IOF-I binding. The vitamin 0 3 compounds had no direct 
effect on the insulin and IOF-I binding after 48 h of treatment. At time points where 
the growth inhibition by the vitamin 03 compounds was observed (8 days), an 
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increase of insulin and IOF-I binding was observed by treatment with 1,25-(OHlzDJ 
and EBI089. The physiological implications of these findings are not clear, but a 
similar inverse relation between receptor regulation and growth inhibition by 1,25-
(OH)zDJ was observed for the epidermal growth factor receptor in BT-20 breast 
cancer cells (42). Possibly the stimulation of the insulin and IOF-I binding is a 
secondary effect of 1,25-(OHh03 and EB1089 treatment, which is not linked to the 
inhibitory effect on cell growth. Also, a role of IOF-BPs in the growth inhibition by 
1,25-(OHlzDJ and EBl089 was urdikely because of the use of insulin and analogues 
of IOF-I which have a reduced binding to IOF-BPs. 
We have also studied two intracellular responses that can be activated by 
insulin and IOF-I: c-fos mRNA expression (22,23) and MAP kinase activity (24). The 
rapid induction of c-fos mRNA expression by insulin was inhibited by 1,25-(OH)z03' 
indicating that c-fos mRNA expression is a possible target for 1,25-(OH)zDJ and 
analogues in the growth inhibition of these breast cancer cells. It should be noted, 
however, that the irdlibition of insulin-induced c-fos mRNA expression could already 
be observed at lower concentrations than the inhibition of proliferation, indicating 
that solely irdlibition c-fos expression is not sufficient to inhibit insulin-induced cell 
growth. Furthermore, a stimulation of c-fos mRNA levels by 1,25-(OH)zDJ was 
associated with an irdlibition of cell proliferation in the MCF-7 cell line (36) and in 
the HL-60 leukemic cell line (43). Finally, we have studied whether MAP kinase is 
involved in the growth inhibition by 1,25-(OH)P3 and EB1089. MAP kinase has 
been detected in a wide variety of cells and tissues and is activated by a number of 
growth factors (insulin, IOF-I, and epidermal growth factor), hormones, and other 
extracellular signals. Activated MAP kinase on its turn phosphorylates other proteins, 
including the proto-oncogene products of myc and jun, which act as transcription 
factors (24). It appeared however that MAP kinase phosphorylation was not detected, 
which may imply that MAP kinase is not involved in the growth stimulation by insulin 
and IOF-I in the MCF-7 breast cancer cells. 
In conclusion, it was shown that 1,25·(OH)zDJ and the more potent analogue 
EB1089 block the mitogenic effect of insulin and IOF-I on MCF-7 breast cancer cells. 
The observed interactions with the insulin/IOF regulatory system could contribute to 
the tumour suppressive activity of vitamin OJ compounds. 
100 
Vitalllin D a1/d IGF-I-/i1/sulifl-stilllulated growth 
ACKNOWLEDGMENTS 
We would like to thank Dr. J.A. Maassen and D.M. Ouwens for the assay of 
MAP kinase phosphorylation. We also thank Dr. J.A. Maassen for his advice on the 
insulin binding studies. 
REFERENCES 
1. Reichel HJ Koerner HP, Norman AW. The role of the vitamin D endocrine system in health and disease. 
N Engl J Med 1989,320,980·991. 
2. Walters MR. Newly identified actions of the vitamin D endocrine system. Endocrine Rev 1992, 13, 719· 
764. 
3. Frampton RJ, Ornond SA, Eisman JA. Inhibition of human cancer cell growth by 1,25-dihydroxyvitamin 
D3 metabolites. Cancer Res 1983, 43, 4443-4447. 
4. Chouvef C, Vlcard E, Del-'onec M, Suez S, 1,25-Dihydroxyvitamin D3 inhibitory effect on the growth of 
two human breast cancer cell lines (MCF-7, BT-20). J Steroid Biochem 1986,24,373-376. 
5. Colston KW, Berger U, Coombes RC. Possible role for vitamin D in controlling breast cancer cell 
proliferation. Lancet 1989, 1, 188·191. 
6. Hno Y, Yoshida M, Sugamata N, el al. la·Hydroxyvitamin D3• hypercalcemia, and growth suppression of 
7,12·dimethylbenz[aJanthraccne·induced rat mammary tumors. Breast Cancer Res Treat 1992, 22, 133· 
140. 
7. Vink-van Wljngual'den T, Pols HAP, Buurman CJ, Birk~nldig~r JC, Van Leeuwen JPTM. Combined 
effects of 1,25·dihydroxyvitamin D3 and tamoxifen on the growth of MCP·7 and ZR-75-1 hUlllan breast 
canccr cclls. Brcast Cancer Res Treat 1993,29,161-168. 
8. Blkle DO. Clinical counterpoint: vitanlin D: ncw actions, new analogs, new therapcutic potential. 
Endocrinc Rev 1992, 13, 765-784. 
9. Pols HAP, Blrkenhiiger JC, Van Leeuwen JPTM. Vitamin D analogues: from molecule to clinical appli-
cation. Clin Endocrinol 1994, 40, 285-291. 
10. Lippman ME, Dickson RB, Kasid A el al. Autocrine and paracrine growth rcgulation of human breast 
cancer. J Steroid Biochem 1986,24, 147-154. 
It. Rosen N, Yee OJ Lippman ME, Palk S, Cullen KJ. Insulin-like growth factors in human breast cancer. 
Breast Canccr Res Treat 1991, 18, S55·S62. 
12. Milazzo G, Giorglno F, Damanle G el al. Insulin reccptor expression and function in human breast 
cancer cell lines. Cancer Rcs 1992, 52, 3924-3930. 
13. Osborne CK, Clemmons DR, Arlengn CL. Regulation of breast cancer growth by insulin-like growth 
factors. J Stcroid Biochem Molec Bioi 1990, 37, 805-809. 
14. Cullen [(J, Yee D, Sly WS el al. Insulin-like grO\vth factor expression and function in human breast 
cancer. Cancer Res 1990, 50, 48·53. 
15. Huff KK, Kaufman I), Gabbay KH, Spencer EM, Lippman MEJ Dickson RB. Secrction of an insulin·like 
growth factor-I-related protein by human breast cancer cells. Cancer Res 1986,46,4613-4619. 
16. Czech MP, Leltis RE, Corvera S. Multifunctional glycoprotcin receptors for insulin and the insulin-like 
growth factors. CIBA Found Syrup 1989, 145, 27-44. 
17. Holly JMP, MOI'Un JL. Insulin-like grO\vth factor binding proteins: a rcview of methodological aspects of 
their purification, analysis and regulation. Growth Regulation 1994, 4, suppl 1, 20·30. 
18. Figueroa JA, Yee D. The insulin-like grmvth factor binding protcins (IGFBPs) in human brcast cancer. 
Breast Cancer Res Treat 1992,22,81-90. 
19. Figueroa JA, Jackson JG, McGuire WL, Kr)wfcki RF, Yee D. Expression of insulin-like growth factor 
binding proteins in brcast cancer correlates with estrogen reccptor status. J Cell Biochem 1993) 52, 196-
101 
Chapter 7 
205. 
20. McGuire SE, HlIscnbeck SG, Figuel'oa JA, Jackson JG, Yce D. Detection of insulin-like growth factor 
binding proteins (IGFBPs) by ligand bloUing in breast cancer tissues. Cancer LeU 1994, 77, 25·32. 
21. Vink·"an Wijngam'den T, Pols HAP, Bum'man CJ el al. Inhibition of breast cancer cell growth by 
combined treatment with vitamin D3 analogs and tamoxifen. Cancer Res 1994,54,5711-5717. 
22. Wilding G, Lippman ME, Gelmann EP. Effects of steroid hormones and growth factors on 
protooncogcllc c-fos expression in human breast cancer cells. Cancer Res 1988, 48, 802-805, 
23. Mehmet H, Regulation of c-fos expression in Swiss 31'3 cells: an interplay of multiple signal transduction 
pathways, Br Mcd Bulletin 1991, 47, 76-86. 
24. Andel'son NG, MAP kinases - ubiquitous signal transducers and potentially important components of the 
cell cycling machinery in eukaryotes, Cell Signalling 1992, 4, 239-246, 
25. Bindcrup E, Calverley MJ, Bindcrup L. Synthesis and biological activity of la-hydroxylated vitamin D 
analogues with poly-unsaturated side chains. In Norman A W, Bouillon R, Thomasset M, eds. Vitamin D: 
Gene regulation, structure-function analysis and clinical application: Proc. 8th Workshop on Vitamin D, 
Berlin, Walter de Gruyter, 1991, 192-193. 
26. Francis GL, Ross M, Ballard FJ e/ al. Novel recombinant fusion protein analogues of insulin-like growth 
factor (IGF)-I indicate the relative importance of IGP-binding protein and receptor binding for enhanced 
biological potency. J Mol Endocrinol1992, 8, 213-223. 
27_ Ballard FJ, Francis GL, Ross M, Bagley CJ, May B, Wallace JC. Natural and synthetic forms of insulin-
like growth factor-I (IGF-I) and the potent derivative, destripeplide IGF-I: biological activities and 
receptor binding. Biochem Biophys Res Commun 1987, 149, 398-404. 
28. J\..Jal\ssen JA, Kllnkhlllllcr MP, Odink RJH et al. Improper expression of insulin receptors on fibroblasts 
from a lepechaun patient. Eur J Biochem 1988, 172, 725-729. 
29. Van den Berghe N, Ouwens DM, Maassen JA, Van Mackelenbel'gh MGH, Sips HCM, Krans HM. 
Activation of the ras/mitogen activated protein kinase signaling pathway alone is not sufficient to induce 
glucose uptake in 3T3-Ll adipocytes. Mol Cell Bioi 1994, 14,2372·2377. 
30. Van Straaten F, MillieI' R, Cnrran T, Van Beyeren C, Verma 1M. Complete nucleotide sequence of a 
human c-onc gene: deduced amino acid sequence of the c-fos protein. Proc Nat! Acad Sci USA 1983, 80, 
3183·3187. 
31. Benham FJ, Hodgkinson S, Dayies KE. A glyceraldehyde-3-phosphate dehydrogenase pseudogene on the 
short arm of the human X chromosome defines a multigene family. EMBO J 1984, 3, 2635-2640. 
32. Vun del' Burg B, Rnttenum GR, D1ankcnstein MA, De Laat SW, VIm Zoelen EJJ. Mitogenic stimulation 
of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and 
estrogen. J Cell Physiol 1988, 134, 101-108. 
33. Stewart AJ, Johnson MD, May FEB, Westley BR. Role of insulin-like growth factors and the type I 
insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J 
Bioi Chern 1990, 265, 21172-21178. 
34. llIOI'Sen T, Lahootl H, Rasmussen M, Ankvaag A. Oestradiol treatment increases the sensitivity of 
MCF-7 cells for the growth slimulatory effect of IGF-I. J Steroid Biochem Molec Bioi 1992, 41, 537-540. 
35. Colston KW, Mackay AG, James SV, Bindel'up L. EB1089: a new vitamin D analogue that inhibits the 
growth of breast cancer cells in vivo and in vitro, Biochem Pharmacol 1992, 44, 2273-2280. 
36. .Mathiasen IS, Colston KW, Blndel'up L. EBI089, a novel vitamin D analogue, has strong 
anliproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem Molec Bioi 1993, 
46,365·371. 
37. Abe J, Naknno T, Nishii V, I\httSUIlIOto T, Ogata E, Ikedn K. A novel vitamin D3 analog, 22-oxa-l,25-
dihYdroxyvitamin D3, inhibits the growth of human breast canccr in vitro and in vivo without causing 
hypercalcemia. Endocrinology 1991, 129,832-837. 
38. Rohlik QT, Adams 0, Kull Jr Fe, Jacobs S, An antibody to the receptor for insulin-like growth factor I 
inhibits the growth of MCF-7 cells in tissue culture. Biochem Biophys Res Commun 1987, 149,276-281. 
39. Papa V, Pezzino V, Coshtntino A e( al. Elevated insulin receptor content in human breast cancer. J Clin 
Invest 1990,86,1503-1510. 
40. Dideriksen LH, Jorgcnsen LN, Dl'cjel' K. Carcinogenic effect on female rats after 12 months 
102 
Vitamin D and IGF-I-/insulin-stimulated growth 
administration of the insulin analogue BlO Asp. Diabetes 1992, 41, suppl I, 143A (Abstract). 
41. Minuto F, Del Monte P, DanceR A, Nlcolin A, Glordftno G. Partial characterization of somatol11cdin c-
like immulloreactivity secreted by breast cancer cells in vitro. Mol Cell Endocrinol 1987, 54, 179-184. 
42. Falette N, Fl'appart L, Lefebvre MF, Suez S. Increased epidermal growth factor receptor level in breast 
cancer ceUs treated by l,25-dihydroxyvitamin D3. Mol CeU Endocrinol1989, 6, 189·198. 
43. Brel"l ZS, Christakos S, Studzinski, GP. Expression of monocyte.specific oncogenes c-fos and c-fms in 
HL-60 cells treated with vitamin D3 analogs correlates with inhibition of DNA synthesis and reduced 
calmodulin concentration, Lab Invest 1986, 55, 269·275. 
103 

Chapter 8 
1,25-DIHYDROXYVITAMIN D3 AND THE VITAMIN D3 
ANALOGUE EBI089 REGULATE INSULIN-LIKE 
GROWl'H FACTOR (IGF) BINDING PROTEIN 
EXPRESSION AND IGF-I SECRETION BY 
HUMAN BREAST CANCER CELLS 
T. Vink-van Wijngaarden, J.e. Birkenhager, C.J. Buurman, H.A.P. Pols, and J.P.T.M. 
van Leeuwen 
Submitted for publicalion 
Chapter 8 
SUMMARY 
Insulin-like growth factor-I (IGF-I) is believed to play an important role in the 
growth of breast cancer cells by paracrine or autocrine effects. In a previous study, we 
showed that 1,25-dihydroxyvitamin D3 (1,25-(OHhD3) and its more potent analog 
EB1089 inhibit insulin- and IGF-I-stimulated growth of MCF-7 breast cancer cells. In 
the present study, we have examined whether 1,25-(OH)zD3 an~ EB1089 regulate the 
expression of IGF binding proteins (IGF-BPs) and the secretion elf IGF-I by MCF-7 
human breast cancer cells. In our serum-free MCF-7 cell cultures, the overall IGF-
BPs produced by the cells appeared to have an inhibitory effect on IGF-I action, since 
IGF-I had no effect on the growth of MCF-7 cells, whereas IGF-I analogs with a 
reduced binding to IGF-BPs, long R3 IGF-I and des(1-3)IGF-I, as well as insulin 
stimulated the cell growth. Western ligand blots showed that IGF-BP2 was 
predominantly produced in the conditioned medium of MCF-7 cells. Further we have 
detected bands of 38-40 kDa and 25 kDa, which were indicative for IGF-BP3 and 
IGF-BP4, respectively. The MCF-7 cells expressed IGF-BP2, IGF-BP4, and IGF-BP5 
mRNA. IGF-BP2 was abundantly expressed, followed by IGF-BP4, whereas the 
expression of IGF-BP5 was relatively low. 1,25·(OHhD3 and EB1089 (0.1 nM) 
stimulated the expression of IGF-BP5 mRNA after 24 h of incubation, which 
persisted up to 48 h. The expression of IGF-BP2 and IGF-BP4 mRNA was 
unaffected. Besides IGF-BPs, MCF-7 cells secrete considerable amounts of 
immunoreactive IGF-I (iIGF-I) into the medium. Strikingly, the growth inhibitors 
1,25-(OHhD3 and EB1089 stimulated the secretion of iIGF-I in a time- and dose-
dependent manner. Already after 48 h a 3-fold stimulation was measured, whereas at 
this time point no effect on cell growth was observed. The stimulation of IGF-I 
secretion was specific for the vitamin D3 compounds as another growth inhibitor, 
tamoxifen, was ineffective. Together, we show for the first time that 1,25-(OHhD3 
and its analog EB1089 change the pattern of expression of IGF-BPs and modulate the 
secretion of immunoreactive IGF-I in breast cancer cells. These data suggest that 
1,25-(OHhD3 and EB1089 can infiuence IGF action on breast cancer cells, but at this 
point it is unclear how these effects directly relate to the growth inhibitory effects of 
vitamin D3 compounds. 
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INTRODUCTION 
In addition to its role in calcium and bone metabolism, 1,25-dihydroxyvitamin 
D3 (1,25-(OHlzD3) regulates growth and differentiation of a wide variety of cells and 
tissues, both normal and malignant (1,2). 1,25-(OHlzD3 mediates its effects via 
binding to the intracellular vitamin D receptor (VDR), which is a member of the 
steroid hormone receptor family (3). The VDR is expressed in most human breast 
tumors and breast cancer cell lines (4,5). 1,25-(OHlzD3 has been shown to inhibit the 
growth of breast cancer cell lines and in animal models for breast cancer 1,25-
(OHlzD3 suppressed tumor growth (6-9). To improve the clinical application of 1,25-
(OHlzD3 as a tumor suppressive drug, new synthetic vitamin D3 analogs have been 
developed with increased anti proliferative and reduced in vivo ca\cemic activity 
(10,11). The analog EBI089 has been shown to inhibit breast cancer cell growth at 
50- to 100-fold lower concentrations than 1,25-(OHlz03 (12-14), whereas ill vivo 
studies with rats have shown that EB1089 has a decreased ability to affect calcium 
metabolism (13). Moreover, Colston et al. showed that EB1089 suppressed tumor 
growth in rats with chemical-induced breast cancer (12). 
Breast cancer growth is regulated by numerous factors, including steroid 
hormones and polypeptide growth factors (15). Insulin-like growth factor-I (IGF-I) is 
a potent stimulator of breast cancer cell growth in vitro and in estrogen receptor 
positive cells IGF-I can contribute to the growth stimulation by estrogen (16,17). IGF-
I can be derived from the circulation, or is produced locally by breast tumor cells 
and/or neighbouring stromal cells. The activity of IGF-I is influenced by specific 
binding proteins (IGF-BPs). These proteins are found in serum, but can also be 
produced by a wide variety of cell types. At present six IGF-BPs have been cloned. 
They can either enhance or inhibit the effect of IGF-I depending on the type of 
IGF-BP or the experimental conditions employed (18-20). Breast tumors and breast 
cancer cell lines express IGF-BP2 to IGF-BP6 in a heterogenous pattern, while little 
or no expression of IGF-BPI is seen (19-21). 
In a previous study" we showed that 1,25-(OHlz03 and the vitamin 03 analog 
EB1089 inhibit the growth stimulation induced by IGF-I in the estrogen receptor- and 
vitamin D receptor-positive MCF-7 human breast cancer cell line. In the present 
study, we have further examined the interactions of the vitamin D3 compounds with 
the IGF regulatory system. TIlerefore, we have studied in MCF-7 cells a possible 
regulation of IGF-BP expression and IGF-I secretion by 1,25-(OHlzD3 and EB1089. 
IT. Vink-van Wijngaarden, HA.P. Pols, C,J. BUUfman, J,e. Birkenhager, and J.P.T.M. van Leeuwen, 
manuscript submitted for publication. 
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MATERIALS AND METHODS 
Chemicals 
l,25-(OH)zD3 and the side-chain analog EB1089 (22) werc kindly donated by Dr. L. Binderup of 
LEO Pharmaceutical Products (Ballerup. Denmark). Insulin, 17B-estradiol, RPMI-l640 cell culture 
medium, human transferrin, and sodium selenite were purchased from Sigma Chemical Co. (St. Louis, 
MO, U.SA.). lOP-I, long R3 IOF-I, and dcs(1-3)IGF-I were from GroPep Pty. Ltd. (Adelaide, 
Australia). Long R3 IOF-! is an analog of human IOF-! synthesized in E,coli and has a substitution of an 
ARG for GLU at position 3 and an extension of 13 amino acids at the N-terminus (23). Des(1-3) is a 
truncated form of IOF-I which lacks three N-termillal amino acids (24). (l25JJ-IGF.II was kindly donated 
by Dr. S. van Buul-Offers (Wilhelmina Childrens Hospital, Utrecht, The Netherlands). Bovine serum 
albumin fraction V (BSA) was purchased from ICN Biomedicals Inc. (Costa Mesa, CA, U.S.A.). 
Glutamine, penicillin, and streptomycin were obtained from Life Technologies (Paisley, U.K.), and fetal 
calf serum was from Sera-Tech Zellbiologische Produkte GmbH (SI. Salvator, Germany). 
Cell culture 
MCF·7 cells were generously provided by Dr. JA. Poekens (Dr. Daniel den Hoed Cancer 
Center, Rotterdam, The Netherlands). MCP-7 cells were routinelY maintained in phenol red-free RPMI-
1640 medium supplemented with 2 mM glutamine, 100 units/ml penicillin, 100 Jlg/mt streptomycin, 24 
mM sodium bicarbonate (= basal RPMI medium), 10% fetal calf serum, and 10 Itg/mi insulin. All 
experiments were performed in serum-free basal RPMI medium, supplemented with 2 mg/ml B.SA., 10 
Itg/ml transferrin, and 30 nM sodium selenite (= SFM). Prior to the start of an experiment, the ceJJs 
were seeded in basal RPMI medium supplemented with 2% charcoal· treated fetal calf serum to allow the 
attachment of the cells. This medium was changed to SFM after 24 h. 
Prolifcl'a(ion experiments 
MCF-7 cells were seeded into 24-well dishes at a density of 4000 cells/cm2. After 24 h the 
medium was changed to SFM and after another 24 h medium was refreshed and the test agents were 
added. Medium and test agents were replaced every two or three days. After 8 days of incubation DNA 
content was measured using the ethidium bromide method as described previously (9). 
RNA isolation and hybridization 
Cells were seeded in 25 cm2 flasks (60,000 cells/cm2), after 24 h the medium was changed to 
SFM, and after another 24 h medium was refreshed and the test agents were added. Total RNA was 
isolated by guanidinium thiocyanate-phenol-chloroform extraction and Northern analysis with 10-20 pg 
RNA was performed as described previously (14). Northern blots were hybridized with e2PJ-labeled 
eDNA fragments specific for IGF·BP2 (25), IGF·BP3 (26), IGF·BP4 (27), IGF·BP5 (28), IGF·BP6 (27), 
and GAPDH (29). After hybridization the Northern blots were washed twice in 2x SSC, 0.1% sns for 5 
min at room temperature, twice in 2x SSC, 0.1% SDS for 20 min at 60 C, and twice in O.5x SSC, 0.1% 
SDS for 20 min at 60 C. Membranes were exposed to medical X-ray films (Fuji Photo Film Co., Tokyo, 
Japan) with intensifying screens at -80 C, and the autoradiographs were quantified using a ScanJet Hex 
scanner (Hewlett-Packard Co., Minneapolis, U.SA.). The exposure time was several hours to overnight 
for the IGF-BP2 and GAPDH probes, overnight to 2 days for the IGF-BP4 probe and 3-7 days for the 
IGF-BP5 probe. Before rehybridization, Northern blots were washed in 5 ruM Tris·HCI (pH 8.0), 0.2 
mM EDTA (pH 8.0), 0.05 % sodium pyrophosphate, and O.Ix Denhardt's solution for at least 2 h 
at 65 C. 
Western ligand blotting and immunoblotting 
Subconfluenl cultures of MCF-7 cells grown in SFM in 25 cml flasks were incubated with the 
vitamin D3 compounds for 48 h in basal RPMI medium supplemented with 1 mg/rul BSA. Proteins were 
precipitated from 100 JIi samples of conditioned medium by an overnight incubation ,vith 7% 
trichloroacetic acid at 4 C, followed by a short centrifugation step. The proteins were dissolved in non-
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reducing loading mix. and heated at 95 C until tbe trichloroacetic acid was evaporated. Western ligand 
blots were prepared essentially as described by Hossenlopp et aL (30). Proteins were separated on a 12% 
SDS gel under non-reducing conditions, and transferred onto nitrocellulose ftiters by electroblotting. The 
filters were washed first in 100 mM Tris-He) (pH 7.5), 0,9% Nael (::: lxTBS) containing 3% Nonidet P-
40 for 30 min, then in TBS, 3% BSA for 2 h, and subsequently incubated overnight with [l25Ij_IGF_1I in 
TBS, 1% BSA, 0.1% T\veen-20 at 4 C, The ftIters were washed twice in TBS, 0.1% Tween-20 for 15 min, 
3 times in TBS for 15 min, and subsequently exposed to medical X-ray films with intensifying screens at -
80 C for lip to 14 days. The position of IGF-BP2 was verified by immullostaining using a polyclonal 
antibody against IGF~BP2. The filters were blocked in a TnS, 3% nSA solution and then incubated with 
the antibody. The filters were washed with TnS, 0.1% Nonidet p.4Q and incubated with an alkaline 
phophatase·conjugated second antibody. Next the filters were washed in TnS, 0.1% Nonidet p.4Q and 
binding was detected by 4·nitro blue tetrazolium chloride (NBT) and S-bromo-4-chloro-3-indolyl-
phosphate (BCIP) substrate solutions (Boehringer, Mannheim, Germany). As an antibody against IGF-
BPS was not available, this binding protein could not identified by immunodetection. 
Determination of IGF-I in conditioned medium 
For the short-term incubations (48 h) the cells were grown to suhconfluence in SFM in 25 cm2 
flasks. Subsequently, the medium was refreshed and the cells were exposed to the vitamin D3 
compounds. For the long-term incubations (up to 8 days) the cells were seeded in six-well dishes (4000 
cells/cm2) and exposed to the test compounds from the start of the experiments as described for the 
proliferation experiments. Immunoreactive IGF-I secreted into the medium was measured using the 
radioimmunoassay kit for somatomedin-C of Medgenix Diagnostics SA (Fleurus, Belgium). To remove 
IGF-BPs the samples were pre-treated by an acid-ethanol extraction according to the protocol of the 
manufacturer. 
RESULTS 
Mitogenic action of IGF-I and IGF-I analogs on MCF-7 cells 
MCF-7 cells in our laboratory are able to grow autonomously in serum-free 
medium. When the cells were treated with IGF-I (1 to 1000 ng/ml) we did not 
observe a stimulation of cell growth (data not shown)_ Next, we have tested two 
analogs of IGF-I, long R3 IGF-I (23) and des(I-3)IGF-1 (24), which have a reduced 
binding to IGF-BPs. As shown in Figure 8.1, long R3 IGF-I and insulin treatment 
resulted in a growth stimulation of MCF-7 cells. Also, with des(1-3)IGF-I (ll'g/ml) a 
growth stimulation was observed. 
Regulation of IGF-binding proteins by vitamin D3 compounds 
We have performed Western ligand blots on conditioned medium of MCF-7 
cells. The ligand blots showed a predominant band migrating just above the position 
of the 30 kDa molecular weight marker, which was identified as IGF-BP2 (34 kDa) 
by immunoblotting (data not shown). Also two faint bands of higher molecular weight 
were detected_ These bands are most likely to be IGF-BP3 (38-40 kDa) which 
migrates as a doublet (20,21)_ In some experiments we have also observed an IGF-BP 
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F~ure 8.1. Mitogenic effect of long 
R IGF~I and insulin on MCF-7 
cells. Cells were grown in serum-
free medium with the indicated 
concentrations of long R3 IGF-I 
and insulin during 8 days as 
described under "Materials and 
Methods", DNA content was 
determined. Data are expressed of 
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mean ± sn of duplicate weUs, 
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Figure 8.2, Western ligand blot of (I2SIJ.IGF.II detected lOP· 
BPs in 48 h conditioned medium of MCF-7 cells. 
Subconfluent cultures of MCF-7 cells were incubated with 
vehicle (C), 10" M 1,25·(OH),D3 ~9D), 10.7 M 1,25·(OH),D3 
(10), 10" M EBI089 (9E), or 10' M EB1089 (7E) ror 4l! h. 
100 1'1 of concentrated conditioned medium was separated on 
a SDS-polyacrylamide gel under non-reducing conditions. The 
proteins were transferred onto nitrocellulose and the IGF~BPs 
were detected by incubation with rt25I]-IGF-II and subsequent 
autoradiography. The exposure time was 17 days. IGF-BP2 
was identified by immunoblotting and its migration position is 
marked. 
species of lower molecular weight, which is probably IOF-BP4 (2S kDa). Treatment 
with 1,2S-(OHhD3 and EBI089 for 48 h did not markedly change this pattern of 
IGF-BPs (Fig. 8.2). 
At mRNA level we have detected IOF-BP2 (1.6 kb), IGF-BP4 (2.6 kb), and 
IGF-BPS (6 kb). IGF-BP2 was abundantly expressed, followed by IGF-BP4, whereas 
the expression of IGF-BPS was much lower. IGF-BP3 and IGF-BP6 mRNA 
transcripts were not detected. MCF-7 cells were treated during 1 to 48 h with 1,2S-
(OHhD3 or EB1089 (10.8 M). As shown in Fig. 8.3, the expression of IGF-BPS 
mRNA was increased by treatment with 1,2S-(OHhD3 and EB1089 in a time-
dependent manner, while the expression of IGF-BP2 and IGF-BP4 was not affected. 
The maximal stimulation of IOF-BPS, 2- to 3-fold the control level, was reached after 
24 h of treatment with the vitamin D3 compounds and after 48 h the IGF-BPS mRNA 
level was still elevated. Dose-response studies with 1,2S-(OHhD3 and EB1089 
revealed that already at 10.10 M a maximal stimulation of IGF-BPS could be observed 
(Fig. 8.4). 
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Figure 8.3. Time course of IGF·BP mRNA 
expression during treatment with l,25.(OHhD3 
and EBI089 in MCF-7 cells, Cells were treated 
with vehicle (C), 10-8 M 1,2S-(OH)2D, (D) or 
10.8 M EBI089 (E) for the indicated time 
periods and RNA was isolated as described in 
the section "Materials and Methods~. The 
Northern blot was hybridized successively with 
IGF-BPS, IGF-BP4, IGF-BP2, and GAPDH 
probes, 
IGF-BP2 IGF-BP4 
'" IGF-BP5 GAPDH 
Figure 8.S. Effect of estradiol and IGP-J on 
IOF-DP mRNA expression. Cells were treated 
with vehicle (C). 10.10 M 17t!-estradiol (E2), or 
50 ng/ml IOP-! (I) during 24 h. RNA was 
isolated and hybridized successively with IGP-
BPS, IGF-BP4, IOF-BP2, and GAPDH probes 
as described in the section "Materials and 
Methods~. 
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Figure 8.4. Dose response of the effect of 1,25-
(OH),D, and EBI089 on IGF-BP mRNA 
expression in MCF-7 cells. Cells were treated 
with the indicated concentrations of 1,25-
(OH),D, and EBI089 for 24 h. Subsequently 
RNA was isolated and hybridized successively 
with IGF-BPS, IGF-BP4, IGF-BP2, and 
GAPDH probes as described in the section 
"Materials and Methods". 
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Figure 8.6. Time course of the 1,25· 
(OHhD3- and EB1089-induced increase of 
the IGP-I secretion of MCF-7 cells. MCF-7 
cells were cultured in SFM and incubated 
with vehicle, 100 oM 1,25-(OHhD3 or 100 
oM EBI089. 72 h conditioned medium was 
collected after 5 and 8 days of incubation 
and the amount of IGF-I in the medium was 
determined using a radioimmunoassay. The 
samples were acid-ethanol pre-treated to 
remove lOP-BPs. 
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Figm'c 8,7. IOP-! secretion after 48 h of incubation 
with 1,2S-(OH),D, and EB1089_ MCF-7 ceUs were 
cultured to subconfluence in SFM and were 
subsequently incubated with vehicle, 1,25-(OHhD3 
or EB1089 for 48 h. The 48 h conditioned medium 
was pre-treated to remove IOF-BPs and the 
concentration of IGF-I was determined using a 
radioimmunoassay. The 48 h treatment with 1)25-
(OH),D, and EB1089 had no effect on DNA 
content. Data are presented as mean ± SD of two 
separate experiments. 
Since IGF-BPs have previously been shown to be regulated by estrogens, 
IGF-I, and insulin in MCF-7 cells (19,31), we have also examined the regulation by 
these compounds in our culture system. It was observed that IGF-BP4 mRNA 
expression was markedly increased by estradiol treatment, whereas estradiol had no 
clear effects on IGF-BP2 and IGF-BPS expression. Insulin and IGF-I had no clear 
effect on the mRNA expression of IGF-BP2, IGF-BP4 and IGF-BPS (Fig. 8.5). 
Regulation of IGF-I secretion by MCF-7 cells 
Immunoreactive IGF-I (iIGF-I) was detected in conditioned medium of MCF-7 
cells, and the concentration increased during the cell culture from 3.3 ng iIGF-I/l'g 
DNA on day S to 4.7 and 6.4 ng iIGF-I/l'g DNA on days 8 and 11, respectively. Fig. 
8.6 shows that incubation with 1,2S-(OHhD3 and EB1089 (100 nM) resulted in a 
time-dependent increase of the secretion of iIGF-I into the medium. Lower 
concentrations of 1,2S-(OHhD3 and EB1089 (1 nM) stimulated iIGF-I secretion on 
day 8 from 4_7 to 9.6 and 18.4 ng IGF-II!,g DNA, respectively. 
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To study whether the increased secretion was related to the growth inhibition 
and specific for the vitamin D3 compounds, we have studied the effect of another 
growth inhibitor. We have previously shown that tamoxifen (10.6 M) as well as 1,25· 
(OHhD3 and EB1089 inhibit the autonomous growth of MCF·7 cells (9,14). It 
appeared, however, that tamoxifen had no effect on the iIGF·I secretion after 8 days 
of incubation (control cultures 4.7, and tamoxifen·treated cultures 5.0 ng iIGF.I/l'g 
DNA). Further, we have studied whether the vitamin D3 compounds were able to 
regulate the iIGF·I secretion independent of the growth inhibitory effects. As shown 
in Figure 8.7, 1,2S·(OHhD3 and EBI089 (1 and 100 nM) resulted in a 3· to Hold 
increase of the iIGF·I concentration after 48 h of treatment, whereas these short· term 
incubations did not yet result in growth inhibition. 
DISCUSSION 
IGF·I is regarded as an important growth factor for breast cancer (16,17). The 
cellular activity of IGF·I is modulated by IGF·BPs. They can either enhance or inhibit 
IGF·I action depending of the type of IGF·BP, cell type, or culture conditions (18,19). 
In our MCF·7 culture system, IGF·I had no effect on cell growth, whereas IGF·I 
analogs with reduced binding affinity for IGF·BPs, long R3 IGF·I (23) and des(1. 
3)IGF.I (24), were able to stimulate the cell growth, indicating that IGF·BPs secreted 
by MCF·7 cells into the medium might block the mitogenic activity of IGF·I. 
Regulation of the pattern of expression of IGF·BPs secreted by breast tumor cells, 
may be an important mechanism to modulate IGF action and thereby tumor growth. 
Previous studies have shown a different regulation of IGF·BP expression by positive 
(estrogen, IGF·I) and negative (retinoic acid, tamoxifen) regulators of MCF·7 cell 
growth (19,32.36), which suggests that the changes in expression of IGF·BPs are 
related to their effects on cell growth. 
The regulation of IGF·BP expression by 1,2S·(OHhD3 or analogs has not yet 
been documented in breast cancer cells. In line with other studies with MCF·7 cells 
(19,20) we have detected IGF·BP2, IGF·BP4, and IGF·BPS mRNA species. IGF·BP3 
was not detected by Northern blot analysis, but a band indicative for IGF·BP3 was 
detected on Western ligand blots. Possibly the expression of IGF·BP3 mRNA was too 
low for detection under the conditions used. The present study shows that treatment 
with 1,2S·(OHhD3 and EB1089 resulted in a strong stimulation of IGF·BPS mRNA 
expression after 24 h of treatment. The effect of the vitamin D3 compounds was 
specific for IGF·BPS because no effect on IGF·BP2 and IGF·BP4 expression was 
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observed. The stimulation of IGF-BPS was also specific for the vitamin D3 
compounds because estradiol had no effect on IGF-BPS expression, but stimulated 
IGF-BP4 expression. It is not clear whether the increased mRNA level resulted in an 
increased secretion of IGF-BPS protein into the medium. IGF-BPS could not be 
visualised on Western ligand blots because its expression is relatively low and IGF-
BPS (28-30 kDa) migrates closely with the predominantly produced IGF-BP2 (34 
kDa). As no specific IGF-BPS antibody was available, also subsequent 
immunodetection was not possible. 
Limited data have been published about the function and regulation of IGF-
BPS. The expression and/or production of IGF-BPS in breast cancer cells has been 
shown to be stimulated by IGF-I, and estradiol in some (19,20,34,36), but not all 
studies (31,36), including ours. Similar to the other IGF-BPs, both inhibitory (37) and 
enhancing (38,39) activity of IGF-BPS on IGF-action has been described. Because a 
functional role of IGF-BPS for breast cancer cells has not yet been reported, the 
physiological significance for the observed upregulation remains to be determined. 
Regulation of IGF-BPs by 1,2S-(OH}zD3 occurs also in other cell types than breast 
cancer cells. In osteoblast-like cells 1,2S-(OH}zD3 has been shown to stimulate the 
expression of IGF-BP2 (40), IGF-BP3 (41), and IGF-BN (42). However, to our 
knowledge there are no reports on the regulation of IGF-BPS mRNA by 1,25-
(OH}zD3' 
We have measured considerable amounts of immunoreactive IGF-I in the 
conditioned medium of MCF-7 cells. So far, conflicting results have been reported 
with respect to the production of IGF-I by breast tumor cells. IGF-I mRNA was not 
detected in human breast cancer cell lines using a sensitive RNAse protection assay 
(43), and the immunoreactive IGF-I in the conditioned medium of MCF-7 cells was 
shown to be due predominantly to the presence of cross reacting IGF-BPs (44). 
However, we and others (45,46) have measured immunoreactive IGF-I after removal 
of the binding proteins. 
The MCF-7 cells we have used are able to grow logarithmically in serum-free 
medium. Possibly, IGF-I supports the autonomous growth via an autocrine action. We 
have previously shown that 1,2S-(OH}zD3 and EB1089 block the mitogenic effect of 
long R3 IGF-I on MCF-7 cells2• In addition, we have shown that the autonomous 
growth of MCF-7 cells is inhibited by 1,2S-(OH}zD3 and analogs (9,14). In the present 
study we have investigated whether the growth inllibitory effects of the vitamin D3 
compounds could be related to an inhibition of IGF-I secretion. However, we have 
observed that the growth inhibition by 1,2S-(OH}zD3 and EBI089 was accompanied 
by a stimulation of the iIGF-I secretion. This stimulation was probably a direct effect 
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of the vitamin D3 compounds and not an aspecific compensatory mechanism for the 
growth inhibition, because the growth inhibition by tamoxifen was not accompanied 
by an increased iIGF-I secretion. This is further supported by the observation that the 
iIGF-I secretion increased already after 48 h of treatment with 1,25-(OH}zD3 and 
EBI089, whereas a growth inhibition could not yet be measured. An explanation for 
this inverse relationship is yet unclear, but these data indicate that the site of the 
growth inhibition by 1,25-(OH}zD3 and EB1089 may be located distal from autocrine 
production of IGF-I or IGF-l-like activity. 
In conclusion, we show for the first time that 1,25-(OH}zD3 and its analog 
EBI089 regulate the expression of IGF-BP5 and the secretion of iIGF-I in human 
breast cancer cells. These data indicate that vitamin D3 compounds interfere with the 
complex IGF regulatory system, and thereby possibly influence IGF action. However, 
presently it is unclear how the regulation of IGF-BP expression and IGF production 
directly relate to the antiproliferative effects of vitamin D3 compounds. 
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GENERAL DISCUSSION 
Chapter 9 
9.1 INTRODUCTION 
1,25-Dihydroxyvitamin D3 has been shown to inhibit the growth of cultured 
breast cancer cells and to suppress the growth of breast tumours in experimental 
animals, which suggested a role of the hormone in the treatment of breast cancer. 
However, a major drawback for the clinical use of 1,25-dihydroxyvitamin D3 is that 
high dosages are needed. When given to patients, these high dosages may cause 
serious complications resulting from a disturbed calcium and bone metabolism. In 
order to make 1,25-dihydroxyvitamin D3 suitable as an anticancer drug, vitamin D3 
analogues have been synthesized with the aim to dissociate the antiproliferative from 
the calcaemic activity. 
The studies described in this thesis were undertaken to investigate the 
antiproliferative action of 1,25-dihydroxyvitamin D3 and several novel vitamin D3 
analogues on the growth of human breast cancer cells in culture (discussed in Section 
9.2). TIle antioestrogen tamoxifen is currently the most widely used endocrine agent 
for the treatment of breast cancer. Therefore, studies were undertaken to investigate 
the potential benefits of a combination therapy of 1,25-dihydroxyvitamin 
D3/analogues and tamoxifen for breast cancer (discussed in Section 9.3). First, the 
effects of combined treatment were studied on breast cancer cell growth and 
subsequently, the investigations were extended to the regulation of bone resorption 
(discussed in Section 9.4). Several studies have been performed in order to gain 
insight into the mechanism of the antiproliferative action of the vitamin D3 
compounds and the results are discussed in Section 9.5. Finally, in Section 9.6 
suggestions for further in vitro and in vivo research are given. 
9.2 ANTIPROLIFERATIVE ACTION OF 1,25-DIHYDROXYVITAMIN 
D3 AND VITAMIN D3 ANALOGUES ON HUMAN BREAST 
CANCER CELLS 
1,25-Dihydroxyvitamin D3 has been shown to inhibit the growth of both 
oestrogen receptor-positive and oestrogen receptor-negative breast cancer cells (1,2). 
Furthermore, it has been shown that the vitamin D receptor is present in 
approximately 80 % of human breast tumours and that its presence is not related to 
the oestrogen receptor status (3). TI1ese data have suggested a role for 1,25-
dihydroxyvitamin D3, and especially vitamin D3 analogues with a low calcaemic 
activity, in the treatment of both oestrogen receptor-positive and -negative breast 
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tumours. Most endocrine therapies that are currently used for breast cancer are based 
on antioestrogenic activity, and therefore treatment with vitamin 03 compounds may 
provide an interesting alternative. 
The studies in this thesis regard the antiproliferative action of 1,25-
dihydroxyvitamin 03 and four novel synthetic vitamin 03 analogues on the oestrogen 
receptor- and vitamin ° receptor-positive MCF-7 and ZR-75-1 human breast cancer 
cell lines. The cell lines have different growth characteristics: MCF-7 cells are able to 
grow autonomously and are growth stimulated by oestradiol, whereas ZR-75-1 cells 
are dependent on oestradiol for their growth. 
The study described in Chapter 4 shows that basal growth of MCF-7 cells and 
oestradiol-induced growth of ZR-75-1 cells is arrested by 10-7 M 1,25-
dihydroxyvitamin 03' By contrast, in the study described in Chapter 5 a partial growth 
inhibition was observed and the cells were less sensitive to the antiproliferative action 
of 1,25-dihydroxyvitamin 03 (higher ECso)' These discrepancies can be explained by 
differences in culture conditions, i.e. the presence of serum in the culture medium 
and the frequency of addition of the hormone. In the earlier studies (Chapter 4) we 
have used medium supplemented with 2 % charcoal-treated foetal calf serum, 
whereas in later studies (Chapter 5) we have used serum-free medium. In an 
additional experiment it was demonstrated that the growth inhibition by 1,25-
dihYdroxyvitamin 03 was increased by the presence of charcoal-treated serum in the 
medium (Fig. 9.1). Therefore, it can be concluded that serum contains factors which 
synergize with 1,25-dihydroxyvitamin 03 to enhance its antiproliferative action. The 
second difference between the two studies is that medium and 1,25-dihydroxyvitamin 
03 were refreshed daily in the earlier studies and every 3 days in the later studies. A 
stronger growth inhibition as a result of more frequent refreshments of hormone and 
medium can be explained as follows: I) the hormone accumulates by adhesion to the 
cells and culture wells resulting in a higher effective concentration, 2) the influence of 
degradation of the hormone is lower, resulting in a higher effective concentration, and 
3) autocrine acting growth factors produced by the cells cannot accumulate and 
thereby the cells may become more sensitive to the antiproliferative action of 1,25-
dihydroxyvitamin 03' 
Chapter 5 describes a study of the effecls of four novel vitamin 03 analogues 
on breast cancer cell growth. The chemical structures of these side-chain analogues, 
CB966, EB1089, KH1060, and 22-oxa-calcitriol, are shown in Figure 2.5. Previous 
studies have shown that these analogues have an increased potency to inhibit the 
growth of leukaemic cell lines. The ill vivo calcaemic activity of these analogues was 
similar or even reduced compared to that of 1,25-dihydroxyvitamin 03 (Table 2.4). 
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FigUl'e 9.1. Effect of charcoal-treated serum on 
the growth inhibition of MCF-7 cells by 1,25-
dihydroxyvitamin D3- MCF-7 cells were cultured 
for 8 days with or without l,25-dihydroxyvitamin 
D) (1,25-(OH)zD3) in serum-free medium (SFM) or in medium containing various 
concentrations charcoal-treated foetal calf serum 
(Cf-FCS). Data are presented as mean ± SD 
of duplicate wells. See Chapter 5 for details of 
culture conditions and determination of DNA 
content. 
These data supported the idea that the 
antiproliferative action of 1,2S-
dihydroxyvitamin 03 can indeed be 
(partly) dissociated from the calcaemic 
activity. 
At the time of our studies little 
data was available on the anti-
proliferative action of these analogues 
on breast cancer cells. It was shown in 
Chapter S that 1,2S·dihydroxyvitamin 
03 and the analogues 22-oxa-calcitriol 
and CB966 were almost equally potent 
in inhibiting the growth of MCF-7 and 
ZR-7S-1 cells, whereas the analogues 
EB1089 and KH1060 were clearly 
more potent. Although the maximal 
inhibition was similar for 1,2S-di-
hydroxyvitamin 03 and the analogues, 
the ECso's of EB1089 and KH1060 
were SO- and 100-fold lower, 
respectively. These data are largely in 
line with other reports of leukaemic and breast cancer cell lines (see Table 2.4 and 
Table 3.1). The variations in the absolute figures can be attributed to differences in 
culture conditions, e.g. presence of serum in the culture medium, frequency of 
medium refreshment and hormone addition (see above), and differences in sensitivity 
between cells. 
The strong antiproliferative action on breast cancer cell lines, combined with 
the low ill vivo calcaemic activity of vitamin 03 analogues offer promise for a clinical 
use of these compounds in the treatment of breast cancer. However, one has to be 
careful in the translation of ill vitro data to the ill vivo situation. In the animal or 
human body the pharmacokinetic properties of the analogues play an important role, 
e.g. an analogue with potent ill vitro effects may be ineffective ill vivo because it is 
rapidly degraded in the body (see also Section 2.5.3). So far, only a few ill vivo studies 
with vitamin 03 analogues have been reported. Yet, the data are very promising. It 
was shown that the analogues 22-oxa-calcitriol and EBI089 caused tumour 
suppression without raising serum calcium in animal models for breast cancer (2,4). 
However, apart from hypercalcaemia other negative side-effect may arise. For 
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instance, some vitamin 03 analogues (22-oxa-calcitriol, KH1060) have been shown to 
exert strong immunosuppressive activity (5). Further, the bone resorbing activity of 
vitamin 03 compounds might increase the risk of bone metastases. 111e latter subject 
is further discussed in Section 9.4. It is clear that more in vivo studies and clinical 
trials are necessary to determine the effectiveness of vitamin 0 3 compounds in the 
treatment of breast cancer. 
9.3 COMBINATION THERAPY OF VITAMIN D AND TAMOXIFEN 
Not only a single-agent treatment with vitamin 03 analogues may have 
potential, but also a combination therapy with established endocrine or cytotoxic 
agents may be of clinical interest. We have studied whether the antioestrogen 
tamoxifen is a good candidate for a combination therapy with a vitamin 03 analogue, 
as this is currently the most frequently used endocrine agent in the treatment of 
breast cancer. 
The antiproliferative action of 1,25-dihydroxyvitamin 0 3 and vitamin 03 
analogues in combination with tamoxifen has been studied in breast cancer cells in 
culture. Combined treatment of 1,25-dihydroxyvitamin 03 and tamoxifen resulted in a 
stronger growth inhibition of MCF-7 and ZR-75-1 cells than treatment with either 
compound alone (Chapter 4). With the vitamin 03 analogues a similar effect was 
observed (Chapter 5). An interesting observation was that in combination with 
tamoxifen the cells were more sensitive to the antiproliferative action of 1,25-
dihydroxyvitamin 03 and the analogues, i.e. the ECso's of the vitamin 03 compounds 
in the presence of tamoxifen were lower (2-fold to 4000-fold) than in the absence of 
tamoxifen (Chapter 5). This shift in ECso values was more pronounced for 1,25-
dihydroxyvitamin 03 and the analogues with an ECso close to 1,25-dihydroxyvitamin 
03 (22-oxa-calcitriol and CB966) than for the compounds with a more favourable 
ECso (EB 1089 and KHI060). A, a result the differences in potency between the 
vitamin D3 compounds were smaller in the presence of tamoxifen, than in its absence. 
In MCF-7 cells, the ECso of 1,25-dihydroxyvitamin 03 shifted from 2 x 10-
8 M in the 
absence of tamoxifen to 5 x 10-11 M in the presence of tamoxifen, which is a decrease 
by 200-fold. It is intriguing that the ECso in the presence of tamoxifen is within the 
normal range of serum concentrations of 1,25-dihydroxyvitamin 03' This raises the 
question whether physiological 1,25-dihydroxyvitamin 03 concentrations may playa 
role in the response to tamoxifen therapy. 
Recent studies of Oemirpence el al. (6) and James el al. (7) have supported our 
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observations that a stronger growth inhibition can be achieved by combined treatment 
of 1,25-dihydroxyvitamin D3/analogues and tamoxifen than by treatment with each 
compound alone. These investigators have observed similar effects using either 1,25-
dihydroxyvitamin D3 and tamoxifen, or EB1089 and the antioestrogen ICI182,780. In 
addition, our data on the interaction between vitamin D3 compounds and tamoxifen 
are consistent with the report of Abe-Hashimoto ef al. (8), that was published at the 
time of our studies. They have observed a synergistic antiproliferative effect of 22-
oxa-calcitriol and tamoxifen in MCF-7 and ZR-75-l cells in culture. Moreover, they 
have observed a synergistic inhibition of MCF-7 tumours grown ill viva in athymic 
mice. The synergism between 1,25-dihydroxyvitamin D3/analogues and tamoxifen 
could be very beneficial for a possible clinical application as the use of lower dosages 
of the vitamin D3 compounds will reduce the risk of negative side-effects. 
The complementary growth inhibition by vitamin D3 compounds and tamoxifen 
indicates that also lower dosages of tamoxifen may be used in a combination therapy, 
which may be beneficial considering the relationship between tamoxifen treatment 
and an incre~sed risk of endometrial and liver cancer (9,10). In ZR-75-1 cells, which 
are fully oestrogen dependent, the entire proliferation could be blocked by a high 
concentration of tamoxifen. Therefore, a lower concentration of tamoxifen was used, 
which resulted in a partial growth inhibition. The growth inhibition by this suboptimal 
tamoxifen concentration was augmented by combined treatment with vitamin D3 
compounds (Chapter 5). Thus, the partial growth inhibition by suboptimal 
concentrations of tamoxifen can be compensated by combined treatment with vitamin 
D3 compounds. However, a complete inhibition of cell growth could not be achieved 
in this way. 
Tamoxifen is believed to act via the oestrogen receptor to suppress the growth 
of breast tumours. Breast tumours are heterogeneous with respect to the steroid 
receptor content, and consist of both oestrogen receptor-positive and -negative cells, 
and thus of putative tamoxifen-responsive and -unresponsive cells. Also, distant 
metastases may loose the oestrogen responsiveness of the primary tumour (11). A 
major advantage of 1,25-dihydroxyvitamin D3 is that it inhibits the growth of breast 
tumours irrespective of the oestrogen receptor status (1,2). Therefore, a tamoxifen-
vitamin D combination therapy may offer better response rates than treatment with 
tamoxifen alone. 
A major problem of tamoxifen therapy is that after prolonged treatment, 
resistance to tamoxifen frequently occurs. A variety of mechanisms have been 
proposed for the development of tamoxifen-resistance that arises in patients, animals 
and cultured breast cancer cells, e.g. mutant oestrogen receptors (12), other dominant 
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Table 9.1. Possible advantages of a vitamin D-tamoxifen combination therapy for breast cancer 
u Bcttcr response ratc 
Stronger growth inhibition by combined treatment 
Both ER·positive and ER·negalive cells are growth inhibited 
• Lower dosages of vitamin D may be used with a reduced risk of negative side-effects 
ECso's for the growth inhibition arc lower in the presence of tamoxifen 
B Lower dosages of tamoxifen may be used 
Complementary growth inhibition 
• Delay of tamoxifen resistance? 
Antioestrogen.resistant cells arc growth inhibited by vitamin D 
Tamoxifen-indueed growth stimulation is inhibited by vitamin D 
• Prevention of tumour flare? 
Tamoxifen·induced growth stimulation is inhibited by vitamin D 
B Reduced risk of bone metastases? 
TanlOxifen attenuates the bone resorption induced by vitamin D 
Vitanlin D, l,25·dihydroxyvitamin D) or synthetic vitamin D) analoguesj ER, oestrogen receptor. See 
Sections 9.3 and 9.4 for further details. 
genetic alterations (13), or the induction of enzyme systems which metabolize 
tamoxifen (14). It has been proposed that tumour progression to the tamoxifen-
resistant state includes not only the selection and expansion of subpopulations that 
have become resistant to tamoxifen, but also of subpopulations that are growth 
stimulated by tamoxifen (14,15). Growth stimulation by tamoxifen, has been attributed 
to a partial oestrogen agonistic activity. 11lis agonistic activity of tamoxifen has been 
shown to be dependent on the tissue, cellular response studied, and concentration 
used (16). Tamoxifen-induced tumour flare, which is sometimes observed in patients 
within the first weeks of therapy, has been attributed to an agonistic activity of low 
concentrations of tamoxifen (17,18). 
We have demonstrated that derivatives of ZR-75-1 cells, which had acquired 
resistance to tamoxifen as a result of retroviral insertional mutagenesis, had not lost 
their responsiveness to the growth-inhibitory action of 1,25-dihydroxyvitamin D3 and 
the analogue KH1060 (Chapter 5). Further, in MCF-7 cells a growth stimulatory 
effect of low concentrations (10.8 M) of tamoxifen in the absence of oestradiol was 
observed (Chapter 4). This growth stimulation by tamoxifen was completely prevented 
by 1,25-dihydroxyvitamin D3 (Chapter 4). These data suggest that treatment with 
vitamin D3 compounds could be useful for both tamoxifen-resistant cells and cells 
that are growth stimulated by tamoxifen. Thereby, it can be hypothesised that a 
combination therapy of tamoxifen and vitamin D3 compounds delays the development 
of tamoxifen-resistance of the tumour. Furthermore, the data indicate that the 
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combined treatment may playa role in the prevention of tumour flare. 
Table 9.1 summarizes the potential benefits of an endocrine therapy for breast 
cancer with 1,25-dihydroxyvitamin 03/analogues combined with tamoxifen. It should 
be stressed that these potential benefits are mostly based on single ill vitro model 
systems for the very complex phenomena of tumour growth and tamoxifen-resistance. 
Of course studies with experimental animals and clinical trials are needed to 
determine whether all these possible advantages can be achieved in the ill vivo 
situation. 
9.4 BONE RESORBING ACTIVITY OF VITAMIN D3 ANALOGUES: 
TIlE EFFECT OF TAMOXIFEN 
Several studies have described a positive relation between bone resorption and 
metastasis to bone (see Section 3.9). As 1,25-dihydroxyvitamin 03 is a potent 
stimulator of bone resorption, treatment of breast cancer patients with this compound 
might increase the risk of bone metastases. This aspect may have severe consequences 
for the potential use of vitamin 03 compounds in the treatment of breast cancer, the 
more so as bone is the most frequent site of metastasis of breast cancer. 
The vitamin 03 analogues we have used have previously been tested for their 
ability to increase serum or urinary calcium concentrations of rats. However, their 
effects on bone turnover have not been examined. We have demonstrated that 1,25-
dihydroxyvitamin 03 and the analogues EBlO89 and KHlO60 stimulated the 
resorption of foetal mouse long bones, using an ill vitro organ culture model (Chapter 
6). The analogues EBlO89 and KHI060 were more potent than 1,25-dihydroxyvitamin 
D3 (10 to lOO-fold) and thereby not only the antiproliferative action of these 
analogues is increased, but also the bone resorbing activity. By contrast, the reported 
ill vivo relative calcaemic activities of EB1089 and KH1060 were only 0.4 and 1.3, 
respectively, compared to 1,25-dihydroxyvitamin 03 (19,20). These differences in 
relative potencies between bone resorbing and calcaemic activity might be explained 
by organ specific effects of the analogues, Le. the sensitivity of bone tissue for the 
analogues is higher than that of the intestine. Alternatively, the pharmacokinetic 
properties of the analogues may result in different relative potencies ill vivo and ill 
vitro (see also Section 2.5.3). III vivo animal studies are needed to determine whether 
EBI089 and KH1060 can exert the same potent effects on bone resorption ill vivo as 
was observed ill vitro. 
Tamoxifen has anti-oestrogenic as well as oestrogenic activity depending on the 
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organ or cellular response studied. On bone tamoxifen acts as a partial oestrogen 
agonist. It has been shown that tamoxifen prevented skeletal changes after 
ovariectomy in rats (21). Further, tamoxifen had protective effects on the skeleton of 
breast cancer patients, whereas bone loss associated with a decreased oestrogenic 
activity was expected (22). 
In Chapter 6 it was studied whether the bone preserving effects of tamoxifen 
offer protection against the bone resorbing activity induced by the vitamin D3 
compounds. It was sbown that the bone resorption induced by 1,25-dihydroxyvitamin 
D3, EBI089, and KH1060 was potently inhibited by tamoxifen. Although bone 
metastases were not directly measured, this study suggested that an increased risk of 
bone metastases due to an increased bone resorption induced by vitamin D3 
compounds, lnight be prevented by combined treatment with tamoxifen. However, ill 
vivo studies are necessary for a direct examination of the relation between vitamin D-
induced bone resorption and the risk of metastasis of breast tumours to bone, and the 
effect of tamoxifen on this process. 
The mechanism by which tamoxifen inhibits vitamin D-induced bone 
resorption is not clear. In this study an oestrogenic effect of tamoxifen is unlikely, as 
oestradiol was ineffective, and the antioestrogen ICI164,384, which lacks oestrogen 
agonistic activity, caused a similar inhibition as tamoxifen. An alternative explanation 
could be the involvement of protein kinase C, as it has been shown that tamoxifen 
inhibits protein kinase C (23) and protein kinase C inhibitors suppress 1,25-
dihydroxyvitamin D3-induced bone resorption (24). 
9.5 MECHANISM OF THE ANTIPROLIFERATIVE ACTION OF 
VITAMIND 
9.5.1 Interaction with oestradiol 
Oestradiol plays an important role in the development and progression of 
breast tumours. Oestradiol acts through the oestrogen receptor, which belongs to the 
same family of steroid hormone receptors as the vitamin D receptor. As part of the 
investigations directed to unravelling the mechanisms responsible for the tumour 
suppressive activity of vitamin D3 compounds, we have addressed the question 
whether 1,25-dihydroxyvitamin D3 and several vitalnin D3 analogues interfere with the 
action of oestradiol (Chapters 4 and 5). It was observed that 1,25-dihydroxyvitamin D3 
and the analogues CB966, EB1089, KH1060 and 22-oxa-calcitriol caused only a small 
inhibition of the oestradiol-stimulated growth of MCF-7 cells, and when expressed in 
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I'g DNA/well, this inhibition was similar to the inhibition of the autonomous growth. 
By contrast, the oestradiol-induced growth of ZR-75-1 cells was potently inhibited by 
the vitamin D3 compounds. Therefore, the inhibition of oestradiol-stimulated growth 
by vitamin D3 compounds seemed to be cell line specific and might be related to the 
oestradiol dependency of the cell line. 
To gain further knowledge of the interactions with oestradiol, it was studied 
whether the vitamin D3 compounds can interfere with oestradiol-induced gene 
transcription and with the oestrogen receptor level. The myc and pS2 genes are 
induced by oestradiol, but the oestradiol-induced mRNA levels of these genes were 
not affected by simultaneous addition of one of the vitamin D3 compounds. Also, the 
oestrogen receptor content of both cell lines was not influenced by the vitamin D3 
compounds. On the contrary, a report of Demirpence el al. (6) showed that 1,25-
dihydroxyvitamin D3 inhibited oestradiol-induced gene expression of an endogenous 
gene (PS2), as well as various exogenous transfected genes in MCF-7 cells. 
Furthermore, James el al. (7) observed a decrease in the oestrogen receptor content 
by 1,25-dihydroxyvitamin D3 and EB1089. An explanation for these differences is 
presently unclear. The presence of foetal calf serum may influence the results as we 
have used serum-free medium and James el al. and Demirpence el al. have used 
medium supplemented with foetal calf serum. As discussed earlier (Section 9.1) 
factors present in serum influence the growth inhibitory effect of 1,25-
dihydroxyvitamin D3 and possibly also the interaction with oestradiol. A second 
explanation could be that the MCF-7 cell line responds differently in the various 
laboratories, due to the many passages of the cells. 
Together, it seems that vitamin D can interact with the action of oestradiol in 
some cases, either directly or indirectly. However, the interaction with oestradiol is 
probably not the main mechanism behind the tumour suppressive activity of vitamin 
D, because 1,25-dihydroxyvitamin D3 and 22-oxa-calcitriol have been shown to inhibit 
breast cancer growth ill vilro and ill vivo irrespective of the presence of the oestrogen 
receptor (1,2). 
9.5.2 Interaction with insulin and IGF-I 
In addition to oestradiol, polypeptide growth factors are believed to play an 
important role in promoting the growth of breast tumours. It has been hypothesized 
that the autonomous, oestrogen-independent growth of breast cancer cells in culture 
is supported by autocrine acting growth factors (25). Therefore, the observed 
inhibition of the autonomous growth of MCF-7 cells by 1,2S-dihydroxyvitamin D3 and 
analogues might be explained by an interaction with autocrine acting growth factors. 
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In Chapters 7 and 8 we have studied the interaction of 1,25-dihydroxyvitamin 
D3 and EBI089 with specific growth factors, namely insulin and IGF-I. Insulin, IGF-I, 
and also IGF-II are structurally related molecules. They act via three receptors, 
namely the insulin, IGF type I, and the IGF type II receptor, however considerable 
cross-reactivity exists between the various ligands and receptors. In addition to the 
three membrane-bound receptors, the IGFs bind to other soluble proteins, the IGF-
binding proteins (IGF-BPs). To date six of these IGF-BPs have been cloned. At 
cellular level IGF-BPs can either potentiate or suppress the activity of the IGFs, 
depending on the type of IGF-BP, cell line, and culture conditions. 
Several lines of evidence support a biological role for IGF-I in the 
proliferation of human breast cancer cells: I) IGF-I is mitogenic for cultured breast 
cancer cells, 2) IGF-I is produced in the tumour by stromal cells, 3) exogenous IGF-I 
supported the growth of oestrogen-dependent MCF-7 breast cancer cells in nude 
mice, in the absence of oestrogen supplementation, and 4) a blocking antibody against 
the IGF type I receptor inhibited MDA-MB-231 tumour growth in nude mice (for 
review see ref. 26). 
TIle mitogenic effect of IGF-I is believed to be mediated via the type I IGF 
receptor. TIlis receptor has a high affinity for IGF-I and a low affinity for insulin. A, 
IGF-I is an expensive peptide, researchers sometimes use high doses of insulin, which 
is much cheaper, to mimic the lnitogenic effect of IGF-I. However, the work 
presented in this thesis and data from the literature demonstrate that insulin may also 
stimulate breast cancer growth via its own receptor: I) insulin receptors have been 
demonstrated on several breast cancer cell lines (Chapter 5 and ref. 27), 2) a blocking 
antibody against the type I IGF receptor did not (completely) block the mitogenic 
action of insulin (Chapter 5, refs. 27 and 28) and 3) the insulin receptor content is 
increased in human breast tumour specimens and positively correlated to tumour size 
and grade (29). Finally, Dideriksen et al. (30) made the interesting observation that 
an insulin analogue with enlmnced mitogenic activity increased the incidence of rat 
mammary tumours. However, it has not been investigated via which receptor this 
insulin analogue exerts its mitogenic activity. 
Both insulin and IGF-I stimulated the growth of MCF-7 cells. It was observed 
that 1,25-dihydroxyvitamin D3 and EB1089 reversed these mitogenic effects, 
suggesting that interruption of the insulin and/or IGF-I mitogenic pathway is involved 
in the antiproliferative action of vitamin D3 compounds. Subsequently, it was tried to 
gain more insight into the mechanism of this anti-growth factor activity. It was studied 
whether the inhibition was achieved via downregulation of the insulin and IGF-I 
receptors. 1,25-Dihydroxyvitamin D3 and EB1089 had no direct effect on the insulin 
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and IGF-I binding after 48 hour of incubation. On the contrary, an increased insulin 
and IGF-I binding was measured at time points on which the growth inhibition was 
measured (8 days) (Chapter 7). The physiological meaning of this observation is not 
clear, but a similar inverse relationship between receptor regulation and growth 
inhibition by I,Z5-dihydroxyvitamin D3 was observed for the EGF receptor in MDA-
MB-Z31 and BT-ZO cells (31,3Z). It seems that the stimulation of growth factor 
receptors by vitamin D3 compounds is a secondary effect, which is not directly 
responsible for the growth inhibition. 
Inhibition of IGF-I-stimulated growth, but not insulin-stimulated growth, may 
also involve regulation of IGF-BPs. It was shown in Chapter 8 that I,Z5-
dihydroxyvitamin D3 and EBI089 stimulated the mRNA expression of IGF-BP5 in 
MCF-7 cells. The physiological role of IGF-BP5 for breast cancer cells is yet 
unknown, and hence the function of IGF-BP5 regulation by vitamin D3 compounds. It 
is unlikely that the regulation of IGF-BP5 by I,Z5-dihydroxyvltamin D3 and EBI089 
plays a dominant role in the inhibition of IGF-I stimulated growth. The inhibition of 
IGF-I-stimulated growth described in Chapter 7 was independent of IGF-BPs, since 
analogues of IGF-I were used, which have a strongly reduced binding to IGF-BPs. 
MCF-7 cells secrete immunoreactive IGF-I into the medium. A possible 
mechanism for the inhibition of the autonomous growth by vitamin D3 compounds is 
an inhibition of the secretion of autocrine acting IGF-I. However, it appeared that the 
secretion of immunoreactive IGF-I by MCF-7 cells was increased rather than 
decreased by treatment with I,Z5-dihydroxyvitamin D3 and EB1089 (Chapter 8). This 
stimulation of IGF-I secretion was already observed after 48 h of treatment and thus 
seemed to be a direct effect of the vitamin D3 compounds. The inhibition of the 
autonomous growth of MCF-7 cells by the vitamin D3 compounds probably takes 
place at a site located distal from IGF-I secretion. 
In summary, it has been shown that I,Z5-dihydroxyvitamin D3 and EB1089 
inhibit the mitogenic effect of insulin and IGF-I in MCF-7 cells. In addition, it has 
been shown that I,Z5-dihydroxyvitamin D3 and KHI060 inhibit the mitogenic action 
of EGF in ZR/HERc cells (Chapter 5). Furthermore, the vitamin D3 compounds 
have been shown to regulate the number of growth factor receptors (insulin, IGF-I, 
and EGF), growth factor production (IGF-I), and IGF-BP expression. Therefore, it 
can be concluded that the vitamin D3 compounds interfere with the action of growth 
factors at different levels. However, it remains to be established how precisely these 
effects relate to the antiproliferative action of vitamin D3 compounds in breast cancer 
cells. 
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9.5.3 The role of the oncogenes myc and fos 
The gene products of myc and fos are nuclear proteins which act as 
transcription factors. The expression of both genes is rapidly and transiently induced 
by multiple external signals, including steroid hormones, polypeptide growth factors, 
and serum. The myc and fos protein products are believed to play important roles in 
cellular proliferation and differentiation. 1,25-Dihydroxyvitamin D3 has been shown to 
regulate the mRNA expression of myc and fos in several cell types, which suggested 
that these oncogenes play a role in the antiproliferative and/or differentiation 
inducing activity of vitamin D3 compounds. 
In breast cancer there is a strong positive correlation between myc expression 
and cell growth (33). Correspondingly, suppression of myc mRNA has been associated 
with growth inhibition by 1,25-dihydroxyvitamin D3 in HL60 leukaemic cells (34) and 
in MCF-7 cells (35). However, we have not observed an inhibition of myc mRNA 
expression in MCF-7 and ZR-75-1 cells, neither under basal growth conditioru, nor in 
the oestradiol-stimulated situation (Chapter 5). 
Stimulation of fos mRNA expression by 1,25-dihydroxyvitamin D3 has been 
associated with growth inhibition of HL60 leukaemic cells (36) and MCF-7 cells (35). 
We have not observed an effect of 1,25-dihydroxyvitamin D3 on basal fos mRNA 
expression of MCF-7 cells, but observed that insulin-induced fos mRNA expression 
was inhibited by 1,25-dihydroxyvitamin D3 (Chapter 7). However, because fos mRNA 
is induced by both growth inhibitory and growth stimulatory agents, fos mRNA 
expression and the proliferative status of breast cancer cells cannot be linked. 
It can be concluded that, in order to define the role of myc, fos and other 
oncogenes or tumour suppressor genes in the antiproliferative action of vitamin D3 
compounds, the study of mRNA regulation is not sufficient. A better answer may be 
obtained from transfection experiments, in which it is possible to overexpress or 
inactivate genes of interest. 
9.6 SUGGESTIONS FOR FURTHER RESEARCH 
9.6.1 III vilro studies 
More studies are needed to clarify the mechanism of the antiproliferative 
action of vitamin D3 compounds. The fact that 1,25-dihydroxyvitamin D3 inhibits the 
growth of cells of many different origins suggests a common mechanism of action. A 
possible site of interaction is the regulation of genes that are directly involved with 
the cell division machinery, e.g. certain oncogenes and tumour suppressor genes. 
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Studies in this thesis and elsewhere (37) have demonstrated an anti-growth factor 
activity of vitamin D3 compounds. This might indicate an interaction at a site 
common in the signal transducing pathway for different polypeptide growth factors. 
Also, the intracellular messenger calcium may play a role, especially as calcium has 
been shown to influence the growth inhibition by vitamin D3 compounds (see Section 
3.8.3). 
Studies on the regulation of differentiation of breast cancer cells by 1,25-
dihydroxyvitamin D3 have been hampered by the lack of good differentiation markers. 
When good markers are available, it can be established whether inhibition of 
proliferation by vitamin D3 compounds is accompanied by induction of differentiation. 
The development of tamoxifen-resistance is a major problem of tamoxifen 
therapy. Tamoxifen is an unnatural pharmaceutical compound, but it acts via the 
oestrogen receptor and changes in this receptor may contribute to tamoxifen 
resistance (12). For a future clinical application of vitamin D3 compounds it is 
important to investigate whether breast cancer cells develop vitamin D resistance 
after prolonged treatment, analogous to tamoxifen resistance. 
The mechanism behind the synergistic inhibition of breast cancer cell growth 
by 1,25-dihydroxyvitamin D31 analogues and tamoxifen has not been clarified and 
needs further study. A possible site of interaction is the regulation of the vitamin D 
receptor number. Tamoxifen had no effect on the vitamin D receptor level of MCF-7 
cells after 24 h of treatment (Chapter 5). However, Escaleira et al. (38) have shown 
that tamoxifen stimulated the vitamin D receptor level of T47-D cells after 72 h of 
treatment. Therefore, this should also be investigated in MCF-7 cells at later time-
points. Tamoxifen and 1,25-dihydroxyvitamin D3 have in common that they both 
inhibit the mitogenic action of certain growth factors, and this may be an other clue 
for the observed interaction between both types of compounds. Further, tamoxifen 
may inhibit the metabolism of the vitamin D3 compounds. As the effect on 
metabolism may differ between the vitamin D3 analogues, this may also explain the 
different extent of synergism of tamoxifen with the various vitamin D3 analogues. 
However, it is very difficult to define the site of interaction when the mechanism of 
the growth inhibitory action of 1,25-dihydroxyvitamin D3 itself is still largely unknown. 
9.6.2 III vivo studies 
In animal models for breast cancer the antiproliferative action of vitamin D3 
compounds has been studied by measuring the size of the tumours. However, much 
more valuable information can be obtained from the tumours. Analysis of parameters 
that have been linked to response to therapy and prognosis, e.g. cell proliferation 
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indices, oncogene expression, steroid receptor content, and growth factor receptor 
content (39), will give a better insight into the activity of vitamin 0 3 compounds. 
Also, an investigation on vitamin D receptor status in relation to response to vitamin 
o therapy may provide helpful information in predicting the responsiveness of a 
tumour to vitamin 0 therapy. 
The promising in vitro results of a vitamin O-tamoxifen combination therapy 
have to be confirmed by more in vivo studies. Several vitamin 0 3 analogue-tamoxifen 
combinations should be tested in the chemical-induced breast cancer model, or in the 
nude mice model, using different breast cancer xenografts. To examine the synergistic 
interaction different concentrations of both compounds may be analyzed. 
Little attention has been given to the effects of vitamin 0 3 analogues on bone 
in relation with tumour suppression. The bone resorbing activity induced by vitamin 
0 3 compounds may increase the risk of skeletal metastases (see Section 3.9), and/or 
may weaken the skeleton after prolonged treatment. These undesired side-effects may 
have consequences for the clinical application of these compounds as tumour 
suppressive agents. 111erefore, it is important to monitor serum markers of bone 
turnover and/or to perform histomorphometrical analysis of bone. These studies 
could be done both in the absence and presence of tamoxifen, as tamoxifen has been 
shown to have protective effects on vitamin D-induced bone resorption in an in vitro 
model (Chapter 6). If these data can be confirmed in an in vivo model, this would 
mean an additional advantage of a tamoxifen-vitamin 0 therapy. 
A direct determination of bone metastases in response to vitamin 0 therapy, 
requires an in vivo model of highly metastatic breast cancer cells, analogous to the 
model described by Krempien ef al. (40). The advantage of the nude mice model 
described by Briinner ef al. (41) is that metastases and suppression of the primary 
tumour can be measured in the same model. TIlese models will make it possible to 
determine whether vitamin 0 3 compounds increase the risk of bone metastases, and 
whether tamoxifen has a protective effect on this process. 
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SUMMARY 
111e biologically most active form of vitamin D, l,25-dihydroxyvitamin D3 is 
mainly known for its important role in calcium and bone metabolism. More recently it 
has been shown that l,25-dihydroxyvitamin D3 inhibits the growth of breast cancer 
cells in culture and suppresses the growth of breast tumours in experimental animals. 
These findings have suggested a potential use of l,25-dihydroxyvitamin D3 in the 
treatment of breast cancer. However, high doses are needed for tumour suppression, 
which could result in a dangerous elevation of blood calcium levels in patients. 
Furthermore, an increased bone turnover induced by l,25-dihydroxyvitamin D3 might 
increase the risk of skeletal metastases. To overcome these problems new vitamin D3 
analogues have been synthesized, which have a strong antiproliferative, but a reduced 
calcaemic activity. 
The studies in this thesis describe the effects of l,25-dihydroxyvitamin D3 and 
several novel vitamin D3 analogues on the growth of the MCF-7 and ZR-75-1 human 
breast cancer cell lines. Both cell lines are vitamin D receptor- and oestrogen 
receptor-positive. In addition, the bone resorption induced by the vitamin D3 
compounds was measured using an organ culture system of 45Ca labelled foetal 
mouse long bones. The effects of the vitamin D3 compounds on cell growth and bone 
resorption were studied both in the absence and presence of the antioestrogen 
tamoxifen, in order to investigate a potential benefit of a combination therapy of 
vitamin D3 compounds and tamoxifen. Tamoxifen is currently the most widely used 
endocrine agent used in the treatment of breast cancer. Although good results have 
been obtained with this agent, alternative or additional endocrine therapies are still 
warranted. 
111e vitamin D3 analogues that have been tested are CB966, EB1089, KHlO60, 
and 22-oxa-calcitriol. Only the analogues EBlO89 and KHlO60 were clearly more 
potent than 1,25-dihydroxyvitamin D3 in the inhibition of MCF-7 and ZR-75-1 cell 
growth. These analogues were active at 30- to 100-fold lower concentrations than 
1,25-dihydroxyvitamin D3. Combined treatment of the vitamin D3 compounds and 
tamoxifen resulted in a stronger inhibition than the inhibition by each of these agents 
alone. Further, it was observed that tamoxifen increased the sensitivity of the cells to 
the vitamin D3 compounds. In the presence of tamoxifen, the vitamin D3 compounds 
were active at 2- to 4000-fold lower concentrations than in its absence. These data 
demonstrate that a combination therapy of 1,25-dihydroxyvitamin D3 or a vitamin D3 
analogue and tamoxifen may have the advantage that I) a stronger growth inhibition 
can be achieved, and 2) lower dosages of the vitamin D3 compounds can be used with 
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a reduced risk on negative side-effects. In addition, it was observed that the growth 
stimulatory effect of low concentrations of tamoxifen was reversed hy co-addition of 
1,25-dihydroxyvitamin D3 to MCF-7 cells, and that 1,25-dihydroxyvitamin D3 and 
KH1060 inhibited the growth of tamoxifen-resistant derivatives of the ZR-75-1 cell 
line. These data suggested a role of vitamin D3 compounds in the treatment of 
tamoxifen-resistant tumours and in the prevention of tamoxifen-induced tumour flare. 
Finally, it was shown that tamoxifen considerably suppressed the bone resorption 
induced by 1,25-dihydroxyvitamin D3, EB1089, and KH1060. These findings suggested 
that an increased risk on bone metastases due to an increased bone resorption 
induced by vitamin D3 compounds, might be prevented by combined treatment with 
tamoxifen. 
Oestradiol and a number of polypeptide growth factors play an important role 
in the development and growth of breast tumours. Therefore, we have studied 
whether the vitamin D3 compounds can interfere with the actions of these mitogens. 
11le inhibition of oestradiol-stimulated growth was cell line specific: 1,25-
dihydroxyvitamin D3 and the analogues inhibited the oestradiol-stimulated growth of 
ZR-75-1 cells, but not of MCF-7 cells. Oestradiol-induced mRNA expression of the 
myc and pS2 genes was not affected, neither was the oestrogen receptor level changed 
by treatment with the vitamin D3 compounds. Therefore, in our culture system, the 
vitamin D3 compounds did not seem to interfere directly with the action of oestradiol. 
By contrast, the vitamin D3 compounds clearly interfered with the action of the 
polypeptide growth factors insulin and IGF-I at different levels. It was observed in 
MCF-7 cells that besides inhibition of the mitogenic effect of insulin and IGF-I, 1,25-
dihydroxyvitamin D3 and EBI089 increased the number of insulin and IGF-I binding 
sites, stimulated the secretion of immunoreactive IGF-I, and stimulated the expression 
of IGF-BP5. Further, 1,25-dihydroxyvitamin D3 inhibited insulin-induced fos mRNA 
expression. However, additional research is needed to assess the direct relation 
between these effects and the antiproliferative action of vitamin D3 compounds. 
In conclusion, 1,25-dihydroxyvitamin D3 and especially the vitamin D3 
analogues EB1089 and KHI060 are potent inhibitors of breast cancer cell growth. As 
EB 1089 and KH 1060 have been shown to have a low ill vivo calcaemic activity, these 
analogues may have potential for treatment of breast cancer. A major advantage of a 
vitamin D therapy in comparison with most established endocrine therapies is that 
vitamin D3 compounds inhibit breast cancer growth irrespective of the oestrogen 
receptor. Studies in this thesis have indicated that a vitamin D-tamoxifen combination 
therapy may offer additional advantages compared to treatment with these agents 
alone. However, in order to establish whether these promising laboratory data have 
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clinical potential, further research with an animal model for breast cancer is an 
essential next step. 
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SAMENVATITNG 
De biologisch meest actieve vorm van vitamine D, 1,25-dihydroxyvitamine D3 
is vooral bekend door zijn belangrijke rol in de calciumhuishouding en in 
botmetabolisme. Meer recent is aangeloond dat 1,25-dihydroxyvitamine D3 de groei 
reml van gekweekte borsttumorcellen en van borsttumoren in proefdieren. Deze 
bevindingen wijzen erop dal 1,25-dihydroxyvitamine D3 mogelijkheden zou kunnen 
bieden voor de behandeling van borslkanker. Er zijn echter hoge doseringen nodig 
voor de tumorremmende werking en dit zou bij patienten kunnen resulteren in een 
gevaarlijke verhoging van de calcium concenlratie in hel bIDed. Verder zou een 
verhoogde botombouw geYnduceerd door 1,2S-dihydroxyvitamine D3 het risico op 
bolmetastases kunnen doen toenemen. Om deze problemen het hoofd te bieden zijn 
nieuwe vitamine D3 analogen gesynthetiseerd die een sterke tumor-remmende 
werking hebben, maar minder de calciumhuishouding verstoren. 
In dit proefschrift worden de resultaten beschreven van de effecten van 1,25-
dihydroxyvitamine D3 en een aanlal nieuwe vitamine D3 analogen op de groei van de 
humane borsttumorcellijnen MCF-7 en ZR-75-1. Beide cellijnen zijn vitamine D 
receptor- en oestrogeen receptor-positief. Ook werd de botresorptie geYnduceerd door 
de vitamine D3 verbindingen gemeten. Hiervoor werd een orgaan-kweeksysteem van 
45Ca gelabelde foe tale muizebotjes gebruikt. De effecten van de vita mine D3 
verbindingen op tumorcelgroei en botresorptie werden bestudeerd in de aan- en 
afwezigheid van het anti-oestrogeen tamoxifen, dit om na te gaan of een combinatie-
behandeling van vitamine D3 verbindingen en lamoxifen belere mogelijkheden zou 
kunnen bieden voor de behandeling van borstkanker. Tamoxifen is momenteel het 
meest gebruikte endocriene middel voor de behandeling van borstkanker. Ondanks de 
goede resultaten die verkregen zijn met dit middel, zijn andere of additionele 
endocriene behandelingen nog steeds gewenst. 
De vitamine D3 analogen die werden getest zijn: CB966, EB1089, KHI060 en 
22-oxa-calcilriol. AIleen de analogen EBI089 en KHI060 waren duidelijk potenter 
dan 1,25-dihydraxyvitamine D3 in de remming van de graei van MCF-7 en ZR-75-1 
cellen. Deze analogen werkten bij een 30 101 100 maal lagere concentratie dan 1,25-
dihydroxyvitamine D3. Gecombineerde behandeling met de vitamine D3 verbindingen 
en lamoxifen resulteerde in een sterkere remming dan de remming door deze stoffen 
afzonderlijk. Verder werd waargenomen dat tamoxifen de gevoeligheid van de cellen 
voor de vitamine D3 verbindingen verhoogt. In de aanwezigheid van tamoxifen waren 
de vitamine D3 verbindingen werkzaam bij 2 tot 4000 maal lagere concentraties dan 
in de afwezigheid van tamoxifen. Deze gegevens wijzen erap dat een gecombineerde 
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behandeling met 1,25-dihydroxyvitamine D3 of een vitamine D3 analoog en tamoxifen 
het voordeel zou Imlmen bieden dat 1) een sterkere groeiremming bereikt kan 
worden, en 2) lagere doseringen van de vitamine D3 verbindingen gebruikt kunnen 
worden met een verminderd risico op bijwerkingen. Verder werd gevonden dat de 
groeistimulerende werking van lage concentraties tamoxifen tegengegaan werd door 
gelijktijdig 1,25-dihydroxyvitamine D3 toe te dienen aan MCF-7 cellen, en dat 1,25-
dihydroxyvitamine D3 en KH1060 de groei remden van tamoxifen-resistente cellen, 
die afgeleid zijn van de ZR-75-1 cellijn. Deze gegevens suggereerden een rol voor 
vitamine D3 verbindingen in de behandeling van tamoxifen-resistente tumoren en in 
de preventie van een door tamoxifen ge1nduceerd "tumour flare" effect. Tenslotte 
werd aangetoond dat tamoxifen de botresorberende activiteit van 1,25-dihydroxyvita-
mine D3, EBI089 en KH1060 aanzienlijk remt. Deze bevindingen suggereerden dat 
een verhoogd risico op botmetastases als gevolg van een verhoogde botresorptie 
geYnduceerd door vita mine 03 verbindingen, voorkomen zou kunnen worden door een 
gecombineerde behandeling met tamoxifen. 
Oestradiol en een aantal polypeptide groeifactoren spelen een belangrijke rol 
in de ontwikkeling en groei van borsttumoren. Oaarom is bestudeerd of de vitamine 
03 verbindingen invloed kunnen uitoefenen op de werking van deze mitogene stoffen. 
1,25-Dihydroxyvitamine 03 en de analogen remden de oestradiol-gestimuleerde groei 
van ZR-75-1 cellen, maar ruet die van MCF-7 cellen. Verder werden noch de mRNA 
expressie van de myc en pS2 genen geYnduceerd door oestradiol, noch het aantal 
oestrogeen receptoren beYnvloed door de vitamine 03 verbindingen. Oaarom lijkt het 
erop dat in ons celkweeksysteem de vitamine D3 verbindingen geen directe invloed 
kunnen uitoefenen op de werking van oestradiol. De vitamine 03 verbindingen 
kunnen echter wei interfereren met de werking van de polypeptide groeifactoren 
insuline en IGF-I op verschillende niveaus. In MCF-7 cellen werd waargenomen dat 
1,25-dihydroxyvitamine 03 en EB 1089 het groeistimulerende effect van insuline en 
IGF-I remden. Daamaast werd een toename gevonden van het aantal 
bindingsplaatsen voor insuline en IGF-I, een stimulatie van de secretie van 
immunoreactief IGF-I en een stimulatie van de expressie van het IGF-bindend eiwit 
5. Verder werd de inductie door insuline van het fos mRNA geremd door 1,25-
dihydroxyvitamine 03' Er is echter meer onderzoek nodig om de directe relatie tussen 
al deze effecten en de groeiremmende werking van de vitamine D3 verbindingen vast 
te stellen. 
Geconcludeerd kan worden dat 1,25-dihydroxyvitamine 03 en vooral de 
vitamine 03 analogen EB1089 en KH1060 potente remmers zijn van de groei van 
borsttumorcellen. Aangezien aangetoond is dat EB1089 en KH1060 een lage ill vivo 
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calcaemische activiteit hebben, zouden deze analogen mogelijkheden kunnen bieden 
voor de behandeling van borstkanker. Een belangrijk voordeel van een vitamine D 
therapie, in vergelijking met de meeste bestaande endocriene therapieen, is dat 
vitamine D3 verbindingen borstkankergroei remmen onafhankelijk van de 
aanwezigheid van de oestrogeen receptor. Het onderzoek beschreven in dit 
proefschrift geeft aan dat een vitamine D-tamoxifen combinatietherapie additionele 
voordelen zou kunnen bieden vergeleken met een behandeling met deze middelen 
afzonderlijk. Maar om te weten of deze veelbelovende laboratoriumresultaten oak 
klinisch toepasbaar zijn is onderzoek in een diermodel voor borstkanker een 
essentiele volgende stap. 
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